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Bacteria in the gastrointestinal tract play an important role in intestinal motility, inflammation, 
homeostasis, and behavior. Bacteria, through the natural synthesis of neuroactive compounds 
and secondary metabolites, can modulate the host immune system and communicate with the 
host along the signaling pathway along the gut-brain axis. Here, we functionally design, 
develop, test, and characterize a platform for the study of microbial-host interactions using 
advancements in the field of synthetic biology.  
 
First, we describe the engineering of Escherichia coli Nissle to biosynthesize serotonin within 
the mammalian gut using a native-plasmid optimized approach. Serotonin is crucial for 
neurotransmission throughout the body and may be playing a role in microbial gut-brain 
communication. In the gastrointestinal tract, serotonin regulates intestinal motility, cell 
turnover, intestinal inflammation, and gastrointestinal homeostasis. Upon serial daily oral 
gavages, our engineered bacterium populates a murine colon to produce serotonin locally in the 
mucosa layers along the epithelial lining. Changes in host physiology were observed including 
decreased gastrointestinal motility, increased colonic Muc2 expression, induction of host 
TPH2, responsible for serotonin biosynthesis in enteric neurons, and upregulation of serotonin 
receptors HTR3, HTR4, and HTR7 in the colon. Behavioral tests revealed a statistically 
significant decrease in anxiety and depression in stress-induced environments in mice treated 
with the engineered bacterium. This work suggests that gut bacteria engineered to modulate 
host gut-brain axis may have both scientific and clinical uses to study microbial-host 
interactions and treat gastrointestinal and behavioral mood disorders in humans.    
 
Second, we engineered bacteria to produce exogenous butyrate and other SCFAs in the murine 
gut. Short chain fatty acids (SCFAs) play an important role in intestinal homeostasis, fluid 
dynamics, inflammation, oxidative stress, and intestinal hypersensitivity and motility. With this 
development, we characterized the effects of our butyrate-producing bacteria on a high-fat diet 
and DSS-induced colitis model within the colon. Although energetically burdensome to 
produce, our strains produced butyrate in the colon at higher density in an actively inflamed 
colitis model. After 14 days of oral administration, our engineered strain (EcN:B) increased the 
colon length of normal wild-type mice, in high fat fed mice, and in mice with recovering and 
actively inflamed DSS-induced colitis. EcN:B increased mucosal barrier thickness, upregulated 
gene expression of the barrier integrity markers Cldn1, Ocln, Zo1, and altered crypt and villus 
height during inflammation recovery. Furthermore, as butyrate is known to induce Foxp3+ 
Regulatory T cells, we saw a 13.01% percent increase in Foxp3+ cells in the colon of mice fed 
our engineered bacteria. This work suggests that synthetic gut bacteria engineered to produce 
short chain fatty acids may have future clinical uses to treat patients with inflammatory bowel 
disease including Crohn’s and Colitis with future potential to serve as a therapeutic for irritable 
bowel syndrome, idiopathic constipation, obesity, and colorectal cancer.  
 This platform, with the use of synthetic biology to natively engineer Escherichia coli Nissle to 
produce bioactive compounds in the distal gastrointestinal tract, creates a framework for future 
characterization of bacterial-host communication and future microbial-based therapeutics.  
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Traditional standards push doctoral candidates in scientific disciplines towards 
scientific understanding, hypothesis driven research, and quantitative metrics. In an attempt to 
further understand what it truly means to have earned, and worked for, a doctorate degree, I 
have taken an albeit similar, yet slightly varied approach.  
 Entering into my doctoral thesis work, I had already completed two bachelor’s degrees, 
three master’s degree, and half of an osteopathic medical degree. I asked myself. What does it 
mean to hold a PhD? Doctorate in Philosophy. The word most often overlooked in scientific 
disciplines, Philosophy. So, what does it mean to hold a Doctorate of Philosophy in a scientific-
based research field? 
 From my own understanding, I have come to believe that we as academics, should work 
to foster the skill of philosophical exploration. Not only in the methods and theories that shape 
our universe, but in the philosophical undertaking as communicators of proven facts. They say 
the world’s most renowned philosophers are such, not for their theories, but for their ability to 
communicate; their ability to convey a message. The art in science is communicating your ideas, 
your findings, and your understandings to your colleagues and the general public. While some 
research bodes reflection on the value it serves, the thoughts and principles behind any scientific 
finding is itself remarkable; and as such, careful attention should be taken to regurgitate it to 





 So, then what is this preface for? If not to only temporarily distract you while you are 
on your way towards reading the findings of my doctoral thesis, but instead to shine light on 
the most overlooked discipline of science: communication. Communication not in how we talk 
to our colleagues, but how we share our findings. 
 Throughout the past 4 years, I knew my weakest skill was writing. While prose and 
poetry flow effortlessly, writing in concrete, scientific voice, has always been a struggle. If 
publications are the bread and butter of conventional scientific appraisal, then writing is the 
diesel that keeps the career alive. But what we fail to remember is that while scientific writing 
advances our understanding, it is prose, poetry, and art that truly communicate how we 
understand the world.  
 During my second year in graduate school, I was fortunate to serve as the lead scientist 
on a BioArt exhibit at the New York City Solomon R. Guggenheim Museum. Through my work 
with renowned contemporary artist Anicka Yi, I went on to help and consult on international 
art projects in Brussels and at the largest exhibit in the world, La Biennale di Venezia in Venice, 
Italy. It was these experiences that opened my eyes on how little I knew about communication. 
While naturally, my writing was improving, it was the exploration of communication through 
art, poetry, and in different mediums, that made me realize how little training we receive on it. 
It is the skill I think every scientist needs to cultivate. 
 I have come to believe that our ability and willingness to share our ideas to the public 
is crucial for the advancement of science in society. Whereas, non-scientific experts find the 
need to decipher our findings to the lay audience, often painting uncharacteristically inaccurate 
portrayals, we continue to hide behind results only laudable for standing ovations. 
xii 
 
 So, as you proceed to read my doctoral work, I hope you take note that while doctoral 
research deserves an applause, it is the communication of the findings that we need to foster. 
From my doctoral work, I hope to pursue future research endeavors in basic science, 
translational and clinical medicine. Findings are meaningless without context. I hope this work 
can shape how we conceptualize our understanding of what is possible in the future as advanced 
bacterial therapeutics evolve to be one of many workhorses in a clinician’s tool belt. 
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The term microbiome first entered circulation in 1969 but for much of history was 
defined as the ecological organization of an environment including animals and plants on a very 
small scale (Prescott, 2017). Today, we define the microbiome as the microorganisms on an 
animal, on the body, on part of the body, or in a specific environment. Combined, the 
microbiome is not only the population of microorganisms present, but also the collective genetic 
material of the organisms often including the genetic material of bacteria, viruses, fungi, and 
protists. It is this genetic material, and the manipulation or introduction of new genetic material, 
that we exploit to study the connections between microbes and the host in this work. 
While terminology has been slow to develop, the hypothesis that bacteria play a role in 
human health and longevity dates back over a century. Nobel Laurate, Elie Metchnikoff, the 
father of cellular immunology, known for his discovery of macrophages, first theorized that 
yogurt could enhance health and delay senility (Metchnikoff E. In: Mitchell PC, 1910). While 
the theory fell out of practice over the succeeding decades, the term microbiota entered 
circulation in 1926; scientific papers dating back to 1966 highlight the role the microbiota plays 
in growth, development, and food utilization for the developing young (Dubos, Savage, & 
Schaedler, 1966). As the use of the term microbiota percolated into conventional scientific 
rhetoric, our understanding continued to expand. In the 1960s, the use of germ-free mice came 
into practice for the specific manipulation of the microbiota and the study of individual 
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pathogens (Lane-Petter, 1962). In the 1980s, Whipps et al. published that, “…bacteria in 
particular, exert controlling influences on other organisms in nature which, coincidently, may 
be harmful [or beneficial], directly or indirectly to man”, making the connection that bacteria 
could be targeted and exploited for therapeutic and environmental purposes (Whipps JM, 1988). 
Whipps et al. went on to give one of the first definitions of the microbiome that fits our modern 
understanding despite most recently published microbiome articles citing Nobel laureate and 
microbiologist Joshua Lederberg as responsible for coining the phrase microbiome/microbiota 
in 2001 (Marchesi & Ravel, 2015).  
Excusably, the terms microbiota and microbiome are often used interchangeably, 
however distinct. The microbiome is technically the collection of bacteria and their associated 
genes while microbiota is the bacterial taxa specifically associated with humans (Ursell, 
Metcalf, Parfrey, & Knight, 2012). For simplicity, throughout this text, microbiome and 
microbiota will be used interchangeably. The term microbiome, although broad, naturally 
requires descriptors to properly articulate the niche or location of discussion. The human body 
has distinct microbiomes on each surface including differences between the right and left hand, 
the right and left cornea, and the right and left nares (Fierer, Hamady, Lauber, & Knight, 2008). 
Most frequently mistaken is the societal use of the microbiome as the collection of bacteria in 
our gastrointestinal tract. The microbes in our gastrointestinal tract, labeled as the gut 
microbiome, require more intimate identifiers marking the differences in microbiota present in 
the stomach versus the small intestines versus the large intestine versus the rectum and fecal 
matter. The subsequent data in this text will only cover microbiota within the gut microbiome 




THE GUT MICROBIOME 
 
The human microbiome consists of between one to ten times the number of human cells 
(Sender, Fuchs, & Milo, 2016). Although the number of microbes is debated, the number of 
bacterial genes present in the human gastrointestinal tract has not been; it is estimated there is 
roughly ~150 times the number of bacterial genes present in a single human’s gut compared to 
the total genes in their own genome – totaling ~3.3 million non-redundant microbial genes (Qin 
et al., 2010). At any one moment, there are thought to be an estimated 500-1000 individual 
species of bacteria on the human body (Sender et al., 2016). The question of if humans are more 
bacterial or more human, continues to be a heavily studied. 
The gut microbiome, at a very broad level, is linked to disease including irritable bowel 
syndrome, inflammation, obesity, inflammatory bowel disease, autism, cancer, and behavioral 
mood disorders (Frank et al., 2007; Jiang et al., 2015; Kang et al., 2017; Kostic et al., 2013; 
Ley, Turnbaugh, Klein, & Gordon, 2006; Manichanh et al., 2014; Scher et al., 2013). The 
interplay between how individual microbes or the collection of or community of microbes 
interact with and affect the host begins at birth (Backhed et al., 2015). Initial influences of the 
gut microbiome include vaginal versus cesarean section birth, breast versus formula feeding in 
infancy, and exposure to antibiotics starting at a young age (Backhed et al., 2015; Harmsen et 
al., 2000; Nogacka et al., 2017; Stinson, Payne, & Keelan, 2018). The largest contributing 
factors for most individuals throughout their life are diet, antibiotic and drug exposure, lifestyle 
including pet ownership, and work schedule (Albenberg & Wu, 2014; Gilbert et al., 2018; 
Leone et al., 2015; Maurice, Haiser, & Turnbaugh, 2013; Song et al., 2013). 
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 With every paper that is published on differences in the gut microbiome between one 
group of individuals versus another, the public grows increasingly interested in its impact on 
human health and disease. The gut microbiome is poised to revolutionize how we approach 
nutritional medicine, how we diagnose gastrointestinal illness, and treat metabolic and lifestyle 
diseases.  
 The field of microbiome research, however, is still naïve. Limitations exist in our ability 
to understand the complex interactions that occur between microbe-to-microbe, microbe-to-
microbial community, microbe-to-host, microbial community-to-host, and host-to-microbe or 
host-to-microbial community. Until recently, we were limited to bulk sequencing microbial 
communities, and in humans, limited to sequencing of communities in fecal matter. Differences 
exist, however, throughout the various geographic regions of the gastrointestinal tract. 
Differences that influence scientific conclusions and lead to a mischaracterization of 
microbiome derived phenomena. Due to these limitations, we have taken a different approach 
in this thesis work by specifically designing systems where we can intimately understand the 
physiological and behavioral effects of biogenic amines and short chain fatty acids, produced 











In addition to metabolic disorders and immune modulation, intestinal microbes produce 
a variety of bioactive chemicals that can have important effects on host physiology (Donia & 
Fischbach, 2015). Recent advancements in synthetic biology have led to exciting 
demonstrations of modified gut bacteria that can act as live therapeutics (Riglar & Silver, 2018). 
These engineered microbes can be orally ingested to target various locations along the GI tract, 
where they are programmed to diagnose diseased states (Daeffler et al., 2017; Mao, Cubillos-
Ruiz, Cameron, & Collins, 2018; Mimee et al., 2018; Riglar et al., 2017), prevent infections 
(Saeidi et al., 2011), or produce different metabolites (Chen et al., 2014), enzymes, and 
biologics (Duan, Liu, & March, 2015; Isabella et al., 2018; C. B. Kurtz et al., 2019; Steidler et 
al., 2000) in situ.  
Through the proceeding chapters, an underlying theme resonates. The growth of the 
field of synthetic biology is changing how we approach microbiome research, gastrointestinal 
research, microbiome-directed therapeutics, and gastrointestinal-mediated therapeutics. 
Synthetic Biology, although only recently grown, has roots tracing back to a 1961 publication 
highlighting the lac operon and potential regulatory elements in Escherichia coli. After the 
development of automated DNA sequencing and the completion of the genome sequence of E. 
coli in the 1990s, the first regulatory, synthetic circuits and genetic networks were developed 
between 2000-2002 (Cameron et al., 2014). Organisms, including bacteria and budding yeast, 
are now engineered for multiple purposes including genetic research, biological discovery, 
6 
 
agricultural and biotechnological applications, and as biomedicines, biofuels, and biosensors 
(Sheth et al 2016).  
In 2006, bacteria were first engineered to treat cancer. Since then, multiple laboratories 
have turned towards bacteria in the promise of advanced bacterial therapeutics, bacteria 
designed to treat an underlying disease process in a host. While different bacterial strains have 
been utilized for different purposes and disease sites; Escherichia coli Nissle 1917 has shown 
promise as a bacterial therapeutic for gastrointestinal-mediated illnesses. E. coli Nissle 1917 
was first identified in the gastrointestinal tract of a soldier in World War II who was immune 
to gastrointestinal illnesses during trench warfare. Since that time, E. coli Nissle 1917 has been 
used as a probiotic bacterium in parts of the world. E. coli Nissle 1917 is a unique bacterial 
strain in that it is as easy to engineer as laboratory E. coli and it also temporarily colonizes the 
large intestine of rodent and humans after oral administration.  
The engineering of, investigation of, and administration of E. coli Nissle 1917 to rodents 






Beyond modulating gut homeostasis, intestinal microbes are thought to also participate 
in a bi-directional signaling pathway with the enteric nervous system (ENS) and the central 
nervous system (CNS) along the gut-brain axis. Communication along this axis can be mediated 
through the stimulation of G-protein coupled receptors (GPCRs), hormonal regulation, 
immunomodulatory and neuroactive compounds (Dinan & Cryan, 2017). Indeed, gut bacteria 
are known to biosynthesize various neurotransmitters such as g-aminobutyric acid, dopamine, 
and acetylcholine (Stanaszek, Snell, & O'Neill, 1977; Strandwitz et al., 2019). More recently, 
it has been shown that oral ingestion of certain bacteria in animal models leads to changes in 
host physiology and behavior, implicating a role of these microbes in gut-brain communication 
(Dinan, Stanton, & Cryan, 2013; Kamiya et al., 2006; Lyte, 2013). However, the molecular 
mode of action of these bacteria is generally not known, leaving the mechanistic underpinning 
difficult to ascertain. 
The biogenic monoamine serotonin (5-hydroxytryptamine, 5-HT) is crucial for 
neurotransmission throughout the body and may be playing a role in microbial gut-brain 
communication. There is growing evidence that the gut microbiome can stimulate 
enterochromaffin (EC) cells in the gut to increase serotonin production (Hata et al., 2017; 
Nzakizwanayo et al., 2015; Reigstad et al., 2015; Yano et al., 2015). Up to 95% of the serotonin 
in the body is produced in the gastrointestinal tract (Gershon, 2013; Gershon, Drakontides, & 
Ross, 1965). In the GI tract, serotonin regulates intestinal motility, cell turnover, intestinal 
inflammation, and gastrointestinal homeostasis (Gershon & Tack, 2007; Mawe & Hoffman, 
2013). In the brain, an imbalance in serotonin levels is linked to anxiety and depression (Y. Liu, 
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Zhao, & Guo, 2018). The two pools of serotonin, peripheral and neuronal, are functionally 
separate as 5-HT does not cross the blood-brain barrier, and peripherally gets taken up by 
platelets. In mammals, serotonin is derived from tryptophan (Trp) in a two-step reaction, 
mediated by a tryptophan hydroxylase (TPH) to form the 5-hydroxytryptophan (5-HTP) 
intermediate and then by tryptophan decarboxylase (TDC). Gut microbes are known to 
modulate host serotonin (Yano et al., 2015) and  have been suggested to biosynthesize serotonin 
(Hsu, Johansson, & Donahue, 1986; Shahkolahi & Donahue, 1993), but direct evidence of the 
bacteria and metabolic pathways involved is lacking. In humans, tryptophan hydroxylase is the 
rate-limiting step for 5-HT biosynthesis and is made in two isoforms, TPH1 and TPH2. TPH2 
is produced in neurons across the body while TPH1 is predominately expressed in 
neuroendocrine cells in the gut (Gershon, 2013).  
In Chapter 2, we describe the engineering of E. coli Nissle to biosynthesize serotonin in 
the GI tract. We show in an animal model, for the first time to our knowledge, that engineered 
serotonin-producing bacteria alter animal physiology including changes in GI motility and 
intestinal gene expression. Interestingly, colonic colonization of our engineered bacteria leads 
to emotional behavioral changes reducing anxiety in a stress-inducing environment. This work 
paves the way for further mechanistic studies of serotonergic pathways along the gut-brain axis 





SHORT CHAIN FATTY ACIDS 
 
Dietary intake is also a major contributor of microbiome diversity and homeostasis 
(David et al., 2014). The primary nutrient implicated in shifts in the microbiome and the primary 
nutrient that feeds the microbes in our gastrointestinal tract is fiber. Bacteria in our 
gastrointestinal tract consume non-digestible fiber generating short chain fatty acids; beneficial 
acids used for colonocyte energy production (Clausen & Mortensen, 1995; Ritzhaupt, Ellis, 
Hosie, & Shirazi-Beechey, 1998) and gene regulation (Schilderink et al., 2016). The primary 
short chain fatty acids produced by bacteria in our gastrointestinal tract are butyrate, propionate, 
acetate, and isobutyrate. Butyrate, while not the most abundant, is thought to be the most 
metabolically active and a crucial energy source and regulator of metabolism for colonocytes 
(Litvak, Byndloss, & Baumler, 2018). Butyrate, unlike other SCFAs (acetate, propionate, 
acetate, isobutyrate), simultaneously is used as a form of energy for healthy colonocytes and 
suppresses its own beta-oxidation for colorectal cancer cells through the loss of the short chain 
acyl-CoA dehydrogenase (SCAD) enzyme (A. Han, Bennett, Ahmed, Whelan, & Donohoe, 
2018). Butyrate acts as tumor suppressant by mediating apoptosis and cell cycle arrest of 
cancerous cells (Archer et al., 2005; Davie, 2003; Hinnebusch, Meng, Wu, Archer, & Hodin, 
2002) exerting its function through the inhibition of histone deacetylases and activation of the 
GPR109A receptor (Thangaraju et al., 2009).   
Butyrate also plays a fundamental role in the inflammatory process reducing intestinal 
inflammation by the activation of Foxp3+ regulatory T cells (Arpaia et al., 2013). It improves 
intestinal barrier function (Peng, Li, Green, Holzman, & Lin, 2009; H. B. Wang, Wang, Wang, 
Wan, & Liu, 2012), increases the production of intestinally-derived satiety hormones (Lin et 
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al., 2012), prevents obesity induced metabolic endotoxemia (Cani et al., 2007; Cani et al., 2008; 
Lecomte et al., 2015), and improves the composition of the gut microbiota (Baxter et al., 2019; 
Zhou et al., 2017).  
There is increasing evidence that butyrate may play a role in the prevention or treatment 
of neurodegenerative diseases via the gut-brain axis. Sodium butyrate, through the modulation 
of histone deacetylase, improves oxidative phosphorylation and transcription ameliorating 
neurodegeneration in a Huntington’s disease mouse model (Ferrante et al., 2003). In germ free 
mice, sodium butyrate increases expression of the tight junction proteins along the blood brain 
barrier effecting neuroinflammation (Braniste et al., 2014; Sherry et al., 2010) and maturation 
of microglia in the central nervous system (Erny et al., 2015; Huuskonen, Suuronen, Nuutinen, 
Kyrylenko, & Salminen, 2004; Stilling et al., 2016). 
 Given butyrate’s physiologic importance, we engineered the probiotic strain E. coli 
Nissle to produce butyrate from glucose as a starting substrate, described in Chapter 3. While 
butyrate is a natural byproduct of dietary fiber fermentation, localized delivery to the colon is 
not possible with commercial supplementation or by dietary intake. Localized colonic delivery 
along the mucosal border of the colon is important for maximal efficacy. In establishing a model 
for localized colonic delivery, we utilized the mucosal colonization of E. coli Nissle for targeted 
butyrate delivery. De novo butyrate synthesis from glucose requires two multistep processes: 
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CHAPTER 2:  
BIOGENIC AMINE PRODUCING BACTERIA 
 
Note: In vitro results and strain engineering in chapter 2 are in collaboration with Mareike 
Bongers and Morten O. A. Sommer of Nova Nordisk Foundation Center for Biosustainability, 
Technical University of Denmark. Initial findings were submitted for publication and under 







Serotonin plays an important role in intestinal motility, homeostasis, and 
gastrointestinal function. Moreover, some bacteria can even modulate host serotonin 
production and host neurocognitive functions through signaling pathways along the gut-brain 
axis. Here, we engineer Escherichia coli Nissle to biosynthesize serotonin within the 
mammalian gut. Oral administration of this engineered bacteria to mice resulted in significant 
colonic localization and production of serotonin along the mucosa layer of the colon near the 
epithelial lining. Numerous physiological changes were observed in these mice including 
decreased gastrointestinal motility, increased colonic Muc2 expression, induction of host 
TPH2 mediated serotonin biosynthesis, and upregulation of serotonin receptors HTR3, HTR4, 
and HTR7 in the colon. Furthermore, behavioral tests revealed a statistically significant 
decrease in anxiety in stress-induced environments in mice treated with the engineered 
bacterium. This work suggests that synthetic gut bacteria engineered to modulate the host 
gut-brain axis may have future clinical uses to treat gastrointestinal and behavioral mood 





Beyond modulating gut homeostasis, intestinal microbes are thought to also participate 
in a bi-directional signaling pathway with the enteric nervous system (ENS) and the central 
nervous system (CNS) along the gut-brain axis. Communication along this axis can be mediated 
through the stimulation of G-protein coupled receptors (GPCRs), hormonal regulation, 
immunomodulatory and neuroactive compounds (Dinan & Cryan, 2017). Indeed, gut bacteria 
are known to biosynthesize various neurotransmitters such as g-aminobutyric acid, dopamine, 
and acetylcholine (Stanaszek, Snell, & O'Neill, 1977; Strandwitz et al., 2019). More recently, 
it has been shown that oral ingestion of certain bacteria in animal models leads to changes in 
host physiology and behavior, implicating a role of these microbes in gut-brain communication 
(Dinan, Stanton, & Cryan, 2013; Kamiya et al., 2006; Lyte, 2013). However, the molecular 
mode of action of these bacteria is generally not known, leaving the mechanistic underpinning 
difficult to ascertain. 
The biogenic monoamine serotonin (5-hydroxytryptamine, 5-HT) is crucial for 
neurotransmission throughout the body and may be playing a role in microbial gut-brain 
communication. There is growing evidence that the gut microbiome can stimulate 
enterochromaffin (EC) cells in the gut to increase serotonin production (Hata et al., 2017; 
Nzakizwanayo et al., 2015; Reigstad et al., 2015; Yano et al., 2015). Up to 95% of the serotonin 
in the body is produced in the gastrointestinal tract (Gershon, 2013; Gershon, Drakontides, & 
Ross, 1965). In the GI tract, serotonin regulates intestinal motility, cell turnover, intestinal 
inflammation, and gastrointestinal homeostasis (Gershon & Tack, 2007; Mawe & Hoffman, 
2013). In the brain, an imbalance in serotonin levels is linked to anxiety and depression (Y. Liu, 
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Zhao, & Guo, 2018). The two pools of serotonin, peripheral and neuronal, are functionally 
separate as 5-HT does not cross the blood-brain barrier, and peripherally gets taken up by 
platelets. In mammals, serotonin is derived from tryptophan (Trp) in a two-step reaction, 
mediated by a tryptophan hydroxylase (TPH) to form the 5-hydroxytryptophan (5-HTP) 
intermediate and then by tryptophan decarboxylase (TDC). Gut microbes are known to 
modulate host serotonin (Yano et al., 2015) and  have been suggested to biosynthesize serotonin 
(Hsu, Johansson, & Donahue, 1986; Shahkolahi & Donahue, 1993), but direct evidence of the 
bacteria and metabolic pathways involved is lacking. In humans, tryptophan hydroxylase is the 
rate-limiting step for 5-HT biosynthesis and is made in two isoforms, TPH1 and TPH2. TPH2 
is produced in neurons across the body while TPH1 is predominately expressed in 
neuroendocrine cells in the gut (Gershon, 2013).  
In Chapter 2, we describe the engineering of E. coli Nissle to biosynthesize serotonin in 
the GI tract. We show in an animal model, for the first time to our knowledge, that engineered 
serotonin-producing bacteria alter animal physiology including changes in GI motility and 
intestinal gene expression. Interestingly, colonic colonization of our engineered bacteria leads 
to emotional behavioral changes reducing anxiety in a stress-inducing environment. This work 
paves the way for further mechanistic studies of serotonergic pathways along the gut-brain axis 







Engineering and optimization of serotonin-producing gut bacteria  
 Given serotonin’s physiological importance, we explored the possibility and 
consequence of in vivo production of serotonin by an engineered gut bacterium in the 
gastrointestinal tract (Figure 1). We chose E. coli Nissle (EcN) as the bacterial strain for 5-HT 
pathway engineering because of its long history as a safe probiotic in humans (C. Kurtz et al., 
2018; Sonnenborn, 2016) and its recent use as an engineered live bacterial therapeutic 
(Daeffler et al., 2017; Isabella et al., 2018; C. B. Kurtz et al., 2019; Riglar et al., 2017; Saeidi et 
al., 2011). A serotonin biosynthetic pathway was previously introduced into an E. coli lab 
strain, but use of the plant cytochrome-P450 enzyme tryptamine monooxygenase required 
expression at 20°C and resulted in low 5-HT yields (Park et al., 2011). We therefore 
combinatorially tested different TPH and TDC genes in E. coli Nissle to establish a synthetic 
serotonin pathway from TRP to 5-HTP and then to 5-HT. We found measurable serotonin 
production using the mouse TPH1 (M1) or human TPH2 (H2), in combination with TDC from 
rice (R) or Cataranthus roseus (C) (Figure 2). When the decarboxylation step was tested alone 
by feeding 5-HTP, the enzyme from rice proved superior (79.5±11.1% yield), which led us to 
focus further optimizations on the ‘M1R’ and ‘H2R’ pathways. Since higher availability of TRP 
increased pathway yield (Figure 3), we increased the tryptophan pathway flux by knocking out 
the tryptophan repressor trpR and tryptophanase tnaA in EcN (Zhao et al., 2011) to generate 
the strain NΔ2. 
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To enable efficient and iterative optimization of the synthetic 5-HT pathway, plasmid-
based expression is preferable. However, for in vivo applications, it is undesirable to use 
antibiotic resistance genes for plasmid maintenance and to have the possibility of horizontal 
transfer of resistance-borne plasmids to other resident microbes. To address this challenge, 
we first attempted to stabilize the high copy number 5-HT production plasmid (pUC-H2R) by 
introducing the essential bacterial gene infA into the pathway operon, and then knocking out 
the genomic copy in EcN (Hagg, de Pohl, Abdulkarim, & Isaksson, 2004). While stable, this 
plasmid caused an undesired growth defect in both NΔ2 and NΔ3 (EcN with ΔtrpR, ΔtnaA, 
ΔinfA), likely due to metabolic burden (Figure 4). We therefore explored an alternative 
approach by moving the pathway to one of the two native plasmids in EcN, pMUT1 (Blum-
Oehler et al., 2003).  We found that this plasmid (pMUT-H2R) was stably maintained in NΔ2 
with no detectable fitness defect for at least 100 generations, without antibiotic selection 
(Figure 3, Figure 5). 5-HT production was stable over this period and comparable to pUC-H2R 
titers (Figure 6). To further ensure plasmid stability in vivo, we introduced the hok/sok toxin-
antitoxin module (Gerdes, Gultyaev, Franch, Pedersen, & Mikkelsen, 1997) into subsequent 
version of the pMUT plasmids.  
Plant TDCs can use both TRP and 5-HTP as substrates to generate tryptamine (TRM) 
and 5-HT, respectively (Figure 1). Correspondingly, we observed a significant amount of TRM 
byproduct with all plant TDC variants tested (Figure 2). To further redirect flux from TRM into 
5-HT, we pursued two additional engineering steps. We first sought to improve TPH activity 
by introducing a genomic mutation (T198I) in folE in NΔ2 to improve tetrahydrobiopterin 
cofactor regeneration (Luo, 2017). We then used this optimized base strain (called oN, for 
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‘optimized Nissle’) to test libraries of pathway variants in which we modulated the relative 
expression strength of TPH and TDC using ribosome binding site (RBS) libraries for both the 
‘M1R’ and ‘H2R’ pathways (Figure 7, Figure 8). Ribosome binding sites are regions upstream 
from the start codon that are responsible for ribosome binding during the initiation of 
translation. In the field of synthetic biology, ribosome binding sites can be modified to 
maximize ribosome binding and recruitment initiating translation. We found that a fine 
balance between the two enzymes’ relative activity is needed to reduce tryptamine formation, 
while avoiding accumulation of the reaction intermediate 5-HTP (Figure 9). From the pathways 
with the highest serotonin production, we chose an ‘M1R’ variant (pMUT14-ser) since TPH1 
has a higher reported oxygen-binding capacity than TPH2 (Nielsen et al., 2008; Windahl, 
Boesen, Karlsen, & Christensen, 2009), which is an important consideration in the low-oxygen 
environment of the gut. The final optimized strain (oN14) carrying pMUT14-ser had superior 
performance to all other tested strains, vectors and pathways (Figure 10), producing serotonin 
at near physiologically relevant levels (Figure 11), and was thus used for subsequent in vivo 
animal studies. Since tryptamine is known to modulate serotonergic pathways and activate 
serotonin receptors in the gut (Bhattarai et al., 2018; Ennis, 1982; Takaki, Mawe, Barasch, 
Gershon, & Gershon, 1985), we also built a construct (pMUT11-trm), which lacks the TPH gene 
and thus exclusively produced tryptamine, in order to untangle the effects of the TRM 
byproduct in vivo. A strain with pMUT11-trm (oN11) and a strain with an empty vector (oN9) 
thus served as controls (Figure 12, Figure 13). Finally, a green fluorescent protein (GFP) gene 
was genomically integrated into all three strains to facilitate immunostaining and detection 




Oral delivery of engineered bacteria and in vivo serotonin production  
 To test our engineered strains in vivo, we used 6-week old, conventional C57BL6/J mice 
(Taconic Biosciences). Mice were first cohoused for 7 days to normalize their gut microbiome 
and reduce intra-animal microbiome variation (Methods). Subsequently, they were then 
divided into separate groups and orally gavaged with 109 CFUs of freshly grown cultures of 
oN9, oN11, and oN14, or sterile phosphate-buffered solution (PBS) daily for 10 days (Figure 
14). Twenty-four hours after the last gavage, we measured changes in host physiology, 
collected serum and fecal matter, and sacrificed the mice to acquire intestinal digesta and 
tissues for further analysis. 
 To assess short-term colonization and localization of oN strains along the GI tract, we 
plated the digesta derived from different intestinal regions and quantified the number of GFP-
positive, kanamycin resistant (KanR) colonies (Figure 15). The highest concentration of oN was 
found in the proximal colon at up to 108 CFU/g (Figure 16), localizing along the mucosal layer 
based on visualization by immunohistochemistry with an anti-GFP antibody (Figure 17). In 
contrast, the small intestine had much fewer oN bacteria (<104 CFUs/g) compared to the 
cecum or colon (Figure 18). Therefore, during our 10-day oral administration protocol, the oN 
strains appear to primarily accumulate in the large intestine near the epithelial lining 
compared to other GI regions.  
 We next measured the level of TRP, 5-HTP, 5-HT and TRM in the serum, mucosa-free 
colonic tissues, and feces of the mice by LC-MS. Tryptophan levels were elevated in colon 
tissues and feces, but not in serum, of mice with oN14 only (Figure 19). 5-HT levels were not 
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statistically different in serum and in colonic tissue across cohorts. In contrast, we observed a 
significant increase in fecal 5-HT in mice with oN14 (13.4-fold, p<0.0001 by ANOVA) compared 
to other groups (Figure 20). Tryptamine and 5-HTP levels were below the limit of detection in 
all samples.  
Since 5-HT levels were not elevated in colonic tissues that have been cleaned to 
remove residual digesta, we speculated that serotonin may be more concentrated in the 
mucosal layers where oN strains are observed. To test this hypothesis, we stained for 5-HT in 
whole-paraffin-embedded colonic sections using an anti-serotonin antibody and visualized the 
distribution along the mucosa (Methods). Indeed, we found that serotonin was enriched along 
the mucosal layers specifically in the oN14 group (Figure 21). Taken together, these results 
demonstrate that the engineered oN14 strain produces 5-HT in vivo along the mucosa of the 
murine colon. 
 
Engineered bacteria elicit changes in host gene expression and physiology in the gut 
 We next performed physiological and gene expression measurements in the gut to 
assess possible host responses to bacterially-produced 5-HT after 10 days of oral delivery. We 
first assessed the level of Muc2, which is a prominent oligomeric mucus-forming protein 
secreted by goblet cells along the epithelial lining that provides a physical protective barrier 
for the gut. A decrease in Muc2 production is associated with gut inflammation and increased 
intestinal permeability (Volynets et al., 2016). Quantitative PCR (qPCR) for expression of the 
MUC2 gene in colonic tissues revealed a ~2-fold increase in mice with oN14 compared to 
control groups (p<0.05 by ANOVA) (Figure 22). Correspondingly, immunohistochemical 
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staining of colonic tissue sections with anti-Muc2 antibodies showed a more prominent 
mucosal layer in the oN14 cohort (Figure 23). However, no difference in expression of goblet 
cell markers CDX2 or intestinal stem cell markers BM1 and LGR5 was observed, suggesting 
that Muc2-producing goblet cells and general intestinal turnover are unchanged (Figure 24). 
Since serotonin derived from EC cells can stimulate intestinal inflammation (Gershon, 
2012), we measured inflammation markers IL6, IL1b, NFKb, IL17A, and TNFα by qPCR and 
found no change in their gene expression in colon tissues in oN14-treated mice (Figure 25). 
Hematoxylin and Eosin (H&E) staining of colonic sections further confirmed the lack of 
histopathological changes associated with gut inflammation (Figure 26). Furthermore, we did 
not observe any change in colon length (Figure 27), which is another hallmark of chronic 
intestinal inflammation if found to be shortened.  
To characterize the effect of oN14 on host serotonin biosynthesis and metabolism, we 
assessed gene expression of TPH1 and TPH2, which encode the tryptophan hydroxylase 
isoforms, and SERT, which encodes the serotonin transporter. While no difference was 
observed in expression of TPH1 and SERT, we detected an unexpected 2.8-fold increase in 
TPH2 expression compared to other groups (p<0.001 by ANOVA) specifically in the colon 
(Figure 28). This suggests that bacterially-derived 5-HT may induce TPH2-mediated host 
neuronal 5-HT biosynthesis in the ENS, which has not been previously seen. The oN14 strain 
does not appear to change the total number or size of EC cells (the primary producers of host 
5-HT in the gut) as quantified by qPCR and by immunohistochemistry of the EC cell marker 
chromogranin A (Figure 29). Our engineered strains also did not alter the expression of TJP1, 
TJP2, or OCLN in the colon, which are markers for maintenance of intestinal barrier function 
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(Figure 30). While tryptophan and serotonin metabolism can also affect the kynurenine 
pathway, whose dysfunction is linked to many neurologic and metabolic disorders (Braidy & 
Grant, 2017), we did not find any changes in expression of IDO1, IDO2, and TDO2, which 
encode the rate-limiting enzymes that convert L-tryptophan to N-formylkynurenine (Figure 
31).  
 Serotonin is a ligand for a number of 5-HT receptors, which are GPCRs mediating 
excitatory and inhibitory neurotransmission throughout the ENS, CNS, and the peripheral 
nervous system. Therefore, we characterized the effects of oN strains on gene expression of 
different serotonin receptors in the colon. Expression of HTR1B and HTR1D increased in the 
oN11 and oN14 cohorts (Figure 32), suggesting a possible tryptamine-mediated effect. 
Although not much is known about the 5HTr1b receptor in the gut, its activation has been 
linked to aggressive phenotypes and depression in the CNS (Gasso et al., 2017; New et al., 
2001; Saudou et al., 1994) and, along with 5HTr1d, is the receptor for tryptamine-based 
treatment of migraines (Tepper, Rapoport, & Sheftell, 2002). We also observed upregulation 
of HTR3, HTR4 and HTR7 in the oN14 cohort only (Figure 33), indicating a specific serotonin-
mediated response. The 5HTr3 receptor has a wide variety of physiological roles, implicated 
in emesis, irritable bowel syndrome (IBS), schizophrenia, anxiety, learning, memory and 
addiction, and is modulated clinically by antiemetic 5HTr3 antagonists (Emesis in anti-cancer 
therapy : mechanisms and treatment, 1993; Thompson & Lummis, 2007). The 5HTr4 receptor 
induces neurogenesis in the enteric nervous system, and is linked to modulation of peristalsis 
in the GI tract, stress-induced feeding behavior, and altered learning and memory, and 
depression in the CNS (Compan et al., 2004; Gershon & Liu, 2007; Kadowaki, Wade, & 
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Gershon, 1996; Lamirault & Simon, 2001; Lucas et al., 2007; Tuladhar, Costall, & Naylor, 1996). 
While 5HTr7 stimulation can improve cognition and memory and 5HTr7 antagonism can 
resolve anti-depressive and anti-psychotic behaviors in the CNS (Roth et al., 1994), its function 
in the gut is not well understood although it has been implicated in irritable bowel syndrome 
and inflammatory bowel disease (IBD) (Abbas et al., 2009; Kim & Khan, 2014).  
The diversity and magnitude of changes in gene expression of 5-HT receptors suggests 
that oN14 may be eliciting physiological responses in the host. Indeed, serotonin is known to 
modulate GI motility by inducing both intraluminal pressure to cause peristaltic reflex and the 
colonic migrating motor complexes that sweep through the intestine during intervals of 
fasting (Fida, Bywater, Lyster, & Taylor, 2000; Gershon, 2005). Interestingly, we found that 
oN14 specifically decreased total GI transit time by as much as 15% (p<0.05 by ANOVA) 
compared to control cohorts (Figure 34). While 5-HT is known to stimulate peristalsis and 
regulate gastrointestinal motility, the decrease in motility is likely from long-term over-
stimulation and continuous 5-HT production by oN14. These motility effects were not seen in 
a separate experiment at 5 days of administration indicating a time-dependent 
pharmacokinetic response. Since changes in gut motility and bacterially-produced biogenic 
amines might affect the gut microbiome (Kwon et al., 2019), we performed 16S ribosomal 
sequencing on fecal matter across the four animal cohorts at Day 0 and Day 11 (Methods). 
However, no significant changes in the gut microbiome were observed between cohorts from 
Day 0 to Day 11 (Figure 35). Together, these results highlight that our engineered bacteria 
elicit a myriad of changes in the gut, including host gene expression and GI motility, while 




Serotonin-producing bacteria alter anxiety profiles in mice 
To explore potential host changes mediated through the gut-brain axis, we performed 
behavioral studies using the same set of oN strains. Previous animal studies have shown that 
some probiotic bacteria could reduce anxiety and depression during behavioral tests (Bravo 
et al., 2011). We thus employed two well-established methods, the forced swim test (FST) 
(Can, 2012) and the open field test (OFT) (Seibenhener, 2015) to study possible behavioral 
changes in mice colonized with oN strains. The FST, commonly used to assess efficacy of 
anxiolytics and anti-depressants in rodents, quantifies behavioral despair by recording the 
time spent immobile in a water-filled container as a measure of hopelessness to escape the 
stressful environment. Using this test, we found that mice given oN14 had statistically reduced 
immobility time during FST by up to 17% (p=0.0040 by ANOVA) compared to control oN 
cohorts (Figure 36). This result could be robustly replicated in a separate and independent 
animal cohort (Figure 37). The OFT measures anxiety levels and willingness to explore in a 
stressful environment by detecting total fecal boli, total distance traveled, and time spent 
exploring the inner and outer zones of a 50x50cm white, well-lit, open field. Mice given oN14 
showed a decreased number of fecal boli during the ten-minute test (Figure 38), which could 
be associated with reduced stress or the decreased total GI transit (Figure 34). While wild-
type mice naturally prefer closed, dark, tight spaces, mice given oN14 showed increased time 
spent exploring the inner 40x40cm zone and decreased time spent near the edges along the 
10x10cm outer zone, with no change in total distance traveled (Figure 39).  
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This test was also repeated on another cohort of mice, which confirmed the effect of 
the oN14-treated mice on a different cohort (Figure 40). We further performed additional 
animal studies on mice obtained from a different commercial vendor (Jackson Laboratory) to 
assess the impact of different initial gut microbiota on our observations. Initial studies, as seen 
above, used mice from Taconic laboratories; a breeding facility where mice have a less diverse 
microbial community. Jackson Laboratory studies confirmed the effects on oN14 when we 
found similar physiological and behavioral results as before. Mice from Jackson laboratories 
naturally have a reduced total gastrointestinal transit time so while we did not see as 
prominent results on TGIT testing and fecal boli testing during the open field test (Figure 41), 
we did see similar results in the behavioral components of the open field test. oN14 treated 
mice spent more time in the inner zone, entered the inner zone more, and moved more in the 
inner zone compared to mice gavaged control strains (Figure 42).  
While initial experiments focused on a 10-day protocol, we sought to understand the 
implications of long-term administration and if there were observable effects at earlier time 
points. At 5 days, we saw no change in Total GI Transit and insignificant changes in total fecal 
boli defecated on the open field test (Figure 43). We saw no change in total distance covered, 
time spent in inner zone, entries into the inner zone, or the distance traveled in the inner zone 
between groups at 5 days (Figure 44). These results reveal that oN14’s effect on motility and 
behavior likely occur from long-term administration. At 30 days of administration, we also 
checked oN14’s effect on colon length, a marker of inflammation, mouse weight, as serotonin 
is known to effect weight loss (Melasch et al., 2016), and fecal boli defecated during the open 
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field test. We saw no change in colon length confirming a lack of effect of oN14 produced 
serotonin on inflammation (Figure 45). On H&E staining, we saw no pathological findings or 
signs of inflammation of mice treated with oN14 but possible differences in mice treated with 
oN11, although these results were not relevant for our overall hypothesis (Figure 46). As 
serotonin is thought to play a role in weight loss and the serotonin-hypothalamic 
neurobiological mechanism linking obesity to emotional distress (Melasch et al., 2016), we 
looked at the weights of mice after 30 days. We found an insignificant reduction in mouse 
weight of mice fed oN14 (p = 0.0526, ANOVA) (Figure 45). As opposed to what we found at 
day 10, we found no change in fecal boli defecated at day 30 of mice administered oN14. After 
30 days, open field-testing data confirmed the findings that there is an increased time spent 
in the inner zone (Figure 47), however the oN14 group was only significantly different than 
mice treated with oN11. More strikingly, oN11 saw a nonsignificant decrease in time spent in 
the inner zone.  
As selective serotonin reuptake inhibitors are serotonergic modulators that effect 
anxiety and depression, we compared our serotonin producing strain oN14 to the SSRI, 
Fluoxetine. Fluoxetine’s results in the open field have been somewhat varied over the years 
with major differences between the gender of the animals used and the age of the animals 
used (Jin et al., 2017). SSRI’s are delivered by intraperitoneal (I.P.) so as a control, all mice, 
received either saline or fluoxetine at 10mg/kg in saline I.P. injections. As our strains are 
administered via oral gavage, all mice were fed either PBS or oN14 in PBS by oral gavage. While 
our previous findings were seen in 10 days, for the comparison with fluoxetine, we used the 
standard SSRI protocol of 21 days. We tested four groups: a negative control (IP: 
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saline/Gavage: PBS), a SSRI positive control (IP: Fluoxetine/Gavage: PBS), oN14 positive 
control (IP: saline/Gavage: oN14), and then the combination of both to see if oN14 provides 
any added benefits to SSRI treatment (IP: Fluoxetine/Gavage: oN14). After 21 days, oN14 
treated mice showed similar effects on time spent in the inner zone, entries in the inner zone, 
and distance in the inner zone as compared to mice treated with Fluoxetine (Figure 48). The 
combination of treatment with oN14 and treatment with fluoxetine yielded a small reduction 
in the total effect when compared to the individual groups treated with only oN14 or 
fluoxetine. 
As behavioral experiments can be location and lab specific, we worked with Columbia 
counterparts at the Mouse NeuroBehavior Core to test the effects of oN14 in a different 
facility, with different equipment, in an independent lab. We first tested a negative control 
open field test using a low-stress exploratory open field-testing protocol. While many of these 
behavioral studies focused on anxiety as a read out, many are masked by willingness to 
explore with anxiety. The OFT at the NeuroBehavior Core utilizes a low stress, quiet, dark room 
at ~30 lux to test exploration in a covered 30x30x18cm box for 10 minutes. We tested mice 
treated with oN9 and oN14 and found that there was no change in fecal boli defecated, total 
distance, distance in the inner zone, or time spent in the inner zone (Figure 49). The only 
positive findings we did see was a statistically increased number of vertical explorations in 
mice fed oN14. These results show us that the differences we found in our stress induced 
protocol were not found from changes in willingness to explore a new environment. These 
differences in open field testing highlights that behavior is a response to stimuli. In the 
absence of a stressful stimuli, serotonin may play a different role in exploratory behavior when 
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introduced to a novel environment. Lastly, we also explored differences in mice in the Acoustic 
Startle test at the NeuroBehavioral core. As previously published with rodents younger than 9 
weeks treated with fluoxetine or with rats treated with paroxetine (Amodeo et al., 2015; 
Homberg et al., 2011; Oh, Zupan, Gross, & Toth, 2009), we saw increased response measured 
by vMax of pulse intensities above 100db with the only significant differences seen at 120db 
intensity (Figure 50). Additional studies are currently being done to explore additional 
behavioral differences between mice treated with oN14 versus control stains. Together these 
findings provide the first evidence to suggest that an engineered serotonin-producing 







In this chapter, we established a direct connection between biogenic amine production 
and the gut microbiota. In designing a novel way to engineer E. coli Nissle 1917, we developed 
a platform that can be used for future research underlying the role bacterial produced 
metabolites play on the host gastrointestinal system and enteric nervous system. 
We established a potentially novel connection along the gut-brain axis by engineering 
a serotonin-producing bacterium (oN14). This oN14 strain could populate the murine large 
intestine to a sufficient density to increase the amount of 5-HT accumulated along the mucosal 
layers. While we did not observe any increase of 5-HT in the serum or in colonic tissues cleaned 
of mucosa, it is perhaps not surprising given that no serotonin transporter is known to be 
present in intestinal epithelial cells and the charged serotonin molecules otherwise cannot 
freely cross the intestinal lining by natural diffusion. Nevertheless, oN14 induced higher 
expression of serotonin receptors 5HTr3, 5HTr4 and 5HTr7 in the colon, which may be 
participating in the physiological changes observed. Indeed, 5HTr4 is found on the apical side 
of epithelial cells in the GI tract (Hoffman et al., 2012; Spohn et al., 2016) and could thus be 
activated by oN14-derived serotonin in the mucosa. Increased expression of these serotonin 
receptors can be explained by feedback regulation of consistent activation or reciprocal 
binding through a different receptor mediated response. Elevated 5-HT levels in the colon led 
to upregulation of MUC2 and increased mucosal thickening, as well as induction of TPH2. 
MUC2 upregulation may occur through the activation of a 5-HT mediated goblet cell activation 
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as goblet cells are known to harbor 5HTR4 receptors which promote Muc2 production through 
Trefoil factor 3 release and CXCR4 promotion of goblet cell actin cytoskeleton re-arrangement 
(Engevik et al 2019). The increase in TPH2 was likely mediated through 5HTR4 mediated 
activation of the enteric nervous system; known to activate the ENS and induce neurogenesis 
and neuronal migration and maturation (Shajib et al 2017). On the other hand, tryptamine 
produced from oN11 and oN14 did not exhibit any measurable changes in host physiology or 
behavior but did increase gene expression of serotonin receptors 5HTr1b and 5HTr1d in the 
gut. Interestingly, our tryptamine-mediated effects differed from a previous study (Bhattarai 
et al., 2018), but direct comparisons cannot be made since a different study design (e.g. single 
dose, shorter-term assays) and different gut bacterium (a Bacteroides that colonizes intestinal 
crypts (Curtis et al., 2014)) was used. Nevertheless, our findings here, along with the emerging 
literature (Duan, Liu, & March, 2015; Isabella et al., 2018; C. B. Kurtz et al., 2019; Riglar et al., 
2017; Saeidi et al., 2011), highlight the potential for engineering gut bacteria for both basic 
research and translational applications. Limitations of this work include our limited 
understanding of local 5-HT measurement and the measurement of 5-HT in Enterochromaffin 
cells and enteric neurons. Future experiments require careful ENS dissection and 
immunostaining to identify potential pools of enteric 5-HT and if the increase in THP2 
correlates with an increase neuronal 5-HT production. 
We expect that future studies using this serotonin-producing bacterium could better 
delineate the role of gut serotonin in modulating host physiology, behavior, and neurological 
changes, and its relationship with peripheral and neuronal serotonin. The signaling pathway 
directing the gut-brain connection mediated by serotonin accumulation in the gut also 
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remains to be identified. The specific mechanistic consequences of modulating serotonin 
receptors and other pathways reported in this study, as well as possible other host effects that 
we have not measured, are not known and will require much deeper exploration. It is 
reasonable to infer that oN14 produced serotonin interacts with epithelial cell HTR4 receptors 
eliciting a cascade of downstream effects including modulation of the enteric nervous system. 
In modulation of Muc2 and the mucosal border, oN14 produced serotonin may interact 
directly with luminal facing goblet cells or through secondary activation through the 
serotonergic interaction with the epithelial cells as described above. In the modulation of 
behavior. We did not see typical behavioral changes in a low stress environment, as in the 
open field test designed to measure exploration. In the stress-induced open field test, while 
we do not know why the oN14 strain altered exploration and willingness to explore, it is 
reasonable to infer that oN14 desensitized the anxiolytic response to stressful stimuli.  
The use of engineered bacteria that localize to defined regions of the GI tract can 
improve specificity and efficacy of various pharmacological compounds, especially those that 
are difficult to formulate for oral delivery. For instance, current serotonin modulators and 
therapeutics alter serotonergic signaling through known 5-HT receptors and transporters, but 
they often suffer from systemic side effects such as serotonin syndrome (Ferguson, 2001). Our 
oN14 strain enables targeted colonic delivery of 5-HT, which is otherwise challenging to 
formulate orally due to its short half-life in vivo. Although oral gavage of 5HT is currently being 
tested by other labs, data of the physiological effects of oral administration has not been 
found. Towards clinical translation, it will be important to define the dose, duration, and 
tolerance of our engineered bacterium in humans to achieve therapeutic efficacy for various 
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possible applications to treat intestinal and neurological conditions. Extending our pathway 
engineering strategy to other biogenic amines, neurotransmitters, and gut peptides could 
provide new avenues to study and modulate the gut-brain axis and ultimately expand the 






E. coli Nissle 1917 (Mutaflor®) was purchased from Ardeypharm GmbH, Germany. The 
gene for green fluorescent protein (GFP, GenBank: CAH64882.1) was placed under control of 
a strong, constitutive promoter (Part BBa_J23101, Registry of Standard Biological Parts, 
www.parts.igem.org) and integrated into the genome at the Tn7 attachment site using 
pGRG25 as described previously (McKenzie & Craig, 2006). Knockouts of trpR, tnaA or infA 
were performed using CRISPR/Cas9 as described previously (Mehrer, Incha, Politz, & Pfleger, 
2018). Briefly, a two- plasmid system consisting of an inducible cas9/λ-Red expression plasmid 
and a guide RNA (gRNA) plasmid were used to introduce double-strand breaks at the desired 
genomic loci. gRNAs were designed using CRISPy-web (Blin, Pedersen, Weber, & Lee, 2016) 
after uploading the EcN genome sequence (GenBank: CP007799.1). Templates for 
homologous recombination at the cut site were generated as follows: where available, strains 
with the desired knockouts (ΔtrpR::FRT-kan-FRT or ΔtnaA::FRT-kan-FRT, respectively) from 
the KEIO collection (Baba et al., 2006) were transformed with pSIJ8 (Jensen, Lennen, Herrgard, 
& Nielsen, 2015) and the FLP recombinase gene was induced to remove the kanamycin 
resistance gene. Resulting colonies were screened for kanamycin sensitivity. The ΔtrpR::FRT 
or ΔtnaA::FRT loci were amplified using oligos binding 500 bp up and downstream of the FRT 
site to generate PCR products of approximately 1 kb. For infA, the fragment was generated by 
first amplifying 500 bp upstream and 500 bp downstream of infA from the EcN genome and 
then fusing these 2 fragments using overlap-extension PCR. For the folE(T198I) genomic 
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mutation, the folE gene was amplified in 2 parts, introducing the T198I mutation in the oligos 
used for the overlap-extension PCR. The resulting dsDNA fragments were purified and co-
transformed with the gRNA plasmid to generate markerless gene knockouts or mutations in 
EcN. CRISPR/Cas9 and gRNA expression plasmids were cured from the strains as described 
previously (Mehrer et al., 2018). In the case of infA, plasmid pUC-H2RD which expresses a 
synthetic infA gene (see below) was transformed into NΔ2 before the CRISPR experiment, to 
provide a functional copy of the infA gene for survival. All genome modifications were verified 
using Sanger sequencing.  
 
Serotonin production genes and plasmids 
Genes and plasmids used in this study are listed below. Genes for serotonin production 
were selected from mammalian or plant protein sequences, codon-optimized for E. coli using 
the online tool from IDT (idtdna.com/CodonOpt), and synthesized by GeneArt® 
(ThermoFischer Scientific) or ordered as gBlocks® from Integrated DNA Technologies, Belgium. 
Plasmid pUC-H2R was used as a template for generating the pUC- series of plasmids. The 
pathway operon consisted of promoter BBa_J23107, a TPH gene, a TDC gene, and a synthetic 
copy of the infA gene. Parts of pUC-H2R were amplified and the TPH and/or TDC gene was 
replaced with alternatives using Gibson assembly. 
Plasmid pMUT1 (GenBank: A84793.1) was isolated from wild-type EcN and amplified 
to serve as the pMUT backbone. Elements that could enable plasmid transfer were removed, 
a kanamycin resistance gene and the H2R or M1R operons (without infA) were inserted to 
generate pMUT-H2R or pMUT-M1R, respectively. To generate the plasmid pMUT14-ser, the 
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hok/sok toxin-antitoxin plasmid stability element (GenBank: MK134376, Region 58002-58601) 
was additionally inserted into the pMUT-M1R backbone. The TPH gene was removed from 
pMUT14-ser to generate pMUT11-trm, and both TPH and TDC were removed to make 
pMUT09-ctrl.  
 
Pathway optimization using RBS libraries 
RBS strength libraries were designed using the ‘RBS calculator v1.1’(Salis, Mirsky, & 
Voigt, 2009) choosing library sizes of  4-6 variants for each gene, ranging in theoretical strength 
from 50 to 50000 arbitrary units. Mutations in the RBS were introduced with oligos containing 
degenerate bases and using Gibson assembly (Gibson et al., 2009). Transformants were picked 
randomly and RBSs sequenced after testing the strains’ metabolite production profiles.  
 
In vitro metabolite production  
For metabolite production, strains were grown in a modified M9 medium containing 
1x M9 salts (M6030, Sigma Aldrich), 0.2% (w/v) glucose, 0.1% (w/v) casamino acids (Cat. No. 
C2000, Teknova), 1 mM MgSO4, 50 µM FeCl3, 0.2% (v/v) 2YT medium (containing 1.6 % (w/v) 
tryptone, 1% (w/v) yeast extract, 0.5% (w/v) NaCl), and 50 mg/L of L-tryptophan unless stated 
otherwise. Kanamycin was added at a final concentration of 50 mg/L unless stated otherwise. 
Three single colonies were picked from each strain, grown in 300 µl medium in 96 deep-well 
plates and shaken at 250 rpm at 37°C for 16 hours. The main culture was inoculated by diluting 
this preculture 1:100 into fresh medium, and cells were grown for 24 h under the same 
conditions. Afterwards, the culture supernatant was separated from cells using a 0.2 µm pore 
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size filter, and frozen at -20°C until analysis by LC-MS. All data shown are mean +/- SD from at 
least 3 biological replicates.  
 
Plasmid stability testing 
Six single colonies each were picked from strains NΔ2 + pMUT-H2R, NΔ2 + pUC-H2R, 
NΔ2 + pUC-H2RD and NΔ3 + pUC-H2RD and grown in 300 µl 2YT medium (containing 1.6 % 
(w/v) tryptone, 1% (w/v) yeast extract, 0.5% (w/v) NaCl) without kanamycin in 96 deep-well 
plates and shaken at 250 rpm at 37°C for 24 hours. The optical density (OD630) of the cultures 
was measured and cultures were diluted 1:1000 into fresh medium, and cells were plated on 
LB-Agar plates with and without kanamycin daily, corresponding to approximately 10 
doublings every 24h. Colony forming units on LB-Agar plates +/- kanamycin were counted 
daily. At time points t=0, 50 and 100 generations, cultures were diluted 1:100 into the 
modified M9 medium described above (without kanamycin) and serotonin production was 
measured as described.   
 
Bacterial growth curves  
Cells were grown as described under ‘In vitro metabolite production’ with the 
following modifications: after inoculation of the main culture, 200 µl were transferred into a 
flat-bottom, clear 96-well microtiter plate and the plate sealed with a gas-permeable 
membrane (Z380059, Sigma Aldrich). Growth was recorded using the BioTek™ ELx800 plate 
reader by measuring the optical density at 630nm every 10 minutes. Cultures were grown at 
37°C with 700 rpm orbital shaking.  
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Quantification of metabolites by LC-MS 
Detection of serotonin, tryptamine, tryptophan and 5-HTP were conducted by liquid 
chromatography mass spectrometry (LC-MS) measurements on a Dionex UltiMate 3000 
UHPLC (Fisher Scientific, San Jose, CA) connected to an Orbitrap Fusion Mass Spectrometer 
(Thermo Fisher Scientific, San Jose, CA). The system used an Agilent Zorbax Eclipse Plus C18 
2.1 x 100 mm, 1.8 µm column kept at 35°C. The flow rate was 0.350 mL/min with 0.1% formic 
acid (A) and 0.1% formic acid in acetonitrile (B) as mobile phase. The gradient started as 5% B 
and followed a linear gradient to 35% B over 1.5 min. This solvent composition was held for 
3.5 min after which it was changed immediately to 95% B and held for 1 min. Finally, the 
gradient was changed to 5% B until 6 min. The sample (1 uL) was passed on to the MS equipped 
with a heated electrospray ionization source (HESI) in positive-ion mode with sheath gas set 
to 60 (a.u.), aux gas to 20 (a.u.) and sweep gas to 2 (a.u.). The cone and probe temperature 
were 380°C and 380°C, respectively, and spray voltage was 3500 V. Scan range was 50 to 500 
Da and time between scans was 100 ms. Detection of serotonin (160.07646 ion), tryptamine 
(144.08158 and 161.10775 ions) and tryptophan (205.09785 ion) was conducted in full scan 
whereas the 5-HTP detection was carried out after HCD fragmentation (221.09>162.05553, 
25% HCD CE). Quantification of the compounds was based on calculations from calibration 








All animal experiments were performed in compliance with Columbia University 
Medical Center IACUC protocols AC-AAAV1460. Male mice (C57BL/6) were purchased from 
Taconic Biosciences at 6 weeks of age. Animals were group-housed on a 12-h light:dark cycle 
(lights on from 7:00-19:00) at constant temperature with ad libitum access to food and water 
in a Specific Pathogen Free (SPF) facility. Upon delivery, mice were given 72 hours to adjust to 
new location. Mice then underwent a 7-day, 3-rotation microbiome normalization protocol. 
On day one, three, and five of the normalization protocol, mice were randomly mixed. On day 
6, mice were mixed one last time and separated in their respective cohorts with 2-3 cages per 
cohort with 3-5 mice in each cage, exact numbers depending on experiment. On day seven of 
the microbiome normalization protocol, mice began day zero of the experimental protocols. 
Mice were tagged for identification and housed in groups of 3-5 mice in bottle fed cages, set 
in designated racks, restricted to PI access only, and opened only under a laminar flow hood. 
Fecal samples were collected at day zero of the experimental protocol. Mice were gavaged 
every 24hrs at the same time of day for 10 days. Mice were gavaged 200ul sterile PBS or freshly 
grown 109 cells of oN9, oN11, or oN14 in sterile PBS. 24 hours after the last gavage, fecal 
pellets were collected and mice were either euthanized for serum, intestinal tissue, and 
intraluminal fecal collection or were used for motility or behavioral testing. For intraperitoneal 
injections mice were given sterile saline or 10mg/kg Fluoxetine in between 200-300ul sterile 
saline by 28G, 1ml insulin syringe. Injection location was first cleaned with ethanol in the right 




In vivo metabolite analysis 
Serum, tissue samples, and fecal samples were analyzed for serotonin, 5-
hydroxytrytophan, tryptamine, and tryptophan. For Serum: blood samples were collected via 
the inferior vena cava post euthanasia, samples were mixed 1:1 with 0.9% NaCl, 0.2% Ascorbic 
acid. Samples were kept at room temperature for 10 minutes then placed on ice until 
centrifugation at 2000g for 10 minutes at 4°C. Supernatant was saved for analysis and 
immediately frozen at -20°C. For tissue analysis: colon tissue was weighed and immediately 
frozen on liquid nitrogen after collection and cryofractured using stainless steel microvials 
(Biospec 2007) with a single 6.34 mm stainless steel bead (Biospec 11079635ss) beat for 30s 
in BeadBeater (Biospec 112011). Tissue was then resuspended in 0.9% NaCl, 0.1% Ascorbic 
Acid, centrifuged at 2000g for 10 minutes at 4°C. Supernatant was saved for analysis and 
immediately frozen at -20°C. For fecal samples: samples were weighed, placed in Corning 
Cryovials with 0.5 ml of 0.9% NaCl, 0.1% Ascorbic Acid with 200ml Zirconia/Silica beads 
(Biospec 11079101z) and beat for 5 minutes in BeadBeater at 4°C. Samples were centrifuged 
at 2000g for 10 minutes at 4°C. Supernatant was saved for analysis and immediately frozen at 
-20°C. 
 
Gene expression analysis 
Tissue cryofractured according to the protocol under ‘in vivo metabolite analysis’ 
above. Tissue was then resuspended in Trizol (Invitrogen) according to the instructions of the 
manufacture for RNA isolation. Total RNA was resuspended in 30 µL of RNase-free water. RNA 
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was converted to cDNA with iScript gDNA Clear cDNA synthesis Kit (BioRad 1725035) 
according to manufacture instructions. Quantitative Real Time polymerase chain reaction 
(qPCR) was performed in triplicates in 384 well-plates on Applied Biosystems QuantStudio6 
Flex Real-Time PCR System according to manufacture instructions. Primers used are listed in 
Table 2. Cyclophilin was used as the housekeeping gene. Relative mRNA levels were quantified 
using the DDCτ method. 
 
Immunohistochemistry analysis 
Colon samples were collected and 5mm sections were cut in the mid-colon and fixed 
in either a Methanol-Carnoy (60% Methanol, 30% Chloroform, 10% Acetic Acid) Solution or 
4% Paraformaldehyde (PFA) in Phosphate Buffered Solution (PBS) for 24 hours. Fixed samples 
were then washed three times and stored in 70% ethanol. Samples were kept intact with 
digesta in the lumen, embedded in Paraffin and cut luminally at 4 µm and either prepped for 
Immunohistochemistry or subjected to Hematoxylin and Eosin staining. For 
Immunohistochemistry: PFA fixed slides were used for Serotonin antibody staining and 
Methacarn fixed samples were used for Muc2, Green Fluorescent Protein (GFP), and 
Chromogranin A (CgA) antibody staining. All slides were baked for 2 hours at 57°C, de-
paraffinized in xylene and an ethanol-water gradient, rehydrated, then treated with an 
antigen retrieval solution of 10mM sodium citrate, pH 6.0 for 30 minutes at 90°C. Slides were 
blocked for 30 minutes at room temperature with 5% fetal bovine serum (FBS) in PBS and then 
incubated with primary antibodies at 4°C overnight in 5% FBS in PBS. Slides were washed with 
PBS three times, incubated with secondary antibody for 2 hours at room temperature in PBS, 
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washed three times in PBS, incubated with DAPI (4’,6-diamidino-2-phenylindole) at 10µg/ml 
for 5 minutes, washed three times in PBS and mounted using glycerol. Slides stained with 
primary antibodies pre-conjugated with Alexa fluorophores did not undergo secondary 
antibody staining. Antibodies Used: Anti-GFP rabbit IgG with Alexa Fluor 594 Conjugate (Life 
Technologies A21312). Anti-Muc2 polyclonal rabbit (Santa Cruz Technologies sc-15334). Anti-
Chromagranin A polyclonal rabbit (Abcam ab15160). Anti-Serotonin polyclonal goat (Abcam 
ab66047). Secondary Anti-Rabbit Alexa Fluor 568 (Thermo-Scientific Novex a11011). 
Secondary anti-goat IgG Alexa Fluor 488 (Abcam ab150077). All images were taken with Nikon 
Eclipse Ti2-E Inverted Microscope System. 
 
Total gastrointestinal transit 
Carmine red, which cannot be absorbed from the lumen of the gut, was used to study 
total GI transit time (Kimball, Palmer, D'Andrea, Hornby, & Wade, 2005). A 6% solution of 
carmine red (300 µl; Sigma-Aldrich) suspended in 0.5% methylcellulose (Sigma-Aldrich) was 
administered by gavage through a 21-gauge round-tip feeding needle. The time at which 
gavage took place was recorded as T0. After gavage, fecal pellets were monitored at 10-minute 
intervals for the presence of carmine red. Total GI transit time was considered as the interval 
between T0 and the time of first observance of carmine red in stool.  
 
16S ribosomal sequencing and analysis 
Fecal pellets were collected from mice at Day 0 and Day 10 and immediately stored at 
-20°C until paired-end sequencing. Genomic DNA was extracted from fecal pellets using the 
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Epicenter gram positive kit plus an initial bead beating step with 0.1mm Zirconia beads. PCR 
amplification of the 16S rRNA V4 region and multiplexed barcoding of samples were done in 
accordance with previous protocols (Kozich, Westcott, Baxter, Highlander, & Schloss, 2013). 
The V4 region of the 16S rRNA gene was amplified with 1x NEBNext q5 Hot Start HiFi PCR 
Master Mix using custom primers according to the method from Kozich et al. (Kozich et al., 
2013). Sequencing was done with the Illumina MiSeq system (300V2 kit). Sequenced pair reads 
were prepared using USEARCH v10.0.240_i86osx64. Forward and reverse reads were paired 
and filtered to a minimum length of 240 with maximum expected error of 1. Sequences were 
dereplicated, clustered with minimum cluster size of 2, and mapped to OTUs at 97% identity 
(Edgar, 2013). OTU taxonomy was assigned with the RDP classifier (Wang, Garrity, Tiedje, & 
Cole, 2007). OTU data analysis and visualization preformed using Graphpad Prism and RStudio 
with gglot2 and phyloseq packages. 
 
Behavioral studies 
Forced Swim Test: Each mouse was placed in clear cylindrical tanks (30cm height x 
20cm) with 15cm of water at 23-25°C for 6 minutes and video recorded following previously 
described methods (Can, 2012). Mice were then towel dried and placed under heat lamp 
under dry to prevent hypothermia and then placed back in their original cage. Recordings were 
de-identified and a blinded observer, scored recordings for the time spent immobile during 
the last 4 minutes of the 6-minute test as described by Can et al (Can, 2012).  
Open Field Test: Each mouse was placed in a white, open-roof, well lite, 50 cm (length) 
x 50 cm (width) x 38 cm (height) chamber and video recorded for 10 minutes following 
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previously described methods (Seibenhener, 2015). Mice were then placed back into their 
original cage. Fecal pellets produced during the 10-minute test were counted. Videos were 
then post processed and analyzed using BehaviorCloud as previously described (Seibenhener, 
2015). Mouse tracking software recorded total path of movement of each mouse, total 
distance traveled, time spent in the inner zone defined as the inner 40 cm square and outer 
zone defined as the outer 10 cm border closest to the walls.  
NeuroBehavioral Core Experiments below: 
Open Field test: Each mouse is gently placed in the center of a clear Plexiglas arena (40 
x 40 x 40 cm, Med Associates ENV-510) lit with dim light (~30 lux) and is allowed to ambulate 
freely for 10 mins. Infrared (IR) beams embedded along the X, Y, Z axes of the arena 
automatically track distance moved, horizontal movement, vertical movement, stereotypies, 
and time spent in center area. Top mounted cameras will record additional behaviors such as 
circling and jumping. At the end of the test, the mouse is returned to the home cage and the 
arena is cleaned with 70% ethanol followed by water and wiped dry. 
The open field is often used to detect if a certain compound produces hyper- or hypo-
locomotor effects. The test chambers and all parts that could get in contact with the mice will 
be wiped with RescueTM wipes at the end of the experiment. (Yang et al., 2012) 
Acoustic Startle: Acoustic startle is measured using the SR-Laboratory System (San 
Diego Instruments, San Diego, CA). The equipment consists of a sound attenuating chamber 
with a tubular animal enclosure placed on a platform atop of a piezoelectric accelerometer 
that measures transduced movement (San Diego Instruments). The tubular animal enclosure 
is constructed of clear acrylic and measures about 19 x 7.6 x 7.6-cm, mounted on the load-cell 
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platform. Different sizes of enclosures are available to test mice of different size. The analog 
output of the load cell is amplified and digitized by hardware interfaced to a PC.Test sessions 
begin by placing the mouse in the Plexiglas holding cylinder for a 5-min acclimation period. 
For the next 8 min, each mouse is presented with each of six trial types across six discrete 
blocks of trials, for a total of 36 trials. The intertrial interval is 10–20 s. One trial type measures 
the response to no stimulus (baseline movement). The other five trial types measure startle 
responses to 40 ms sound bursts of 80, 90, 100, 110 or 120 dB. Startle amplitude is measured 
every 1 ms over a 65 ms period beginning at the onset of the startle stimulus. The six trial 
types are presented in pseudorandom order such that each trial type is presented once within 
a block of six trials. The maximum startle amplitude over this sampling period is taken as the 
dependent variable. Background noise level of 70 dB is maintained over the duration of the 
test session. (Yang et al., 2012) 
 
Statistical analysis 
Group means, fold change, standard errors/deviations were calculated in Microsoft 
Excel. For statistical significance, when only two means were compared, Student t-tests were 
performed. When two or more samples were compared ordinary one-way ANOVA with 
Tukey’s post hoc correction was performed with plotted statistical values using ANOVA 
multiple comparisons in Graphpad Prism unless otherwise stated. A value of p<0.05 was 
considered significant and exact ANOVA P values marked accordingly in text and multiple 
comparisons ANOVA P values marked on corresponding figures. Error bars represent standard 
error of the mean, unless otherwise noted.  
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Table 1. Strains, plasmids, and genes used in this study. 
Name Relevant features Source / 
Reference 
N Wild-type E. coli Nissle 1917 (EcN) Ardeypharm 
GmbH 
NΔ2 EcN ΔtrpR,  ΔtnaA, attTn7::GFP this study 
NΔ3 EcN ΔtrpR,  ΔtnaA, ΔinfA,   attTn7::GFP this study 
NΔ2 –pMUT1 EcN ΔtrpR,  ΔtnaA,  attTn7::GFP , cured of pMUT1 this study 
oN EcN ΔtrpR,  ΔtnaA, folE(T198I),  attTn7::GFP , cured of 
pMUT1 
this study 
oN9 oN + pMUT09-ctrl this study 
oN11 oN + pMUT11-trm this study 
oN14 oN + pMUT14-ser this study 
Plasmids    
pUC-H2R PBBa_J23107, human cTPH2 (RBS=5000), rice TDC 
(RBS=10000), infA, pUC backbone 
GeneArt® / 
this study 
pUC-H2Ropt PBBa_J23107, human cTPH2 (RBS=5000), rice TDC 
(RBS=700), infA, pUC backbone 
this study 
pUC-H2RD PBBa_J23107, human cTPH2 (RBS=5000), rice TDC (RBS=50), 
infA, pUC backbone 
this study 
pUC-H1R PBBa_J23107, human cTPH1 (RBS=5000), rice TDC 
(RBS=10000), infA, pUC backbone 
this study 
pUC-M1R PBBa_J23107, mouse cTPH1 (RBS=3700), rice TDC 
(RBS=10000), infA, pUC backbone 
this study 
pUC-M2R PBBa_J23107, mouse cTPH2 (RBS=5000), rice TDC 
(RBS=10000), infA, pUC backbone 
this study 
pUC-H2G PBBa_J23107, human cTPH2 (RBS=10000), guinea pig TDC 
(RBS=xx), infA, pUC backbone 
this study 
pUC-H2C PBBa_J23107, human cTPH2 (RBS=5000), Catharanthus 
roseus TDC (RBS=1000), infA, pUC backbone 
this study 
pMUT-H2R PBBa_J23107, human cTPH2 (RBS=5000), rice TDC 
(RBS=700), pMUT1 backbone 
this study 
pMUT-M1R PBBa_J23107, mouse cTPH1 (RBS=2300), rice TDC 
(RBS=250), pMUT1 backbone 
this study 
pMUT09-ctrl PBBa_J23110, pMUT1 backbone, hok/sok locus this study 
pMUT11-trm PBBa_J23110, rice TDC (RBS=700), pMUT1 backbone,  
hok/sok locus 
this study 
pMUT14-ser PBBa_J23110, mouse THP1 (RBS=18000), rice TDC 
(RBS=700), pMUT1 backbone,  hok/sok locus 
this study 




Table 2. qPCR primers used in this study. 
Gene Forward Primer Reverse Primer 
CYCLO 5’-GACGAAGGTAGCCAGTCACAAG-3’ 5’-AATCAGGCCTGTGGAATGTGAG-3’ 
MUC2 5’-ATGCCCACCTCCTCAAAGAC-3’ 5’- GTAGTTTCCGTTGGAACAGTGAA-3’ 
CDX2 5’-CAAGGACGTGAGCATGTATCC-3’ 5’-GTAACCACCGTAGTCCGGGTA-3’ 
BM1 5’-AAATCCCCACTTAATGTGTGTCC-3’ 5’- CTTGCTGGTCTCCAAGTAACG-3’ 
LGR5 5’-GGACCAGATGCGATACCGC-3’ 5’- CAGAGGCGATGTAGGAGACTG-3’ 
IL6 5’-CTGCAAGAGACTTCCATCCAG-3’ 5’-AGTGGTATAGACAGGTCTGTTGG-3’ 
IL1b 5’- GCAACTGTTCCTGAACTCAACT-3’ 5’-ATCTTTTGGGGTCCGTCAACT-3’ 
NFKb 5’-ATGGCAGACGATGATCCCTAC-3’ 5’-TGTTGACAGTGGTATTTCTGGTG-3’ 
IL17A 5’-TTTAACTCCCTTGGCGCAAAA-3’ 5’- CTTTCCCTCCGCATTGACAC-3’ 
TNFα 5’- CAGGCGGTGCCTATGTCTC-3’ 5’-CGATCACCCCGAAGTTCAGTAG-3’ 
TPH1 5’- AACAAAGACCATTCCTCCGAAAG-3’ 5’- TGTAACAGGCTCACATGATTCTC-3’ 
TPH2 5’-GTGACCCTGAATCCGCCTG-3’ 5’-GGTGCCGTACATGAGGACT-3’ 
SERT 5’- CTCCGCAGTTCCCAGTACAAG-3’ 5’- CACGGCATAGCCAATGACAGA-3’ 
CHGA 5’- CAGGCTACAAAGCGATCCAG-3’ 5’- GCCTCTGTCTTTCCATCTCC-3’ 
TJP1 5’-GCCGCTAAGAGCACAGCAA-3’ 5’-TCCCCACTCTGAAAATGAGGA-3’ 
TJP2 5’- GTTTGCCGTTCAGCAGCTTAG-3’ 5’-CTTCAAAACCTCGGTCGTCAT-3’ 
OCLN 5’-TGAAAGTCCACCTCCTTACAGA-3’ 5’-CCGGATAAAAAGAGTACGCTGG-3’ 
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UniProt ID  
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Figure 1: Overview of engineering of serotonin-producing bacteria.  
Overall study design to engineer a serotonin biosynthetic pathway into E. coli Nissle and to 






Figure 2: In vitro characterization of serotonin-producing variants. 
Characterization of candidate serotonin production pathways from different eukaryotic 
tryptophan hydroxylase (TPH) and tryptophan decarboxylase (TDC) genes. Combinations of 
TPH and TDC genes were expressed from a high copy plasmid in NΔ2. Serotonin (5-HT) 
production was observed with pathways ‘H2R’, ‘H2C’, and ‘M1R’ (left panel). Feeding the 
substrate 5-HTP to TDC showed that all enzymes produced some serotonin, but the ‘R’ enzyme 







Figure 3: Tryptophan concentration effects serotonin production. 
Effect of tryptophan concentration in the medium on 5-HTP, Tryptamine, and 5-HT 







Figure 4: pUC vector induces growth defect in EcN 
Moving the 5-HT pathway from a high copy pUC vector to the native EcN plasmid pMUT1 








Figure 5: Plasmid stability and growth rate of engineered variants. 
Stability of pUC-based and pMUT-based serotonin production plasmids over 100 generations 
of growth without antibiotic selection. At each time point, cells were plated on LB Agar plates 
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+/- kanamycin, and ratios of colonies were calculated (n=6). Growth curves for all key strains 
shown (lower panel). A clear growth defect is visible when combining strain NΔ2, but not 
N(wild-type), with pUC-based 5-HT production plasmids. pMUT-based pathway expression 





Figure 6: pMUT-H2R serotonin production without antibiotic selection. 








Figure 7: RBS binding site controls expression of TPH and TDC. 
Plasmids pMUT-H2R and pMUT-M1R were optimized for serotonin production in oN by 
combinatorially varying the relative expression levels of TPH and TDC. Fermentation products 
of generated strains were analyzed by LC-MS to identify combinations maximizing 5-HT 








Figure 8: RBS optimization influences metabolite production. 
Metabolite production with RBS library from pUC-H2R, generating plasmids pUC-H2Ropt 





Figure 9: RBS optimization for serotonin production. 
Corresponding RBS strengths for ‘H2R’ pathway from (Figure 8) is shown; x-axis TPH, y-axis 








Figure 10: Major variants engineered for optimal 5-HT producing strain. 
Engineering steps to improve serotonin production. From left to right: EcN wild-type + pUC-
H2R produced about 2 mg/L 5-HT, and 25-fold more tryptamine. Knockout of trpR and tnaA 
(NΔ2) further increased tryptamine, but not serotonin production, leading to a ≈60:1 ratio. 
Lowering the RBS for TDC (pUC-H2Ropt) improved this ratio to 6:1. Pathway transfer from a 
pUC to a pMUT1-based plasmid reduced both titers, but serotonin production was recovered 
when introducing a mutation in the folE gene (oN). The highest 5-HT titer (7.8 mg/L +/- 0.4) 
was achieved with plasmid pMUT-M1R, and in strain oN the tryptamine to 5-HT ratio was 







Figure 11: Theoretical intestinal serotonin production. 
Theoretical considerations for required serotonin productivity (P, in mg/L*OD630*h) and 
colonization to achieve physiologically relevant concentrations of around 5-30 mg/L (Liu et al., 
2008) 5-HT in the gut. Underlying assumptions were based on expected bacterial load and the 
surface area of the intestinal tract (Casteleyn, Rekecki, Van der Aa, Simoens, & Van den 






Figure 12: Complete plasmids experimentally used. 
Key plasmid designs used in this study testing in vivo. Figures below using oN9 (pMUT9-ctrl), 





Figure 13: Metabolite production of strains used experimentally. 
Final strains for in vivo testing were derived from oN + pMUT-M1R and show either no (oN9: 
oN + pMUT09-ctrl), tryptamine only (oN11: oN + pMUT11-trm) or serotonin and tryptamine 
(oN14: oN with pMUT14-ser) production in vitro. All data shown are mean values with error 
bars of standard deviation from n=3 biological replicates. 5-HT, 5-hydroxytryptamine 
(serotonin); 5-HTP, 5-hydroxytryptophan; H1, human TPH1; H2, human TPH2; M1, mouse 
TPH1; M2, mouse TPH2; C, cataranthus TDC; G, guinea pig TDC; R, rice TDC; RBS, ribosome 







Figure 14. In vivo bacterial localization and serotonin production in the mice gut.  
Experimental overview of mice studies shown. Overall experiment replicated on five 







Figure 14. In vivo bacterial localization and serotonin production in the mice gut.  
Graphical illustration of the elongated mouse intestines from esophageal hiatus at the 
diaphragm to the rectum. Red markers illustrate locations of sample collection for engineered 




Figure 16: Bacterial density in the proximal colon. 
Concentration of engineered strains in the proximal colon, which is the most densely 
populated region 24 hours after the last gavage. Colonies on LB+kanamycin plates, measured 






Figure 17: Engineered strain localization in the colon by immunohistochemistry.  
Immunohistochemical staining with anti-Green Fluorescent Protein (GFP) antibody in a 








Figure 18: Bacterial density throughout the gastrointestinal tract. 
Bacterial concentration in the Duodenum, Jejunal-ileal junction, cecum, proximal colon, distal 
colon, and fecal matter 24 hours after last gavage. Samples plated on LB Agar plates plus 
kanamycin and colonies counted measured as colony forming units (CFU) per gram of fecal 





Figure 19: Tryptophan concentrations in the serum, colon, and fecal matter. 
Tryptophan concentration measured as mg/L in the serum, mg/g biomass in cleaned 
homogenized colon tissue, mg/g biomass of fecal material. (n=7-8). All p-values shown are 
from one-way ANOVA with Tukey’s post hoc correction for multiple comparison testing. All 
other comparisons not shown were not significant with p>0.05. Data are mean values with 






Figure 20: Serotonin concentration in the serum, colon, and fecal matter. 
Mean serotonin (5-HT), in mg/L in the serum, mg/g biomass in cleaned homogenized colon 
tissue, and mg/g biomass in fecal matter, are shown for each cohort (n=7-8). Error bars are 
the standard error of the mean. All p-values are from one-way ANOVA with Tukey’s post hoc 






Figure 21: Serotonin staining in the colon with oN14 administration. 
Immunohistochemical staining with anti-serotonin antibody in the mid-colon, with a scale bar 





Figure 22. Changes in colonic Muc2 expression by oN14. 
Quantitative Real Time-PCR (RT-PCR) measurements of gene expression of MUC2 in colonic 
tissue measured as relative mRNA by DDCτ (n=6). Error bars are the standard error of the 








Figure 23: Muc2 immunofluorescence with oN14 administration. 







Figure 24: No change in goblet cell or stem cell expression with oN14. 
RT-PCR of CDX2, a marker for goblet cells, and BM1 and LGR5, markers for intestinal stem 
cells, (n=6). Data are mean values with error bars as standard error of the mean. All 





Figure 25: oN14 derived serotonin does not increase colonic inflammation. 
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RT-PCR of known markers for intestinal inflammation including IL6, IL1b, NFKb, IL17A, TNFα, 
(n=6). Data are mean values with error bars as standard error of the mean. All comparisons 





Figure 26: No pathological changes seen on H&E staining in the colon. 







Figure 27: Colon length does not change with oN14 administration. 
Colon length used as measure for chronic inflammation, tissue measured immediately after 
euthanasia, outstretched from proximal colon at cecal-colonic junction to distal colon 5 mm 
before the rectum measured in centimeters. (n=7-8). For bar plots: data are mean values with 
error bars as standard error of the mean. For box plot: center line, mean; box limits, minimum 





Figure 28: oN14 increases TPH2 gene expression. 
Expression of serotonin biosynthesis and transporter genes TPH1, TPH2, and SERT in the colon 
by RT-PCR (n=6). Data are mean values with error bars as standard error of the mean. All p-
values are from one-way ANOVA with Tukey’s post hoc correction for multiple comparison 








Figure 29: oN14 does not affect Chromogranin A+ cells. 
RT-PCR of known neuroendocrine marker, Chromogranin A, CGA (n=6). Enterochromaffin 
cell size measured as CgA positive cells measured as analyzed particles using ImageJ Particle 
Analysis tool limited to cells of physiological relevance at least 5 µm in size and no greater 
than 70 µm in size, (n=75-123) (Ginzberg, Kafri, & Kirschner, 2015). For box plot: center line, 
mean; box limits, set at group standard deviation. Immunohistochemical staining with anti-
CgA antibody in the mid-colon, scale bar is 100µm. Data are mean values with error bars as 




Figure 30: Engineered strains have no effect intestinal barrier gene expression. 
RT-PCR of TJP1 (Tight Junction Protein 1 or ZO-1), TJP2 (Tight Junction Protein 2 or ZO-2), and 
OCLN all measures of intestinal integrity and intestinal permeability, (n=6). Data are mean 







Figure 31: Engineered strains do not alter kynurenine pathway. 
RT-PCR of IDO1, IDO2, and TDO2 the rate limiting enzymes of the Kynurenine pathway, (n=6). 
Data are mean values with error bars as standard error of the mean. All comparisons were not 






Figure 32: Tryptamine mediates increase in HTR1B and HTR1D gene expression 
Expression of 5-HT receptors HTR1B and HTR1D, in the colon by RT-PCR (n=6). Data are mean 
values with error bars as standard error of the mean. All p-values are from one-way ANOVA 
with Tukey’s post hoc correction for multiple comparison testing.  All comparisons not shown 






Figure 33: oN14 derived serotonin increases HTR3, HTR4, HTR7 gene expression 
HTR3, HTR4, and HTR7 in the colon by RT-PCR (n=6). Data are mean values with error bars as 
standard error of the mean. All p-values are from one-way ANOVA with Tukey’s post hoc 







Figure 34: oN14 increases total GI transit time. 
Total gastrointestinal transit time from mouth to anus using a 6% Carmine Red solution 
(Methods) (n=7-8). All p-values shown are from one-way ANOVA with Tukey’s post hoc 
correction for multiple comparison testing. Data are mean values with error bars as standard 







Figure 35. Analysis of composition and diversity of fecal microbiome during in vivo studies.  
(a) Fecal microbiome 16S sequencing phylum level classification of all four groups combined 
at day 0 and at day 11, twenty-four hours after the last gavage. Colors represent the seven 
identified phyla in the samples. Each phyla represents percent relative abundance of the 
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average of (n=8-32 per group) the samples in that group(s) at that time point. Each column 
cumulatively sums to 100% of the total identifiable microbes (b) At the genus level, the 
heatmap represents the average relative abundance of genus found in the fecal matter at 
greater than 0.1% in groups PBS, oN9, oN11, and oN14 at day 11 (n=8 per group). (c) Weighted 
UniFrac distance plotted as a 2D principle component analysis. ANISOM R value of 0.07403 
with insignificance of p=0.155. All data generated using USEARCH and plotted by GraphPad 






Figure 36 Assessment of anxiety in mice with forced swim test.  
Time spent immobile of mice during the last four minutes of a six-minute Forced swim test 
(FST) (n=9-10). Data are mean values with error bars as standard error of the mean. All p-
values are from one-way ANOVA with Tukey’s post hoc correction for multiple comparison 





Figure 37: Forced swim test experimental confirmation with oN14. 
Forced swim test time spent immobile of additional cohort of mice during the last 4 minutes 
of a 6-minute test analyzed by a blinded trained observer, time spent immobile recorded in 
seconds, (n=9-10). Data are mean values with error bars as standard error of the mean. All p-
values are from one-way ANOVA with Tukey’s post hoc correction for multiple comparison 




Figure 38: oN14 decreases stress induced defecation during open field testing. 
Number of fecal pellets (# of fecal boli) produced during 10-minute open field test (OFT) (n=7-
10). Data are mean values with error bars as standard error of the mean. All p-values are from 
one-way ANOVA with Tukey’s post hoc correction for multiple comparison testing. All 







Figure 39: Open Field Test with oN14 administration. 
Average total distance traveled of mice during OFT (n=7-10). Time spent in both the inner 40 
cm x 40 cm zone or outer 10 cm ring during OFT (n=7-10). Representative tracking pattern of 
a single mouse from each cohort. Tracking patterns for all mice are shown in Figure 40. All p-
values shown are from one-way ANOVA with Tukey’s post hoc correction for multiple 
comparison testing. Data are mean values with error bars as standard error of the mean. All 






Figure 40: Complete data and additional parameters for open field testing. 
Average total distance traveled of additional mice cohort in each experimental group 
measured by BehaviorCloud animal tracking software, (n=9-10) and time spent in the 40 cm x 
40 cm inner zone measured by BehaviorCloud animal tracking software, recorded in seconds, 
(n=7-10). Video tracking pattern of each mouse from experimental cohort in Figure 39 
(tracking patterns for each mouse in each group, n=7-10). All p-values shown are from one-
way ANOVA with Tukey’s post hoc correction for multiple comparison testing. All other 
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comparisons not shown were not significant with p>0.05. Data are mean values with error 






Figure 41: No difference in TGIT seen between mice from different vendors. 
Physiological and behavioral findings are also confirmed in mice ordered from Jackson 
Laboratories (original experiments from mice from Taconic Laboratories). Total 
gastrointestinal transit time from mouth to anus using a 6% Carmine Red solution (Methods). 
(n=9-10). Number of fecal boli from mice during open field test (OST) (n=9-10). All p-values 
shown are from one-way ANOVA with Tukey’s post hoc correction for multiple comparison 
testing. All other comparisons not shown were not significant with p>0.05. Data are mean 








Figure 42: No difference in open field test seen between mice from different vendors. 
Average total distance traveled of additional mice cohort in each experimental group 
measured by BehaviorCloud animal tracking software, (n=9-10). Average time spent in the 40 
cm x 40 cm inner zone, number of entries into inner zone, and the total distance traveled in 
inner zone during OFT (n=7-10). All p-values shown are from one-way ANOVA with Tukey’s 
post hoc correction for multiple comparison testing All other comparisons not shown were 
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Figure 43: Total GI transit and stress induced defecation after 5-day administration.  
No change seen in total gastrointestinal transit time after 5 days of bacterial administration 
and non-significant changes seen in stress induced defecation during open field test. All other 
comparisons not shown were not significant with p>0.05. Data are mean values with error 







Figure 44: Open field test results after 5 days of administration.  
No change seen in open field-testing parameters after 5 days of bacterial administration. All 
comparisons were not significant with p>0.05. Data are mean values with error bars as 






Figure 45: Colon length, mouse weight, and stress induced defecation after 30 days of 
administration. 
After 30 days of administration, no change in colon length, mouse weight or stress induced 
defecation. All comparisons were not significant with p>0.05. Data are mean values with error 






Figure 46: H&E of colon after 30day treatment with engineered strains. 
 






Figure 47: Open-Field testing after 30-day administration 
Average time spent in the 40 cm x 40 cm inner zone, number of entries into inner zone, the 
total distance traveled, average distance traveled in the inner zone, and time spent not moving 
during OFT (n=9-10). Average total distance traveled of additional mice cohort in each 
experimental group measured by BehaviorCloud animal tracking software.  All p-values shown 
are from one-way ANOVA with Tukey’s post hoc correction for multiple comparison testing All 
other comparisons not shown were not significant with p>0.05. Data are mean values with 







Figure 48: Open-field testing compared to a current pharmaceutical model 
Total Fecal Boli during 10 minute OFT test. Average time spent in the 40 cm x 40 cm inner 
zone, number of entries into inner zone, the total distance traveled, average distance traveled 
in the inner zone, and time spent not moving during OFT (n=9-10). Average total distance 
traveled of additional mice cohort in each experimental group measured by BehaviorCloud 
animal tracking software. All p-values shown are from one-way ANOVA with Tukey’s post hoc 
correction for multiple comparison testing All other comparisons not shown were not 







Figure 49: Low-stress exploratory open field testing at alternative laboratory. 
We saw no change in exploratory behavior other than vertical explorations (p=0.0111 by 
student’s t-test) in an alternative lab utilizing a low light, laser based, open field test of 
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exploratory space of 30x30x18cm. All comparisons not shown were not significant with 




Figure 50: oN14 treated mice have increased startle reflex. 
Although counterintuitive, these results match previous Acoustic Startle results for young 
mice treated with serotonin selective reuptake inhibitors. There was only a significant 
difference (p=0.0426) measured by 2way ANOVA multiple comparisons between oN9 and 
oN14 treated mice under 120db pulse intensity. On normal Student’s t-test, no change was 
seen. All comparisons not shown were not significant with p>0.05. Data are mean values with 
error bars as standard error of the mean.  






























CHAPTER 3:  
SHORT CHAIN FATTY ACID PRODUCING BACTERIA 
 
Note: In vitro results and strain engineering in chapter 3 are in collaboration with Carlotta 
Ronda, PhD at Columbia University. Partial data collection done in collaboration with Madeline 








 Short chain fatty acids (SCFAs), bacterial bioproducts of dietary fiber fermentation, 
play an important role in intestinal homeostasis, fluid dynamics, inflammation, oxidative stress, 
and intestinal hypersensitivity and motility. Although the relevance and importance of dietary 
fiber is known, in the setting of intestinal inflammation and/or gastrointestinal distress, dietary 
fiber is not the ideal nutritional component to consume for symptom resolution. Insoluble fiber 
frequently causes both bloating and pain in the setting of intestinal inflammation and/or 
gastrointestinal distress. Here, we engineered bacteria to produce exogenous butyrate and other 
SCFAs in the murine gut and characterized the effects of our butyrate-producing bacteria on a 
high-fat diet (Table 1) and DSS-induced colitis model within the colon. Although energetically 
burdensome to produce, our strains produced butyrate in the colon at higher density in an 
actively inflamed colitis model. After 14 days of oral administration, our engineered strain 
(EcN:B) increased the colon length of normal wild-type mice, in high fat fed mice, and in mice 
with recovering and actively inflamed DSS-induced colitis. EcN:B increased mucosal barrier 
thickness, upregulated gene expression of the barrier integrity markers Cldn1, Ocln, Zo1, and 
altered crypt and villus height during inflammation recovery. Furthermore, as butyrate is known 
to induce Foxp3+ Regulatory T cells, we saw a 13.01% percent increase in Foxp3+ cells in the 
colon of mice fed our engineered bacteria. This work suggests that synthetic gut bacteria 
engineered to produce short chain fatty acids may have future clinical uses to treat patients with 
inflammatory bowel disease including Crohn’s and Colitis with future potential to serve as a 






Dietary intake is also a major contributor of microbiome diversity and homeostasis 
(David et al., 2014). The primary nutrient implicated in shifts in the microbiome and the primary 
nutrient that feeds the microbes in our gastrointestinal tract is fiber. Bacteria in our 
gastrointestinal tract consume non-digestible fiber generating short chain fatty acids; beneficial 
acids used for colonocyte energy production (Clausen & Mortensen, 1995; Ritzhaupt, Ellis, 
Hosie, & Shirazi-Beechey, 1998) and gene regulation (Schilderink et al., 2016). The primary 
short chain fatty acids produced by bacteria in our gastrointestinal tract are butyrate, propionate, 
acetate, and isobutyrate. Butyrate, while not the most abundant, is thought to be the most 
metabolically active and a crucial energy source and regulator of metabolism for colonocytes 
(Litvak, Byndloss, & Baumler, 2018). Butyrate, unlike other SCFAs (acetate, propionate, 
acetate, isobutyrate), simultaneously is used as a form of energy for healthy colonocytes and 
suppresses its own beta-oxidation for colorectal cancer cells through the loss of the short chain 
acyl-CoA dehydrogenase (SCAD) enzyme (A. Han, Bennett, Ahmed, Whelan, & Donohoe, 
2018). Butyrate acts as tumor suppressant by mediating apoptosis and cell cycle arrest of 
cancerous cells (Archer et al., 2005; Davie, 2003; Hinnebusch, Meng, Wu, Archer, & Hodin, 
2002) exerting its function through the inhibition of histone deacetylases and activation of the 
GPR109A receptor (Thangaraju et al., 2009).   
Butyrate also plays a fundamental role in the inflammatory process reducing intestinal 
inflammation by the activation of Foxp3+ regulatory T cells (Arpaia et al., 2013). It improves 
intestinal barrier function (Peng, Li, Green, Holzman, & Lin, 2009; H. B. Wang, Wang, Wang, 
Wan, & Liu, 2012), increases the production of intestinally-derived satiety hormones (Lin et 
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al., 2012), prevents obesity induced metabolic endotoxemia (Cani et al., 2007; Cani et al., 2008; 
Lecomte et al., 2015), and improves the composition of the gut microbiota (Baxter et al., 2019; 
Zhou et al., 2017).  
Although our understanding is limited, patients with irritable bowel syndrome and 
inflammatory bowel diseases are both predisposed to and at an increased risk of developing 
psychological conditions including anxiety and depression. Preliminary research even points to 
a connection between short chain fatty acids and anxiety and depression. In 2014, researchers 
discovered that sodium butyrate could serve as an antidepressant improving cognition and 
response to chronic and mild stress (Valvassori et al 2014).  
There is increasing evidence that butyrate may play a role in the prevention or treatment 
of neurodegenerative diseases via the gut-brain axis. Sodium butyrate, through the modulation 
of histone deacetylase, improves oxidative phosphorylation and transcription ameliorating 
neurodegeneration in a Huntington’s disease mouse model (Ferrante et al., 2003). In germ free 
mice, sodium butyrate increases expression of the tight junction proteins along the blood brain 
barrier effecting neuroinflammation (Braniste et al., 2014; Sherry et al., 2010) and maturation 
of microglia in the central nervous system (Erny et al., 2015; Huuskonen, Suuronen, Nuutinen, 
Kyrylenko, & Salminen, 2004; Stilling et al., 2016). 
 Given butyrate’s physiologic importance, we engineered the probiotic strain E. coli 
Nissle to produce butyrate from glucose as a starting substrate, described in Chapter 3. While 
butyrate is a natural byproduct of dietary fiber fermentation, localized delivery to the colon is 
not possible with commercial supplementation or by dietary intake. Localized colonic delivery 
along the mucosal border of the colon is important for maximal efficacy. In establishing a model 
for localized colonic delivery, we utilized the mucosal colonization of E. coli Nissle for targeted 
122 
 
butyrate delivery. De novo butyrate synthesis from glucose requires two multistep processes: 
first glycolysis in the conversion of glucose to Acetyl-CoA followed by butyrate synthesis with 
the conversion of Acetyl-CoA to butyrate through an eight-enzyme process described 
previously (Aboulnaga el et al., 2013). 
In Chapter 3, we describe the engineering of E. coli Nissle to biosynthesize butyrate in 
the GI tract. We show in an animal model, that engineered butyrate-producing bacteria alter 
animal physiology, prevents inflammation and changes the microbial community. Interestingly, 
colonic colonization of our engineered bacteria leads to FoxP3+ regulatory T cell activation in 
the intracolonic lymphocytes minimizing DSS-induced colitis. This work paves the way for 
further clinical studies of butyrate’s ability to modulate inflammation, improve colonic health, 







Engineering and optimization of butyrate-producing gut bacteria 
Given butyrate’s physiological importance, we explored the possibility and 
consequences of modifying a known butyrate biosynthesis pathway for in vivo production by 
an engineered gut bacterium in the gastrointestinal tract (Figure 1). Butyrate is traditionally 
synthesized by beneficial bacteria in the intestinal tract from dietary fiber. Dietary fiber is 
fermented by microbes to produce the short chain fatty acids butyrate, propionate, acetate, and 
isobutyrate (De Filippis et al., 2016). Alternatively, butyrate biosynthesis can occur through a 
two-step process with glucose as the starting substrate. Glucose is first converted to Acetyl-
CoA through the traditional glycolysis pathway (Chaudhry & Varacallo, 2019). Next, Acetyl-
CoA is converted to Butyrate through an eight-enzymatic process with Butyryl-CoA as the 
primary intermediate (Figure 2). In engineering an intestinal bacterium for this biosynthesis 
pathway, we used a previously described pASG vector used to produce butyrate in a laboratory 
adapted Escherichia coli strain with ampicillin resistance (Aboulnaga el et al., 2013). pASG, 
plasmid, is 11029 base pairs where the enzymatic pathway requires induction with 
anhydrotetracycline (Figure 3). In conditions free of tetracycline (tet) or anhydrotetracycline 
(aTC), the tetracycline repressor (tetR) binds the tetracycline operator (tetO) at the promoter 
site blocking transcription of the downstream pathway. In the presence of aTC, Tet dissociates 
the tetracycline repressor from the DNA allowing expression (Gossen & Bujard, 1993). Due to 
the metabolic burden of the butyrate biosynthesis pathway, anhydrotetracycline at 200ng/ml 
induces gene expression. 
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The butyrate synthesis genes in pASG are from clostridium difficile DSM 1296. The 
genes include butyryl-CoA dehydrogenase (bcd2), electron transfer flavoprotein subunit beta 
(etfB2), electron transfer flavoprotein subunit alpha (etfA2), enoyl-CoA dehydratase (crotonase 
- crt2), 3-hydroxybutyryl-CoA dehydrogenase (hbd), acetyl-CoA C-acetyl-transferase (thiolase 
– thiA1), phosphate butyruyl-transferase (pbt), and butyrate kinase (buk) (Figure 4). Each 
gene’s functionality in Escherichia Coli has already been characterized (Aboulnaga el et al., 
2013). 
In establishing a model for localized colonic delivery, we engineered the probiotic strain 
Escherichia coli, E. coli Nissle 1917 (Tradename Mutaflor in Europe) to produce butyrate from 
glucose as a starting substrate. We chose E. coli Nissle (EcN) as the bacterial strain for butyrate 
and short chain fatty acid production because of its long history as a safe probiotic in humans 
(Sonnenborn, 2016) and its recent uses as an engineered live bacterial therapeutic (Isabella et 
al., 2018; Kurtz et al., 2019). First, we modified the strain and introduced the red fluorescent 
protein mRFP1.5 (mCherry) from Discosoma sp (Shaner et al., 2004) (Figure 5) and the 
streptomycin resistance gene from staphylococcus aureus into the genome to identify 
engineered colonies visually on plating, through antibody-directed immunohistochemistry in 
vivo, and with selection on LB+StrepR agar plates.  
 After transformation of EcN with pASG (labeled as EcN:B), we induced butyrate 
synthesis and measured butyrate production by high performance liquid chromatography 
(HPLC). As a control, we also engineered the laboratory strain Escherichia Coli BL21 (BL21_1 
& BL21_2) as the typical strain for protein expression. As oxygen is required for butyrate 
biosynthesis, we tested butyrate production in both aerobic and anaerobic conditions. EcN:B, 
BL21_1, and BL21_2 produced butyrate in the presence of oxygen (Figure 6) with the highest 
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production in BL21_2. In the absence of oxygen, only EcN:B and BL21_1 had measurable 
concentrations of butyrate with slightly higher concentration produced by EcN:B. From these 
data, it is unclear if the limit of butyrate production in anaerobic conditions is from oxygen 
requirements for the biosynthesis production of butyrate or if oxygen-dependent growth of the 
strains is the limiting factor. These results informed that we were ready to move our EcN:B 
strain into an in vivo rodent model. 
 
Oral delivery of engineered bacteria and in vivo butyrate production 
To characterize butyrate production from EcN:B in vivo, we first assessed baseline 
butyrate production in the fecal matter. Rodent chow diets are naturally high in plant 
polysaccharides and we knew that this could mask any measure increase in butyrate production 
from our strains. To ensure we could detect even slight increases in butyrate production, we 
separated our study into 4 groups: chow control diet with EcN:wt (wild-type EcN) or with 
EcN:B and another cohort on a high fat, low carbohydrate diet with EcN:wt (wild-type EcN) or 
with EcN:B.  
After a ten-day protocol administering 109 bacterial cells in sterile PBS, we collected 
fecal matter and cleaned, homogenized colonic tissue and measured butyrate production in both 
mice fed the chow diet and the high fat diet. There was a measurable increase in butyrate 
production in colon tissue and fecal matter of groups gavaged EcN:B (Figure 7). As the other 
major short chain fatty acids, acetate, isobutyrate, and propionate are also physiologically 
relevant and as some are bi-products of the butyrate biosynthesis pathway, we also measured 
their accumulation in the fecal matter and colon tissue. Not only did our strain produce butyrate 
in the colon, it increased the amount of isobutyrate and propionate in the colon of mice fed the 
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high fat diet and increased the amount of propionate in colon tissue of mice fed the chow diet. 
In the fecal matter, EcN:B increased propionate in both the high fat and the chow diet fed mice 
while it only increased the amount of isobutyrate levels in mice fed the chow diet but lowered 
the amount of isobutyrate in mice fed the high fat diet (Figure 8). These results showed we 
could not only produce butyrate in the colon, but also improve the total short chain fatty acid 
profile of the colon. 
As both high fat diets and butyrate are known to effect the fecal microbial composition 
and diversity (Zhou et al., 2017), we collected fecal samples before dietary intervention (high 
fat diet), at day zero of EcN and EcN:B administration, and at day eleven after mice were 
administered the strains for ten days. While, mice from this experiment were not homogenized 
on previously explained normalization protocol (Chapter 2), we still saw noticeable and 
identical changes between cages put on the high fat diet (Figure 9). After 5 days with dietary 
intervention, we then began our probiotic administrative protocol for 10 days. By day 11, we 
found clear differences in the microbial composition plotted by PCoA of weighted UniFrac 
distances (Figure 10). Plotted are the distances for each group at all three timepoints: before 
dietary intervention (BFD), after dietary intervention labeled as normal chow diet (ND) or as 
high fat diet (HFD), and then ND or HFD with EcN:wt or EcN:B gavaged for 10 days. There 
is a significant difference between groups (ANISOM R: 0.658 and P = 0.001) with mice in the 
normal diet cohort receiving EcN:B with the most obvious shift.  
 




As butyrate has been extensively studied on its effects on the gastrointestinal epithelial 
cells and regulatory T cells (Arpaia et al., 2013). We characterized the changes in the 
gastrointestinal tract after 10 days of administration with EcN:B on either a chow diet or high 
fat diet. In this protocol, our dietary intervention was a total of 15 days, with the last 10 days 
where cohorts either received EcN:wt (wildtype strain) or EcN:B (EcN with pASG).  
Colon length is a frequently used measurement of chronic (week(s) to months) colonic 
inflammation. We saw significant increase in colon length between our normal diet EcN mice 
and our normal diet EcN:B cohorts (P = 0.0316, student’s t-test) (Figure 11). Alternatively, this 
could be explained by a reduction in colonic length in our controls. To ensure there were no 
physiological differences between cohorts or changes in inflammation, we looked at 
hematoxylin and eosin (H&E) stained sections of the colon to assess gross changes in the 
pathology on histology (Figure 12) and checked the inflammatory cytokines interleukin 6 (IL6) 
and tumor-necrosis factor alpha (TNFa) by quantitative real rime polymerase chain reaction 
(qPCR) using cyclophilin as a control (Figure 13). There is no clear change in inflammation or 
histology except a potentially thicker mucosal layer between the epithelial border and the 
luminal digesta. On Immunohistochemistry, we confirmed this finding with an anti-Muc2 
antibody showing an increases in Muc2 staining in mice receiving EcN:B (Figure 14). 
Although staining shows a visually thicker mucosal layer, we saw a decrease in Muc2 gene 
expression by qPCR (Figure 15).  
To further assess barrier function, we characterized changes in Claudin1, Occludin, and 
Zona occludin1 – three proteins fundamental for intestinal barrier integrity. We measured an 
increase in gene expression of Claudin1, Occludin, and Zona Occludin1 (Figure 16). In vitro, 
butyrate is known to increase Occludin and Zona occludin-1 in Caco-2 (Peng, Li, Green, 
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Holzman, & Lin, 2009). This increase has been previously explained through butyric activation 
of the G-Protein Coupled Receptor GPR41 (Han et al., 2016; Lin et al., 2012). Lastly, butyrate 
is known to inhibit HDAC3 stimulating retinoic acid and differentially affecting the polycomb 
complex protein BMI-1 (BM1), Leucine Rich Repeat containing G Protein-Coupled receptor 5 
(Lgr5), and chromogranin A (CgA) in neuroendocrine cells (Schilderink et al., 2016; 
Swarovsky, Eissele, Eisenacher, Trautmann, & Arnold, 1994). Our results and the increase of 
Bm1, Lgr5, and CgA show preliminary evidence (Figure 17) that gut bacteria engineered to 
produce butyrate could increase intestinal stemness and chromogranin A expression or 
neuroendocrine cell number. 
 
Engineered bacteria elicit changes in host gene expression and physiology in DSS-induced 
colitis model 
In 1994, Arpai et al showed that butyrate induces Foxp3+ cells, a marker for regulatory 
T cells, in extrathymic tissues including colonic lymph nodes (Arpaia et al., 2013). Regulatory 
T cells play an important role in mediating the inflammatory response in the intestine 
(Josefowicz et al., 2012). As we previously found that engineered EcN resides along the 
mucosal layer of the epithelium in the colon, EcN:B holds the potential to mediate the 
inflammatory response in the colon by targeted butyrate delivery. 
To test this theory, we used a chemical-induced inflammatory model of colitis with 
dextran sulfate sodium (DSS) to characterize both susceptibility and recovery of inflammation 
in mice fed with EcN:B. In chronic colitic models, C57BL/6 mice are fed DSS at 1-5% in water 
for 7 days (Chassaing, Aitken, Malleshappa, & Vijay-Kumar, 2014). As EcN:B requires 
anhydrotetracycline induction, our mice received 2% DSS in 5% sucrose water with 200ng/ml 
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aTC. After microbiome normalization, we seperated mice in 6 groups for three different 14 day 
experimental protocols. Two control arms were fed water, 5% sucrose and 200ng/ml aTC with 
no DSS and gavaged daily with either EcN:wt or EcN:B for fourteen days. Two groups were 
fed 2% DSS, 5% sucrose, and 200ng/ml aTC for the first 7 days then given 7 days to recover 
with only 5% sucrose and 200ng/ml aTC, no DSS, with daily gavages of EcN:wt or EcN:B for 
the full 14 days (PreDSS). The last two groups were pretreated for the first 7 days with EcN:wt 
or EcN:B fed 5% sucrose and 200ng/ml aTC then fed 2% DSS, 5% sucrose and 200ng/ml for 
the last 7 days (PostDSS). Experimental groups were designed to understand the role that 
buytrate plays in the prevention of intestinal inflammation and the role butyrate plays in 
recovery of colitis induction (Figure 18).  
In looking at the 6 groups, our EcN:B butyrate producing strain again had significant 
effects on colonic length and inflammation. EcN:B groups, on average, had colon lengths 1cm 
longer than mice fed EcN (Control: p = 0.0005, PreDSS: p = 0.0003, PostDSS: p = 0.0183, by 
ANOVA multiple comparisons) (Figure 19). While one experiment (labeled CR2) showed 
significant differences, when we combine results from multiple experiments, we only see a 
significant change in the PreDSS mice group fed EcN:B (PreDSS: p=0.0074 by ANOVA 
multiple comparisons). We understand there is debate whether it is appropriate to combine 
results from multiple experiments, but interesting to understand both results as in each 
experiment microbial differences exhist and experimental conditions vary. On H&E staining of 
colon tissue, we see marked inflammation in mice who underwent either the PreDSS or 
PostDSS protocol (Erben et al., 2014). In the control mice, as with the HFD experiment above, 
we see a thicker mucosal border in mice treated with EcN:B (Figure 20). In the preDSS treated 
mice, there is an increased number of visible goblet cells present per villi but no other observible 
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differences. In the post DSS model, we do not see a quantitative improvement in the colon, 
except mice treated with EcN:B have a more cleraly definined epithelial border indicating less 
epithelial cell sloughing and enterocyte shedding, a hallmark of inflammation induced 
coloncyte damage (Erben et al., 2014; Matthijsen et al., 2009). When looking at collapsed 
sections of the proximal colon, without a fecal pellet in the lumen, (Figure 21), there is no 
difference in our control cohorts but we see an increase in crypt height in the recovering PreDSS 
cohort fed EcN:wt compared to mice fed EcN:B. This difference is most likely a response to 
the inflammation during the recovery phase leading to moderate epithelial hyperplasia due to 
an increase in epithelial cell turnover.  In the PostDSS treated mice, there is the presence of 
crypt absesses in the EcN:wt treated mice, not seen in mice treated with EcN:B. 
 On immunohistochemistry to understand changes in the mucosal layer as noted in the 
controls above, we see a stark difference between the presence of Muc2 in the lumen in mice 
who received EcN:wt versus our mice who received EcN:B (Figure 22). These findings are 
consistent with previous research showing butyrate stimulates Muc2 production (Gonzalez et 
al., 2019; Hatayama, Iwashita, Kuwajima, & Abe, 2007; Renes et al., 2002).  
 In understanding the role butyrate plays in accelerating post DSS treatment recovery, 
we looked to the immune system. As butyrate is known to bind GPR41 and increase FoxP3+ 
cells in the colon, we isolated immune cells from the colon after experimentation. Although 
these studies need to be replicated, we are beginning to understand the role butyrate plays in 
the innate immune inflammatory response. Neutrophils are the first immune cells to respond to 
injury, stress, damage, or infection. EcN:B reduced neutrophil levels by roughly 50% in the 
colon in mice on the PostDSS treatment (Figure 23). As neutrophils make up about 50% of the 
white blood cells, their response to injury dictates the downstream inflammatory cascade.  
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Another measure of neutrophil response is Lipocalin-2 (LCN2), a neutrophil gelatinase-
associated lipocalin released during the inflammatory response after ischemia, injury, or 
infection. Measured in the fecal matter, lipocalin-2 is a reliable biomarker for intestinal 
inflammation (Moschen, Adolph, Gerner, Wieser, & Tilg, 2017). In comparing results from our 
3 cohorts, we see a clear decrease in lipocalin-2 levels in mice fed EcN:B in both the PreDSS 
and PostDSS model (Figure24). In the lymphoid lineage, we see a slight increase in Foxp3+ | 
CD4+ regulatory T cells in the control mice receiving EcN:B (Figure 25), although not 
significant, this experiment is currently being replicated to confirm previous findings (Arpaia 
et al., 2013) and opens the door to a EcN:B therapeutic by promoting the formation of T 
regulatory cells.   
 As DSS is known to effect weight where most mice gain weight the first few days of 
DSS treatment then lose 10-20% of their bodyweight starting around day 5 (Kim, Shajib, 
Manocha, & Khan, 2012), we recorded weights for our control mice and our mice in the PreDSS 
and PostDSS cohorts (Figure 26). There was no difference between mice fed EcN:wt in the 
control or PreDSS treatment groups compared to mice gavaged EcN:B. In the PostDSS model, 
by day 14, there was a significant difference between groups. Mice gavaged EcN:B weighed 
roughly 1.5 grams more than the mice in the EcN:wt group (p=0.0087 by student’s t test) 
(Figure 27). 
 Comparing the effects of butyrate on the microbiota in an inflammatory setting we first 
looked at the amount of EcN:wt and EcN:B present in the fecal matter at day 14 measured by 
colony forming units (CFU). As expected, EcN:wt was present at between 10^6 - 10^8 in fecal 
matter of all groups (Figure 28). EcN:B however showed an unconventional density pattern 
across groups in the fecal matter. While we did not check CFU in the colon itself, we saw 
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greater density from Control to PreDSS to PostDSS. EcN:B may preferentially graft at higher 
densities during active inflammation. Alternatively, in healthy tissue EcN:B may be 
concentrated to the mucosal layer and may not be actively expelled in the fecal matter; because 
the 11kb plasmid for butyrate production in EcN creates a strong metabolic burden, it is likely 
that in healthy conditions when competition for nutrients is high, EcN may lose the plasmid. In 
inflammatory conditions when nutrient competition is low because of an overall reduced 
microbial load, EcN:B may retain the plasmid and continue to produce Butyrate. These 
unexpected results can be easily understood by adding a stability element into the plasmid 
design and also plating and measuring engineered bacterial density at different parts of the 
gastrointestinal tract.  
 Looking at the microbial composition with EcN:B treatment with DSS treatment we see 
a shift in the composition with DSS treatment (Figure 29). Plotting weighted unifrac distances 
between samples on a 2-dimentional principle coordinates analysis (PCoA), samples at Day 0 
and control groups gavaged EcN:wt and EcN:B cluster together. In the PreDSS cohorts, they 
also cluster together but separately from controls. PostDSS samples however segregate between 
EcN:wt and EcN:B. Those gavaged EcN:B cluster with the PreDSS cohorts possibly showing 
that butyrate treatment in active DSS alters the microbial composition to a state similar to a 
hypothetical state of recovering colitis. EcN:wt gavaged samples in the PostDSS cohort 
separate separately from all other groups. Between all groups there is a significant difference, 
p=0.001, measured by ANISOM with R: 0.3271.  
 At the phyla level, we see DSS and EcN:wt shift the composition away from primarily 
Firmicutes to a higher abundance of Proteobacteria and Bacteroidetes (Figure 30). EcN:B at 
Day 7 in the PreDSS cohort decreased the abundance of Bacteroidetes and increased the 
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abundance of Proteobacteria to an even higher level. At Day 14 in the Post DSS cohort, EcN:B 
also decreased the abundance of Bacteroidetes and increased the abundance of proteobacteria. 









 In this chapter, we established the therapeutic potential for a butyrate-producing 
advanced bacterial therapeutic. Our strain, EcN:B populated the murine large intestine in an 
inflammatory setting increasing the concentration of butyrate along the mucosa in the fecal 
matter and in cleaned colon tissue. While did not see high concentrations of EcN:B in all groups, 
we saw physiological differences between mice gavaged EcN:B indicating bacterial produced 
butyrate can alter host physiology.  
 One major limitation to our work is that we did not characterize the changes we found 
in the fecal microbiota. The microbiome is known to alter host physiology and community 
differences have been linked to irritable bowel syndrome and inflammatory bowel disease. 
Many of the physiological effects we found, may have been a consequence of microbial 
community changes observed by 16S sequencing. Future work should seek to understand if the 
effects on the host were caused by butyrate itself or changes in the microbial community. With 
such prominent differences, it is important to understand which genus are most effected and if 
they themselves, can recapitulate any of the physiological findings we saw. Identifying other 
beneficial microbes could help us understand how individual bacteria communicate with and 
effect host physiology. 
 While future efforts will likely look at the mechanism of action of our Butyrate 
producing strain, initial findings by qPCR highlight and confirm results previously seen. 
Butyrate is known to not only increase the expression of proteins found in the mucosal layer, 
but also strengthen intestinal permeability by upregulating expression of epithelial barrier 
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proteins. We saw an increase in Muc2 on immunohistochemistry and gene expression changes 
in Zona Occludin-1, Occludin, and Claudin-1 confirming previous results. 
 Most intriguingly are the differences seen in colon length in not only our experimental 
models, but also our control mice. While butyrate is known to increase the health and 
metabolism of the colon, no one has shown, to our knowledge, that butyrate can increase the 
length of the colon in a rodent model.  
 Lastly, if EcN:B is indeed activating FoxP3+ regulatory T cells and reducing the innate 
immune response by neutrophil activation, EcN:B could serve as a potent prophylaxis and 
treatment for those suffering with inflammatory bowel disease.  
 Towards clinical translation, it will be important to re-engineer the strain to 
constitutively produce butyrate.  We will need to define the dose, duration and tolerance of the 
strain to achieve therapeutic efficacy for various applications to treat inflammatory bowel 
disease and possibly neurodegenerative disease with future characterization. Extending our 
pathway engineering strategy to other biogenic amines, neurotransmitters, and gut peptides 
could provide new avenues to study and modulate the gut-brain axis and ultimately expand the 







Animal studies and sample collections.  
All animal experiments were performed in compliance with Columbia University 
Medical Center IACUC protocols. Male mice (C57BL/6) were purchased from Charles River 
Laboratories at 6-8 weeks of age. Animals were group-housed on a 12-h light:dark cycle (lights 
on from 7:00-19:00) at constant temperature with ad libitum access to food and water in a 
Specific Pathogen Free (SPF) facility. Upon delivery, mice were given one week to adjust to 
new location. Mice then underwent a 7-day, 3-rotation microbiome normalization protocol. On 
day one, three, and five of the normalization protocol, mice were randomly mixed. On day 6, 
mice were mixed one last time and separated in their respective cohorts with 2 cages per cohort 
with 1-4 mice in each cage, exact numbers depending on experiment. On day seven of the 
microbiome normalization protocol, mice began day zero of the experimental protocols. Mice 
were tagged for identification and housed in groups of 3-5 mice in bottle fed cages, set in 
designated racks, restricted to PI access only, and opened only under a laminar flow hood. Fecal 
samples were collected, and mice were then orally gavaged every 24hrs at the same time of the 
day. Mice were gavaged 200ul sterile PBS or freshly grown 109 cells of EcN:wt or EcN:B  in 
sterile PBS. 24 hours after the last gavage, fecal pellets were collected, and mice were 
euthanized for intestinal tissue collection. 
 
In vivo metabolite analysis.   
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Tissue samples and fecal samples were analyzed for Butyrate, Acetate, Isobutyrate, and 
Propionate. For tissue analysis: colon tissue was weighed and immediately frozen on liquid 
nitrogen after collection and cryofractured using stainless steel microvials (Biospec 2007) with 
a single 6.34 mm stainless steel bead (Biospec 11079635ss) beat for 30s in BeadBeater (Biospec 
112011). Tissue was then resuspended in HPLC grade water and centrifuged at 2000g for 10 
minutes at 4°C. Supernatant was lypholized and saved for analysis and immediately frozen at -
20°C. For fecal samples: samples were weighed, placed in Corning Cryovials with 500ml 
HPLC grade water with 200ml Zirconia/Silica beads (Biospec 11079101z) and beat for 5 
minutes in BeadBeater at 4°C. Samples were centrifuged at 2000g for 10 minutes at 4°C. 
Supernatant was lypholized and saved for analysis and immediately frozen at -20°C. 
 
Gene expression analysis.  
Tissue cryofractured according to the protocol under ‘in vivo metabolite analysis’ 
above. Tissue was then resuspended in Trizol (Invitrogen) according to the instructions of the 
manufacture for RNA isolation. Total RNA was resuspended in 30 µL of RNase-free water. 
RNA was converted to cDNA with iScript gDNA Clear cDNA synthesis Kit (BioRad 1725035) 
according to manufacture instructions. Quantitative Real Time polymerase chain reaction 
(qPCR) was performed in triplicates in 384 well-plates on Applied Biosystems QuantStudio6 
Flex Real-Time PCR System according to manufacture instructions. Primers used are listed in 
Table 2. Cyclophilin was used as the housekeeping gene. Relative mRNA levels were 





Immunohistochemistry analysis.  
Colon samples were collected and 5mm sections were cut in the mid-colon and fixed in 
a Methanol-Carnoy (60% Methanol, 30% Chloroform, 10% Acetic Acid) Solution for 24 hours. 
Fixed samples were then washed three times and stored in 70% ethanol. Samples were kept 
intact with digesta in the lumen, embedded in Paraffin and cut luminally at 4 µm and either 
prepped for Immunohistochemistry or subjected to Hematoxylin and Eosin staining. For 
Immunohistochemistry: All slides were baked for 2 hours at 57°C, de-paraffinized in xylene 
and an ethanol-water gradient, rehydrated, then treated with an antigen retrieval solution of 
10mM sodium citrate, pH 6.0 for 30 minutes at 90°C. Slides were blocked for 30 minutes at 
room temperature with 5% fetal bovine serum (FBS) in PBS and then incubated with primary 
antibodies at 4°C overnight in 5% FBS in PBS. Slides were washed with PBS three times, 
incubated with secondary antibody for 2 hours at room temperature in PBS, washed three times 
in PBS, incubated with DAPI (4’,6-diamidino-2-phenylindole) at 10µg/ml for 5 minutes, 
washed three times in PBS and mounted using glycerol. Slides stained with primary antibodies 
pre-conjugated with Alexa fluorophores did not undergo secondary antibody staining. 
Antibodies Used: Anti-Muc2 polyclonal rabbit (Santa Cruz Technologies sc-15334). Secondary 
Anti-Rabbit Alexa Fluor 568 (Thermo-Scientific Novex a11011). All images were taken with 
Nikon Eclipse Ti2-E Inverted Microscope System, image conversion and cell size (particle) 
analysis performed using NIS-Elements, Advanced Research Software and ImageJ (FIJI) for 






16S sequencing and analysis.  
Fecal pellets were collected from mice at Day -5, 0 and Day 11 and Day 14 and 
immediately stored at -20°C until paired-end sequencing. Genomic DNA was extracted from 
fecal pellets using the Epicenter gram positive kit plus an initial bead beating step with 0.1mm 
Zirconia beads. PCR amplification of the 16S rRNA V4 region and multiplexed barcoding of 
samples were done in accordance with previous protocols (Kozich, Westcott, Baxter, 
Highlander, & Schloss, 2013). The V4 region of the 16S rRNA gene was amplified with 1x 
NEBNext q5 Hot Start HiFi PCR Master Mix using custom primers according to the method 
from Kozich et al.(Kozich et al., 2013). Sequencing was done with the Illumina MiSeq system 
(300V2 kit). Sequenced pair reads were prepared using USEARCH v10.0.240_i86osx64. 
Forward and reverse reads were paired and filtered to a minimum length of 240 with maximum 
expected error of 1. Sequences were dereplicated, clustered with minimum cluster size of 2, 
and mapped to OTUs at 97% identity (Edgar, 2013). OTU taxonomy was assigned with the 
RDP classifier (Wang, Garrity, Tiedje, & Cole, 2007). Sequences aligned using PyNAST within 
Conda with QIIME1, python 2.7, matplotlib 1.4.3. Tree built with FastTree read with RStudio 
package ape. OTU data analysis and visualization preformed using Graphpad Prism and 
RStudio with gglot2 and phyloseq packages. Statistical significance performed by ANISOM 
using RStudio with phyloseq and vegan packages. 
 
Statistical analysis.  
Group means, fold change, standard errors/deviations were calculated in Microsoft 
Excel. For statistical significance, when two samples were compared, student’s t test was used, 
when more than two samples were compared ordinary one-way ANOVA with Tukey’s post 
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hoc correction was performed with plotted statistical values using ANOVA multiple 
comparisons in Graphpad Prism unless otherwise noted. 16S weighted unifrac distance metric 
significance compared by ANISOM using RStudio with phyloseq and vegan packages. A value 
of p<0.05 was considered significant and all significant P values marked accordingly in text 
and multiple comparisons ANOVA P values marked on corresponding figures. Error bars 





Table 1: High Fat Diet Contents. 
 
Teklad Custom Diet 







Soybean Oil 30 
Cellulose 65.5 
Mineral Mix, AIN-93G-MX (94046) 48 
Calcium Phosphate, dibasic 3.4 
Vitamin Mix, AIN-93-VX (94047) 21 
Choline Bitartrate 3 
Blue Food Color 0.1 
Selected Nutrient Information 





Table 2: Quantitative Real Time PCR Primers. 
 
Gene Forward Primer Reverse Primer 
CYCLO 5’-GACGAAGGTAGCCAGTCACAAG-3’ 5’-AATCAGGCCTGTGGAATGTGAG-3’ 
MUC2 5’-ATGCCCACCTCCTCAAAGAC-3’ 5’- GTAGTTTCCGTTGGAACAGTGAA-3’ 
BM1 5’-AAATCCCCACTTAATGTGTGTCC-3’ 5’- CTTGCTGGTCTCCAAGTAACG-3’ 
LGR5 5’-GGACCAGATGCGATACCGC-3’ 5’- CAGAGGCGATGTAGGAGACTG-3’ 
IL6 5’-CTGCAAGAGACTTCCATCCAG-3’ 5’-AGTGGTATAGACAGGTCTGTTGG-3’ 
TNFα 5’- CAGGCGGTGCCTATGTCTC-3’ 5’-CGATCACCCCGAAGTTCAGTAG-3’ 
CHGA 5’- CAGGCTACAAAGCGATCCAG-3’ 5’- GCCTCTGTCTTTCCATCTCC-3’ 
TJP1 5’-GCCGCTAAGAGCACAGCAA-3’ 5’-TCCCCACTCTGAAAATGAGGA-3’ 
TJP2 5’- GTTTGCCGTTCAGCAGCTTAG-3’ 5’-CTTCAAAACCTCGGTCGTCAT-3’ 
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Figure 1: Butyrate experimental overview. 
Project overview: pASG pathway engineered with aTC induction and Ampicillin resistance 
carries 8 genes needed to convert glucose and Acetyl-CoA to Butyrate. This vector is 
transformed into Escherichia Coli Nissle 1917 engineered to contain an mCherry tag with 
Streptomycin resistance. This new strain EcN:B is then fed to mice and explored as a treatment 






Figure 2: Butyrate biosynthesis from Glucose and Acetyl-CoA. 
Overview of the conversion of Glucose to Butyrate through the intermediates Acetyl-CoA and 
Butyryrl-CoA. This total process requires 8 fully functional enzymes found on the pASG 
plasmid. Other short chain fatty acids like acetate, propionate, and isobutyrate are often formed 




Figure 3: pASG_ButdD construct used in high fat and inflammatory protocols. 
 
The complete pASG_ButD plasmid used in this experiment. This plasmid produces butyrate in 
vitro and in vivo. Butyrate biosynthesis pathway is inducible by anhydrotetracycline.    
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LOCUS       pASG_ButD_wt           11029 bp ds-DNA     circular SYN 
19-FEB-2019 
DEFINITION  synthetic circular DNA. 
   
ACCESSION   urn.local...j-a4unud9 
   
  SOURCE      synthetic DNA construct 
   
  ORGANISM  synthetic DNA construct. 
   
REFERENCE   1  (bases 1 to 11029) 
   
AUTHORS   . 
    
TITLE     Direct 
Submission 
    
OURNAL   Exported Oct 17, 2017 from SnapGene Viewer 
4.0.6 
 
            http://www.snapgene.com 
   
COMMENT     Assemble of: Fragment : 
   
            pE_bcdABC.rbs_thiA1.rbs3a_Hbd2.rbs_Crt2.rbs_Pbt.rbs3a_Buk : 
Esp3I 
            at 1693 to Esp3I at 9565. Fragment : pASG.wt : Esp3I at 3755 to 
            Esp3I at 3060. Assembled on 14.01.2010. 
  
Name Type Minimum Maximum Length Direction 
buk CDS 9,857 10,932 1,076 forward 
rbs3a misc_feature 9,845 9,850 6 forward 
pbt CDS 8,936 9,834 899 forward 
rbs3a misc_feature 8,924 8,928 5 reverse 
crt2 CDS 8,120 8,914 795 forward 
rbs3a misc_feature 8,108 8,118 11 reverse 
hbd CDS 7,256 8,098 843 forward 
rbs3a misc_feature 7,244 8,118 875 reverse 
thiAI CDS 6,062 7,234 1,173 forward 
rbs3a misc_feature 6,050 6,058 9 reverse 
etfA2 CDS 5,033 6,040 1,008 forward 
rbs3a misc_feature 5,021 6,040 1,020 reverse 
etfB2 CDS 4,217 5,011 795 forward 
rbs3a misc_feature 4,205 5,011 807 reverse 
bcd2 CDS 3,062 4,195 1,134 forward 
tetP promoter 2,939 2,975 37 forward 
tetP misc_feature 2,939 2,975 37 forward 
rep origin rep_origin 2,246 2,835 590 forward 
tetR CDS 1,467 2,091 625 forward 
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Amp CDS 600 1,458 859 forward 
1 misc_feature 1 3,060 3,060 forward 
 
 
Figure 4: pASG_ButD full accession. 
pASG full accession and assembly including the length of each gene. Original construct by 
TransMIT Gesellschaft fuer Technologietransfer mbH published in the Journal of Bacteriology 







MVSKGEEDNM AIIKEFMRFK VHMEGSVNGH EFEIEGEGEG RPYEGTQTAK LKVT
KGGPLP FAWDILSPQF MYGSKAYVKH PADIPDYLKL SFPEGFKWERVMNFEDGGV
V TVTQDSSLQD GEFIYKVKLR GTNFPSDGPV MQKKTMGWEA SSERMYPEDG AL
KGEIKQRL KLKDGGHYDA EVKTTYKAKK PVQLPGAYNVNIKLDITSHN EDYTIVE
QYE RAEGRHSTGG MDELYK 
 
 
Figure 5: mCherry fluorophore for in vivo identification. 
 







Figure 6: In vitro Butyrate measurement in Escherichia Coli Nissle. 
 
In testing butyrate production in vitro, we transformed the pASG_ButD plasmid into both 
Escherichia coli Nissle 1917 and Escherichia coli BL21. Three versions were tested: EcN (later 
called EcN:B), BL21_1, and BL21_2. These three strains were tested without the plasmid 
(control) and with and without oxygen, labeled +/- O2. We found BL21_2 produced the highest 
level of Butyrate in aerobic conditions. In anaerobic conditions, EcN produced the highest 









































































Figure 7: Butyrate concentration in fecal matter and colon with EcN:B. 
 
In testing EcN:wt and EcN:B in a normal chow or high fat diet environment in vivo, we found 
an increase in butyrate in both the fecal matter and colon tissue of mice gavaged EcN:B. 
Butyrate measured by HPLC as mM/g with n=2-3. Groups labeled “+ Butyrate” gavaged with 
EcN:B, all other groups gavaged with EcN:wt. ND=Normal Diet. HFD=High Fat Diet. Tissue 














































































Figure 8: Short chain fatty acid in normal or high fat diet with EcN:B. 
 
Short Chain Fatty Acid Panel: In testing EcN:wt and EcN:B in a normal chow or high fat diet 
environment in vivo, we found an increase in butyrate and other short chain fatty acids in both 
the fecal matter and colon tissue of mice gavaged EcN:B. Short chain fatty acids measured by 
HPLC as mM/g with n=2-3. Groups labeled “+ Butyrate” gavaged with EcN:B, all other groups 





















































































Figure 9: Microbial changes in the fecal microbiome after High Fat Diet. 
 
Metagenomic 16S sequencing results looking at genus level changes in the fecal microbiome 
of mice put on a high fat diet or kept on the same normal chow diet for 5 days. On the left, BFD 
refers to the two groups of mice before dietary intervention. On the right, HFD refers to mice 
put on a high fat diet for 5 days, or ND, were kept on the normal chow diet. Each row represents 
a different OTU, each column represents a different animal. Heatmap includes OTU’s where at 
least one sample has a relative abundance above 1%. Scale on the right is relative abundance 






Figure 10: 2D-Principle coordinates analysis of Bray Curtis dissimilarity. 
 
Beta Diversity calculated by Bray-Curtis dissimilarity plotted as non-metric multidimensional 
scaling (NMDS). Data includes samples from before dietary change (BFD), 5 days after dietary 
change (HFD & ND), and 11 days after EcN:B and EcN:wt administration as indexed on the 
right with identifying markers for each group. We see clear separation of butyrate samples 
(ND::EcN:B) on the normal diet. All samples in the high fat diet cluster from normal chow 
samples. All data generated using USEARCH and plotted by RStudio as described in the 









Figure 11: Effect of high fat diet and butyrate on colon length. 
Colon length used as measure for chronic inflammation, tissue measured immediately after 
euthanasia, outstretched from proximal colon at cecal-colonic junction to distal colon 5 mm 
before the rectum measured in centimeters. (n=1-3). Statistical significance calculated by 









































Figure 12: H&E sections after dietary intervention and EcN:B administration.  
 
Hematoxylin and Eosin stained section after 15 days with dietary intervention and 10 days of 
probiotic administration. Samples show no clear change in inflammation or histopathology 
except a potentially thicker mucosal layer between the epithelial border and the luminal digesta 






Figure 13: Inflammatory response to high fat diet and EcN:B.  
RT-PCR of interleukin-6 (IL-6) and tumor necrosis factor alpha (TNFa), both proinflammatory 
cytokines with normal diet (ND) and high fat diet (HFD) with EcN:wt or EcN:B. n=1-3. No 
significant differences seen at p>.05 Error bars as standard error of the mean. HFD=high fat 













































































Figure 14: Butyrate upregulates Muc2 in normal and high fat diet. 
 











Figure 15: Gene expression of Muc2 decreases with butyrate from EcN:B. 
 
Gene expression of Muc2 in the colon of mice fed a normal chow diet or a high fat diet gavaged 
with either EcN:wt or EcN:B. n=1-3. No significant differences seen at p>.05 Error bars as 











































Figure 16: Butyrate increases per Occludin, intestinal integrity. 
 
RT-PCR of Claudin-1, Occludin, and Zona Occludin-1 all markers of intestinal barrier with 
normal diet (ND) and high fat diet (HFD) with EcN:wt or EcN:B. n=1-3. There was a significant 
difference between EcN:wt and EcN:B cohorts fed normal chow diet at p=0.0283 by student’s 
t-test. All other comparisons not significant at p>.05 Error bars as standard error of the mean. 















































































































Figure 17: Non-significant changes seen in stemness and neuroendocrine markers. 
RT-PCR of Polycomb complex protein (BM1), Leucine-rich repeat containing G protein-
coupled receptor 5 (Lgr5), and Chromogranin A (CgA) markers for colonic stemness and 
neuroendocrine cells with normal diet (ND) and high fat diet (HFD) with EcN:wt or EcN:B. 
n=1-3. All other comparisons not significant at p>.05 Error bars as standard error of the mean. 

















































































































Figure 18: Inflammatory DSS experimental overview. 
 
Project overview: Mice separated into 6 groups and 3 cohorts, 2 groups within each cohort. A 
control cohort gavaged daily with EcN:wt or EcN:B, PreDSS and PostDSS cohorts fed 2%DSS 









Figure 19: EcN:B reduces colonic shortening from chronic inflammation. 
 
Mice gavaged EcN:B have increased colon lengths, a sign of a reduction in chronic 
inflammation compared to mice gavaged EcN:wt. On a single experiment Cr2 we see 
significant differences between control, PreDSS, and PostDSS cohorts when comparing 
EcN:wt with EcN:B but when we combine results from multiple experiments we only see a 
significant difference in the PreDSS inflammatory model. Colon tissue measured immediately 
after euthanasia, outstretched from proximal colon at cecal-colonic junction to distal colon 5 
mm before the rectum measured in centimeters. (n=6-14). Statistical significance calculated by 



































































































Figure 20: Pathological findings of filled colon tissue with EcN:B. 
H&E staining of the colon revealed subtle differences in the intestinal architecture and 
prominent inflammatory pathology. Particular attention on the thickness of the mucosal layer, 
the number of visible goblet cells, epithelial cell border, and epithelial sloughing and enterocyte 





Figure 21: Pathological findings of collapsed colon tissue with EcN:B. 
H&E staining of the collapsed colon tissue revealed subtle differences in the intestinal 
architecture and prominent inflammatory pathology. Particular attention on crypt height and 





Figure 22: EcN:B administration shows prominent increase in Muc2 in the acute and 
recovery phase of inflammation. 
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EcN:B increases Mucin-2 protein (Muc2) in both PreDSS and PostDSS model seen on 
immunohistochemistry. Red is antibody against Muc2 protein, green is antibody against 
mCherry fluorophore, and blue is nuclear DAPI stain as explained in the methods section. Scale 






Figure 23: EcN:B decreases percentage of neutrophils in the myeloid lineage. 
Althought findings need to be replicated with larger sample number, EcN:B decreases 
percentage of neutrophils in myeloid+ cells, a sign of differences in the innate immune 
response. On the left we see neutrophil gating by flow cytometry. On the right, results from 









Figure 24: Butyrate reduces lipocalin-2. 
 
Mice undergoing inflammatory protocols gavaged daily with EcN:B saw a decrease in total 
lipocalin-2 levels measured in fecal matter at time of euthanasia measured by enzyme-linked 
immunosorbent assay (ELISA). n: 2-4. All comparisons not significant at p>.05 Error bars as 


















































Figure 25: Butyrate activation of CD4+ / FoxP3+  T regulatory cells. 
Although not significant, we see a slight increase in FoxP3+ cells in mice treated with EcN:B 
although data is currently being replicated with larger sample number, this data, if it 
recapitulates the findings of Arpaia et al, lays the ground work for EcN:B as a therapeutic for 







Figure 26: EcN:B does not affect weight loss or weight gain. 
 
EcN:B does not affect weight loss or weight gain in control mice or mice treated in the PreDSS 
model. Given the short duration of this study, no assumption can be made about the long term 





Figure 27: EcN:B decreases weight loss severity in PostDSS model. 
 
Pretreatment with EcN:B decreases total weight loss between day 5 and 7 of DSS-induced 
colitis. P=0.0087 by student’s t-test. Given the short duration of this study, no assumption can 








Figure 28: EcN:B colonization density dependent on inflammatory status. 
 
EcN:wt and EcN:B bacterial density in fecal matter measured as CFU per gram using antibiotic 
selection. Fecal matter collected 24 hours after last gavage, day 14 of protocol. Lower limit of 
detection 10^2 CFU/g. n=4  







Figure 29: 16S Beta-diversity, weighted UniFrac distant metric between samples. 
 
Beta Diversity calculated by weighted UniFrac plotted on a 2-dimensional principle coordinates 
analysis (PCoA). Data includes Day 0 and Day 14 samples. All data generated using 





Figure 30: 16S fecal Phylum level changes at day 0, day 7 and day 14. 
 
Phylum level changes at day 0, day 7 and day 14 of mice treated with EcN:wt and EcN:B. Each 
column represents average phyla composition per group, n=8. All data generated using 









Synthetic biology has expanded our capability to not only understand biology but to 
diagnose and treat human disease. The use of engineered probiotic bacteria or advanced 
bacterial therapeutics in the study of and treatment of human disease is a burgeoning new area 
of scientific exploration poised to expand the resources of researchers and clinicians alike. 
Through the integration of genetic pathways in E. coli Nissle 1917 for metabolite production 
of both biogenic amines and short chain fatty acids, we discovered a novel connection between 
mucosal serotonin and stress induced anxiety and a bacterial-mediated therapeutic for 
inflammatory gastrointestinal illnesses. 
In Chapter 2, we established a direct connection between biogenic amine production 
and the gut microbiota. In designing a novel way to engineer E. coli Nissle 1917, we developed 
a platform that can be used for future research underlying the role bacterial produced 
metabolites play on the host gastrointestinal system and enteric nervous system. 
We established a potentially novel connection along the gut-brain axis by engineering a 
serotonin-producing bacterium (oN14). This oN14 strain could populate the murine large 
intestine to a sufficient density to increase the amount of 5-HT accumulated along the mucosal 
layers. While we did not observe any increase of 5-HT in the serum or in colonic tissues cleaned 
of mucosa, it is perhaps not surprising given that no serotonin transporter is known to be present 
in intestinal epithelial cells and the charged serotonin molecules otherwise cannot freely cross 
the intestinal lining by natural diffusion. Nevertheless, oN14 induced higher expression of 
serotonin receptors 5HTr3, 5HTr4 and 5HTr7 in the colon, which may be participating in the 
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physiological changes observed. Indeed, 5HTr4 is found on the apical side of epithelial cells in 
the GI tract (Hoffman et al., 2012; Spohn et al., 2016) and could thus be activated by oN14-
derived serotonin in the mucosa. Increased expression of these serotonin receptors can be 
explained by feedback regulation of consistent activation or reciprocal binding through a 
different receptor mediated response. Elevated 5-HT levels in the colon led to upregulation of 
MUC2 and increased mucosal thickening, as well as induction of TPH2. MUC2 upregulation 
may occur through the activation of a 5-HT mediated goblet cell activation as goblet cells are 
known to harbor 5HTR4 receptors which promote Muc2 production through Trefoil factor 3 
release and CXCR4 promotion of goblet cell actin cytoskeleton re-arrangement (Engevik et al 
2019). The increase in TPH2 was likely mediated through 5HTR4 mediated activation of the 
enteric nervous system; known to activate the ENS and induce neurogenesis and neuronal 
migration and maturation (Shajib et al 2017). On the other hand, tryptamine produced from 
oN11 and oN14 did not exhibit any measurable changes in host physiology or behavior but did 
increase gene expression of serotonin receptors 5HTr1b and 5HTr1d in the gut. Interestingly, 
our tryptamine-mediated effects differed from a previous study (Bhattarai et al., 2018), but 
direct comparisons cannot be made since a different study design (e.g. single dose, shorter-term 
assays) and different gut bacterium (a Bacteroides that colonizes intestinal crypts (Curtis et al., 
2014)) was used. Nevertheless, our findings here, along with the emerging literature (Duan, 
Liu, & March, 2015; Isabella et al., 2018; C. B. Kurtz et al., 2019; Riglar et al., 2017; Saeidi et 
al., 2011), highlight the potential for engineering gut bacteria for both basic research and 
translational applications. Limitations of this work include our limited understanding of local 
5-HT measurement and the measurement of 5-HT in Enterochromaffin cells and enteric 
neurons. Future experiments require careful ENS dissection and immunostaining to identify 
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potential pools of enteric 5-HT and if the increase in THP2 correlates with an increase neuronal 
5-HT production. 
We expect that future studies using this serotonin-producing bacterium could better 
delineate the role of gut serotonin in modulating host physiology, behavior, and neurological 
changes, and its relationship with peripheral and neuronal serotonin. The signaling pathway 
directing the gut-brain connection mediated by serotonin accumulation in the gut also remains 
to be identified. The specific mechanistic consequences of modulating serotonin receptors and 
other pathways reported in this study, as well as possible other host effects that we have not 
measured, are not known and will require much deeper exploration. It is reasonable to infer that 
oN14 produced serotonin interacts with epithelial cell HTR4 receptors eliciting a cascade of 
downstream effects including modulation of the enteric nervous system. In modulation of Muc2 
and the mucosal border, oN14 produced serotonin may interact directly with luminal facing 
goblet cells or through secondary activation through the serotonergic interaction with the 
epithelial cells as described above. In the modulation of behavior. We did not see typical 
behavioral changes in a low stress environment, as in the open field test designed to measure 
exploration. In the stress-induced open field test, while we do not know why the oN14 strain 
altered exploration and willingness to explore, it is reasonable to infer that oN14 desensitized 
the anxiolytic response to stressful stimuli.  
The use of engineered bacteria that localize to defined regions of the GI tract can 
improve specificity and efficacy of various pharmacological compounds, especially those that 
are difficult to formulate for oral delivery. For instance, current serotonin modulators and 
therapeutics alter serotonergic signaling through known 5-HT receptors and transporters, but 
they often suffer from systemic side effects such as serotonin syndrome (Ferguson, 2001). Our 
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oN14 strain enables targeted colonic delivery of 5-HT, which is otherwise challenging to 
formulate orally due to its short half-life in vivo. Although oral gavage of 5HT is currently being 
tested by other labs, data of the physiological effects of oral administration has not been found. 
Towards clinical translation, it will be important to define the dose, duration, and tolerance of 
our engineered bacterium in humans to achieve therapeutic efficacy for various possible 
applications to treat intestinal and neurological conditions. Extending our pathway engineering 
strategy to other biogenic amines, neurotransmitters, and gut peptides could provide new 
avenues to study and modulate the gut-brain axis and ultimately expand the therapeutic 
applications of engineered living bacteria in humans.   
In chapter 3, we established the therapeutic potential for a butyrate-producing advanced 
bacterial therapeutic. Our strain, EcN:B populated the murine large intestine in an inflammatory 
setting increasing the concentration of butyrate along the mucosa in the fecal matter and in 
cleaned colon tissue. While did not see high concentrations of EcN:B in all groups, we saw 
physiological differences between mice gavaged EcN:B indicating bacterial produced butyrate 
can alter host physiology.  
 One major limitation to our work is that we did not characterize the changes we found 
in the fecal microbiota. The microbiome is known to alter host physiology and community 
differences have been linked to irritable bowel syndrome and inflammatory bowel disease. Both 
irritable bowel syndrome and inflammatory bowel diseases have a microbiome-host connection 
and a gut-brain connection. Future work should include interrogation of any potential 
behavioral effects of engineered short-chain fatty acid-producing bacteria. 
Many of the physiological effects we found, may have been a consequence of microbial 
community changes observed by 16S sequencing. Future work should seek to understand if the 
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effects on the host were caused by butyrate itself or changes in the microbial community. With 
such prominent differences, it is important to understand which genus are most effected and if 
they themselves, can recapitulate any of the physiological findings we saw. Identifying other 
beneficial microbes could help us understand how individual bacteria communicate with and 
effect host physiology. 
 While future efforts will likely look at the mechanism of action of our Butyrate 
producing strain, initial findings by qPCR highlight and confirm results previously seen. 
Butyrate is known to not only increase the expression of proteins found in the mucosa, but also 
strengthen intestinal permeability by upregulating expression of epithelial barrier proteins. We 
saw an increase in Muc2 on immunohistochemistry and gene expression changes in Zona 
Occludin-1, Occludin, and Claudin-1 confirming previous results. 
 Most intriguingly are the differences seen in colon length in not only our experimental 
models, but also our control mice. While butyrate is known to increase the health and 
metabolism of the colon, no one has shown, to our knowledge, that butyrate can increase the 
length of the colon in a rodent model. These findings highlight the potential for clinical 
application and future mechanistic characterization.  
 Lastly, if EcN:B is indeed activating FoxP3+ regulatory T cells and reducing the innate 
immune response by neutrophil activation, EcN:B could serve as a potent prophylaxis and 
treatment for those suffering with inflammatory bowel disease. The use of short-chain fatty 
acids for the treatment of and prevention of gastrointestinal related illness is promising as there 
are three primary ways for fatty acid administration: fiber administration, short-chain fatty acid 
supplementation, and short-chain fatty acid producing bacteria administration.  
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Towards clinical translation, it will be important to re-engineer the strain to 
constitutively produce butyrate and define the dose, duration, and tolerance of our engineered 
bacterium in humans to achieve therapeutic efficacy for various possible applications to treat 
intestinal and neurological conditions. Extending our pathway engineering strategy to other 
biogenic amines, neurotransmitters, and gut peptides could provide new avenues to study and 
modulate the gut-brain axis and ultimately expand the therapeutic applications of engineered 
living bacteria in humans. This doctoral thesis work paves the way for future work on biogenic 
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ABSTRACT  18 
Bacteria in the gastrointestinal (GI) tract play an important role in intestinal motility, homeostasis, 19 
and dysfunction and can also elicit neurocognitive changes in the host along the gut-brain axis. However, 20 
delineating the mechanistic underpinnings of microbial-mediated host modulation is challenging due to 21 
the vast diversity of metabolites that can be produced by any given bacterium in the gut. As such, there is 22 
a great need for well-controlled approaches to study how specific metabolites impact host physiology and 23 
function when produced in the gut. Here, we describe the engineering of a gut commensal bacterium, 24 
Escherichia coli Nissle, to biosynthesize the human metabolite serotonin as a new model to study the 25 
microbiota-gut-brain axis. When administered orally to mice, our engineered bacteria colonize the mucosa 26 
layers along the epithelial lining of the colon where they produce serotonin. Compared to non-producing 27 
controls, mice treated with serotonin-producing bacteria responded with biological changes at the cellular, 28 
tissue, and organ level. Furthermore, behavioral testing of these mice in stress-inducing environments 29 
revealed robust and statistically significant decreases in anxiety. This work provides a new framework that 30 
uses engineered bacteria to better study gut-brain communication and hints at future clinical uses of this 31 





INTRODUCTION  33 
Intestinal bacteria help metabolize foods, modulate host immune responses, and produce different 34 
bioactive chemicals that together promote gastrointestinal (GI) health and homeostasis1. Gut microbes 35 
are also linked to a bi-directional signaling pathway with the enteric nervous system (ENS) and central 36 
nervous system (CNS) along the gut-brain axis2. While gut-brain communication can act through 37 
stimulation of G-protein coupled receptors (GPCRs), hormonal regulation, or transmission of neuroactive 38 
compounds, recent studies have suggested that oral ingestion of certain probiotic bacteria can alter host 39 
physiology and behavior in animal models3, 4. Since these microbes produce numerous diverse and often 40 
uncharacterized metabolites5, it is challenging to isolate the specific underlying molecular mechanism of 41 
action. While non-bioactive bacteria are often used as control strains in these studies6, their genomic and 42 
metabolic differences compared to bioactive species can be quite large, which does little for honing in on 43 
the identity of the acting compounds. Nevertheless, specific examples of microbial biosynthesis of 44 
neuroactive molecules by gut bacteria do exist (e.g. γ-aminobutyric acid or GABA7), suggesting a potential 45 
direct communication between gut microbiota and host neurons. In order to understand the function of 46 
intestinal metabolites and determine their causal role along the gut-brain axis, better models are needed 47 
to produce and deliver specific metabolites to the host under physiologically relevant experimental 48 
settings.  49 
A key metabolite for neurotransmission throughout the human body is the biogenic monoamine 50 
serotonin (5-hydroxytryptamine, 5-HT). Up to 95% of the serotonin in the body is produced in the GI  tract8. 51 
Serotonin is derived from tryptophan (TRP) in a two-step pathway: first TRP is hydroxylated by a 52 
tryptophan hydroxylase (TPH) to form the 5-hydroxytryptophan (5-HTP) intermediate, which is then 53 
decarboxylated by tryptophan decarboxylase (TDC). In humans, TPH is the rate-limiting enzyme of 5-HT 54 
biosynthesis and exists as two isoforms, TPH1 and TPH2. TPH2 is produced in neurons across the body 55 
while TPH1 is predominately expressed in neuroendocrine cells in the gut8. While commensal bacteria 56 
and probiotic strains can stimulate host serotonin production in the gut in ex vivo9 and animal models10, 57 
there has been no evidence thus far that serotonin can be made directly by gut microbes.  58 
In the GI tract, serotonin regulates intestinal motility, cell turnover, and homeostasis11. In the brain, 59 
serotonin modulates a variety of essential functions such as cognition, learning, and memory12. Peripheral 60 
and neuronal serotonin are generally regarded as separate pools since peripheral 5-HT is not thought to 61 
cross the blood-brain barrier8, although there is some evidence to the contrary13. In the clinical setting, 62 
use of selective-serotonin reuptake inhibitors (SSRI) to increase 5-HT levels in the CNS to treat depression 63 
has been effective but can cause systemic side effects such as serotonin syndrome14 (i.e. toxic 64 
accumulation of excess peripheral 5-HT) and other GI changes15. Despite its importance for GI and brain 65 
function, our understanding of intestinal 5-HT homeostasis and the relationship between gut-derived and 66 





With recent advances in synthetic biology and gut bacteria engineering, there are emerging efforts 68 
to make orally-ingestible live therapeutics16 that can be programmed to diagnose diseased states17-20, 69 
prevent infections21, or produce different metabolites, enzymes, and biologics22-25. Here, we describe the 70 
engineering of E. coli Nissle to biosynthesize serotonin in the mammalian GI tract. We show in a murine 71 
model that engineered serotonin-producing bacteria alter mammalian physiology including changes in GI 72 
motility and host intestinal gene expression. Furthermore, bacterially-derived serotonin in the colon leads 73 
to behavioral changes and reduced anxiety in a stress-inducing environment. This work highlights the use 74 
of a commensal bacterium engineered to produce a human neurotransmitter in the mammalian gut as an 75 
approach to study microbial modulation of the gut-brain axis and suggests possible new therapeutic 76 
strategies.     77 
 78 
 79 
RESULTS  80 
 81 
Engineering and optimization of serotonin-producing gut bacteria  82 
 Given serotonin’s physiological importance, we explored the possibility and consequence of in vivo 83 
production of serotonin by an engineered gut bacterium in the GI tract (Figure 1a). Several challenges 84 
exist for microbial production of 5-HT. First, no bacterial genes for de novo serotonin biosynthesis have 85 
been identified. Known eukaryotic 5-HT biosynthetic enzymes require molecular oxygen, which is scarce 86 
in the lower GI tract and rules out strict anaerobes as production hosts. Second, many tryptophan 87 
hydroxylases require non-native cofactors and tryptophan decarboxylases are often promiscuous, thus 88 
causing both an increase in side-products and a decrease in 5-HT production. While plant cytochrome-89 
P450 enzyme tryptamine monooxygenase has been used to produce 5-HT in laboratory E. coli at low 90 
yields26, the approach is not suitable for the 37°C environment of the body since the enzyme only functions 91 
at 20°C. Other two-step fermentation processes can improve 5-HT yield, but cannot be feasibly 92 
implemented in the gut27.  93 
In order to establish an efficient microbial biosynthetic pathway tailored for the mammalian gut, we 94 
chose the facultative anaerobe E. coli Nissle (EcN) as the chassis strain, which has a long history as a 95 
safe probiotic in humans28 and is amenable to genetic engineering as a live therapeutic in the GI tract 22, 96 
23. We first combinatorially tested different TPH and TDC genes in E. coli Nissle and found measurable 97 
serotonin production using the mouse TPH1 (M1) or human TPH2 (H2), in combination with TDC from 98 
rice (R) or Cataranthus roseus (C) (Figure 1b). When the decarboxylation step was tested alone by 99 
feeding 5-HTP, the enzyme from rice proved superior (79.5 ±11.1% yield), which led us to focus further 100 
optimizations on the ‘M1R’ and ‘H2R’ pathways. Since higher availability of TRP increased pathway yield 101 
(Suppl. Figure 1a), we increased the tryptophan pathway flux by knocking out the tryptophan repressor 102 





To enable efficient and iterative optimization of the synthetic 5-HT pathway, plasmid-based 104 
expression is preferable. However, for in vivo applications, it is undesirable to use antibiotic selective 105 
pressure for plasmid maintenance and to have the possibility of horizontal transfer of plasmids to other 106 
resident microbes. To address this challenge, we first attempted to stabilize the high copy number 5-HT 107 
production plasmid (pUC-H2R) by introducing the essential bacterial gene infA into the pathway operon, 108 
and then knocking out the genomic copy in EcN30. While stable, this plasmid caused an undesired growth 109 
defect in both NΔ2 and NΔ3 (EcN with ΔtrpR, ΔtnaA, ΔinfA), likely due to metabolic burden (Figure 1c). 110 
We therefore explored an alternative approach by moving the pathway to one of the two native plasmids 111 
in EcN, pMUT131. We found that this plasmid (pMUT-H2R) was stably maintained in NΔ2 with no 112 
detectable fitness defect for at least 100 generations, without antibiotic selection (Figure 1c, Suppl. 113 
Figure S1b, c). 5-HT production was stable over this period and comparable to pUC-H2R titers (Figure 114 
1d). To further ensure plasmid stability in vivo, we introduced the hok/sok toxin-antitoxin module32 into 115 
subsequent versions of the pMUT plasmids.  116 
Plant TDCs can use both TRP and 5-HTP as substrates to generate tryptamine (TRM) and 5-HT, 117 
respectively (Figure 1a). Correspondingly, we observed a significant amount of TRM byproduct with all 118 
plant TDC variants tested (Figure 1b). To redirect flux away from TRM toward 5-HT, we pursued two 119 
additional engineering steps. We first sought to improve TPH activity by introducing a genomic mutation 120 
(T198I) in folE in NΔ2 to improve tetrahydrobiopterin cofactor regeneration33. We then used this optimized 121 
base strain (called oN, for ‘optimized Nissle’) to test libraries of pathway variants in which we modulated 122 
the relative expression strength of TPH and TDC using ribosome binding site (RBS) libraries for both the 123 
‘M1R’ and ‘H2R’ pathways (Figure 1e-f, Suppl. Figure S1d). We found that a fine balance between the 124 
two enzymes’ relative activity is needed to reduce TRM formation, while avoiding accumulation of the 125 
reaction intermediate 5-HTP. From the pathways with the highest serotonin production, we chose an ‘M1R’ 126 
variant (pMUT14-ser) since TPH1 has higher reported oxygen-binding capacity than TPH234, which is an 127 
important consideration in the low-oxygen environment of the gut. The final optimized strain carrying 128 
pMUT14-ser (oN14) had superior performance to all other tested strains, vectors and pathways (Figure 129 
1g), producing serotonin at near physiologically relevant levels (Suppl. Figure S1e), and was thus used 130 
for subsequent in vivo animal studies. Since tryptamine is known to modulate serotonergic pathways and 131 
activate serotonin receptors in the gut35, we also built a construct (pMUT11-trm), which lacks the TPH 132 
gene and thus exclusively produced tryptamine, in order to untangle the effects of the TRM byproduct in 133 
vivo. This strain (harboring pMUT11-trm, oN11) and a strain with an empty vector (oN9) thus served as 134 
controls (Figure 1h, Suppl. Figure S1f). Finally, a green fluorescent protein (GFP) gene was genomically 135 
integrated into all three strains to facilitate immunostaining and detection for in vivo studies.  136 
 137 





 To test our engineered strains in vivo, we used 6-week old, conventional C57BL6/J mice (Taconic 139 
Biosciences). Mice were first cohoused for 7 days to normalize their gut microbiome and reduce intra-140 
animal microbiome variation (Methods). Subsequently, they were divided into separate groups and orally 141 
gavaged with 109 colony-forming units (CFUs) of freshly grown cultures of oN9, oN11, and oN14, or sterile 142 
phosphate-buffered solution (PBS) daily for 10 days (Figure 2a). Twenty-four hours after the last gavage, 143 
we measured changes in host physiology, collected serum and fecal matter, and sacrificed the mice to 144 
acquire intestinal digesta and tissues for further analysis. 145 
 To assess short-term colonization and localization of oN strains along the GI tract compared to a 146 
lab E. coli MG1655 strain (Suppl. Figure S2a), we plated the digesta derived from different intestinal 147 
regions (Suppl. Figure S2b) and quantified the number of GFP-positive, kanamycin resistant (KanR) 148 
colonies. The highest concentration of oN was found in the proximal colon at more than 108 CFU/g (Figure 149 
2b), localizing along the mucosal layer based on visualization by immunohistochemistry with an anti-GFP 150 
antibody (Figure 2c). In contrast, the small intestine had much fewer oN bacteria (<104 CFUs/g) compared 151 
to the cecum or colon (Suppl. Figure S2c). Therefore, during our 10-day oral administration protocol, the 152 
oN strains appear to primarily accumulate in the large intestine near the epithelial lining compared to other 153 
GI regions.  154 
 We next measured the level of TRP, 5-HTP, 5-HT and TRM in the serum, colonic tissues, and 155 
feces of the mice by LC-MS. Tryptophan levels were elevated in colon tissues and feces, but not in serum, 156 
of mice with oN14 only (Suppl. Figure S2d). 5-HT levels were not statistically different in serum and in 157 
colonic tissue across cohorts (p>0.4 by ANOVA) (Figure 2d, e). However, we observed a significant 158 
increase in fecal 5-HT in mice with oN14 (13.4-fold increase, p<0.0001 by ANOVA) compared to other 159 
groups (Figure 2f). Tryptamine and 5-HTP levels were below the limit of detection in all samples.  160 
Since 5-HT levels were not elevated in colonic tissues that have been cleaned to remove residual 161 
digesta, we speculated that serotonin may be more concentrated in the mucosal layers where oN strains 162 
are observed. To test this hypothesis, we stained for 5-HT in whole-paraffin-embedded colonic sections 163 
using an anti-serotonin antibody and visualized the distribution along the mucosa (Methods). Indeed, we 164 
found that serotonin was enriched along the mucosal layers specifically in the oN14 group (Figure 2g). 165 
Taken together, these results demonstrate that the engineered oN14 strain produces 5-HT in vivo along 166 
the mucosa of the murine colon. 167 
 168 
Engineered bacteria elicit changes in host gene expression and physiology in the gut 169 
 We next performed physiological and gene expression measurements in the gut to assess 170 
possible host responses to bacterially-produced 5-HT after 10 days of oral delivery. We first assessed the 171 
level of Muc2, which is a prominent oligomeric mucus-forming protein secreted by goblet cells along the 172 
epithelial lining that provides a physical protective barrier for the gut. A decrease in Muc2 production is 173 








expression of the MUC2 gene in colonic tissues revealed a ~2-fold increase in mice with oN14 compared 175 
to control groups (p<0.05 by ANOVA) (Figure 3a). Correspondingly, immunohistochemical staining of 176 
colonic tissue sections with anti-Muc2 antibodies showed a more prominent mucosal layer in the oN14 177 
cohort (Figure 3b). However, no difference in expression of goblet cell markers CDX2 or intestinal stem 178 
cell markers BM1 and LGR5 was observed (Suppl. Figure S3a), suggesting that Muc2-producing goblet 179 
cells and general intestinal turnover are unchanged. 180 
Since excess serotonin derived from EC cells can stimulate intestinal inflammation37, we measured 181 
inflammation markers IL6, IL1β, NFKβ, IL17A, and TNFα by qPCR and found no change in their gene 182 
expression in colon tissues in oN14-treated mice (Suppl. Figure S3b). Hematoxylin and Eosin (H&E) 183 
staining of colonic sections further confirmed the lack of histopathological changes associated with gut 184 
inflammation (Suppl. Figure S3c). Furthermore, we did not observe any change in colon length (p=0.66 185 
by ANOVA) (Suppl. Figure S3d), which is another indicator of chronic intestinal inflammation if found to 186 
be shortened.  187 
To characterize the effect of oN14 on host serotonin biosynthesis and metabolism, we assessed 188 
gene expression of tryptophan hydroxylase isoforms TPH1 and TPH2, and the serotonin transporter 189 
SERT. While no difference was observed in expression of TPH1 and SERT, we detected an unexpected 190 
2.8-fold increase in TPH2 expression compared to other groups (p<0.001 by ANOVA) in the colon (Figure 191 
3c). This suggests that bacterially-derived 5-HT may induce TPH2-mediated host neuronal 5-HT 192 
biosynthesis in the ENS, which has not been previously seen. The oN14 strain does not appear to change 193 
the total number or size of EC cells (the primary producers of host 5-HT in the gut) as quantified by qPCR 194 
and by immunohistochemistry of the EC cell marker chromogranin A (Suppl. Figure S4a-c). Our 195 
engineered strains also did not alter the expression of TJP1, TJP2, or OCLN in the colon, which are 196 
markers for maintenance of intestinal barrier function (Suppl. Figure S4d). While tryptophan and 197 
serotonin metabolism can also affect the kynurenine pathway, whose dysfunction is linked to many 198 
neurologic and metabolic disorders38, we did not find any changes in expression of IDO1, IDO2, and 199 
TDO2, which encode the rate-limiting enzymes that convert L-tryptophan to N-formylkynurenine (Suppl. 200 
Figure S4e).  201 
 Serotonin is a ligand for a number of 5-HT receptors, which are GPCRs mediating excitatory and 202 
inhibitory neurotransmission throughout the ENS, CNS, and the peripheral nervous system. Therefore, 203 
we characterized the effects of oN strains on gene expression of different serotonin receptors in the colon. 204 
Expression of HTR1B and HTR1D increased in the oN11 and oN14 cohorts (both are p<0.05 by ANOVA) 205 
(Figure 3d), suggesting a possible tryptamine-mediated effect. Although not much is known about its 206 
function in the gut, 5HT1b receptor activation in the CNS has been linked to reduced aggressiveness39 207 
and, along with 5HTr1d, it is the target receptor for tryptamine-based treatment of migraines40. We also 208 
observed upregulation of HTR3, HTR4 and HTR7 in the oN14 cohort only (all are p<0.01 by ANOVA) 209 





physiological roles, implicated in emesis, irritable bowel syndrome (IBS), schizophrenia, anxiety, learning, 211 
memory and addiction, and is modulated clinically by antiemetic 5HTr3 antagonists41. The 5HT4 receptor 212 
induces neurogenesis in the enteric nervous system, and is linked to modulation of peristalsis in the GI 213 
tract, stress-induced feeding behavior, and altered learning and memory, and depression in the CNS42-44. 214 
While 5HTr7 stimulation can improve cognition and memory45 and 5HTr7 antagonism can resolve anti-215 
depressive and anti-psychotic behaviors in the CNS46, its function in the gut is not well understood 216 
although it has been linked to IBS and inflammatory bowel disease (IBD)47.  217 
The diversity and magnitude of changes in gene expression of 5-HT receptors suggests that oN14 218 
may be eliciting physiological responses in the host. Indeed, serotonin is known to modulate GI motility by 219 
inducing both intraluminal pressure to cause peristaltic reflex and the colonic migrating motor complexes 220 
that sweep through the intestine during intervals of fasting48, 49. Interestingly, we found that oN14 221 
specifically decreased total GI transit time by as much as 15% (p<0.05 by ANOVA) compared to control 222 
cohorts (Figure 3f). Since changes in gut motility and bacterially-produced biogenic amines might affect 223 
the gut microbiome, we performed 16S metagenomic sequencing on fecal matter across the four animal 224 
cohorts at Day 0 and Day 11 (Methods). However, no significant changes in the gut microbiome was 225 
observed between cohorts from Day 0 to Day 11 (Suppl. Figure S5). Together, these results highlight 226 
that our engineered bacteria elicit a number of changes in the gut, including host gene expression and GI 227 
motility, while leaving the resident microbial community undisturbed.   228 
 229 
Serotonin-producing bacteria alter anxiety profiles in mice 230 
To explore potential host changes mediated through the gut-brain axis, we performed behavioral 231 
studies using the same set of oN strains. Previous animal studies have shown that some probiotic bacteria 232 
could reduce anxiety and depression during behavioral tests6. We thus employed two well-established 233 
methods, the forced swim test (FST)50 and the open field test (OFT)51 to study possible behavioral changes 234 
in mice colonized with oN strains. The FST, commonly used to assess efficacy of anxiolytics and anti-235 
depressants in rodents, quantifies behavioral despair by recording the time spent immobile in a water-236 
filled container as a measure of hopelessness to escape the stressful environment. Using this test, we 237 
found that mice given oN14 had statistically reduced immobility time during FST by up to 17% (p=0.004 238 
by ANOVA) compared to control oN cohorts (Figure 4a). This result could be robustly replicated in a 239 
separate and independent animal cohort (Suppl. Figure S6a). The OFT measures anxiety levels and 240 
willingness to explore in a stressful environment by detecting total fecal boli, total distance traveled, and 241 
time spent exploring the inner and outer zones of a 50x50cm white, well-lit, open field. Mice given oN14 242 
showed a decreased number of fecal boli during the ten-minute test (Figure 4b), which could be 243 
associated with reduced stress or the decreased total GI transit (Figure 3e). While wild-type mice naturally 244 
prefer closed, dark, tight spaces, mice given oN14 showed increased time spent exploring the inner 40x40 245 





distance traveled (Figure 4c-e). This test was repeated on another cohort of mice, which confirmed the 247 
effect of the oN14-treated mice (Suppl. Figure S6b). We further performed additional animal studies on 248 
mice obtained from a different commercial vendor (Jackson Laboratory) to assess the impact of different 249 
initial gut microbiota on our observations and found similar physiological and behavioral results as before 250 
(Suppl. Figure S7). Together these findings provide the first evidence that serotonin produced by 251 
engineered gut bacteria can modulate host anxiety. 252 
 253 
DISCUSSION  254 
In this study, we established a novel tool for investigating and modulating the gut-brain axis by 255 
comparing a serotonin-producing gut bacterium (oN14) that elicits clinically relevant effects on host 256 
physiology and behavior to its non-serotonin producing control. This oN14 strain could populate the murine 257 
large intestine to a sufficient density to increase the amount of 5-HT accumulated along the mucosal 258 
layers. While we did not observe any increase of 5-HT in the serum or in colonic tissues cleaned of 259 
mucosa, oN14 induced higher expression of serotonin receptors 5HTr3, 5HTr4 and 5HTr7 in the colon, 260 
and these receptors may be participating in the physiological changes observed. Indeed, 5HTr4 is found 261 
on the apical side of epithelial cells in the GI tract52, 53 and could thus be activated by oN14-derived 262 
serotonin in the mucosa. Elevated 5-HT levels in the colon also led to upregulation of MUC2 and increased 263 
mucosal thickening, indicating a benefit of oN14 on mucosal integrity with potential relevance in 264 
inflammatory bowel diseases. Whether the unexpected induction of TPH2 by oN14 plays a role in the 265 
observed host changes warrants further investigation. On the other hand, tryptamine produced from oN11 266 
and oN14 did not cause any measurable changes in host physiology or behavior but did increase gene 267 
expression of serotonin receptors 5HTr1b and 5HTr1d in the gut. Interestingly, the tryptamine-mediated 268 
effects seen here differed from a previous study35, but direct comparisons are challenging due to 269 
differences in study design (e.g. single dose, shorter-term assays) and gut bacterium used (a Bacteroides 270 
that colonizes intestinal crypts). While gut 5-HT is known to regulate intestinal transit time4, our study is 271 
the first to demonstrate the effect of luminal 5-HT on transit time in the context of a conventional healthy 272 
microbiome. 273 
The use of engineered bacteria that can be genetically controlled and colonize the mice gut without 274 
the use of antibiotics or germ-free models enables the study of bacterially-produced metabolites under 275 
physiologically relevant conditions. The findings presented here, along with the emerging literature17, 21-24 276 
highlight the potential utility of engineered commensal bacteria in both basic research and translational 277 
applications. Our approach will enable future studies aiming to better delineate the role of gut-derived 278 
serotonin in modulating host physiology, behavior, and neurological changes, and its relationship with 279 
peripheral and neuronal serotonin. The precise signaling pathway underlying the observed gut-brain 280 





consequences of modulating serotonin receptors and other pathways reported in this study, as well as 282 
possible other host effects that we have not measured, are not known and will require further exploration.  283 
Finally, the use of engineered commensal bacteria that localize to defined regions of the GI tract 284 
can improve specificity and efficacy of various pharmacological compounds, especially those that are 285 
difficult to formulate for oral delivery. For instance, current serotonin-modulating therapeutics alter 286 
serotonergic signaling through known 5-HT receptors and transporters, but they can cause systemic side 287 
effects such as serotonin syndrome14. Our oN14 strain enables targeted colonic delivery of 5-HT, which 288 
is otherwise challenging to formulate orally due to its short half-life in vivo. Towards clinical translation, it 289 
will be important to define the dose, duration, and tolerance of our engineered bacterium in humans to 290 
achieve therapeutic efficacy for treating various intestinal and neurological conditions.  291 
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MATERIALS AND METHODS 316 
 317 
Strain construction. E. coli Nissle 1917 (Mutaflor®) was purchased from Ardeypharm GmbH, Germany. 318 
The gene for green fluorescent protein (GFP, GenBank: CAH64882.1) was placed under control of a 319 
strong, constitutive promoter (Part BBa_J23101, Registry of Standard Biological Parts, 320 
www.parts.igem.org) and integrated into the genome at the Tn7 attachment site using pGRG25 as 321 
described previously54. Knockouts of trpR, tnaA or infA were performed using CRISPR/Cas9 as described 322 
previously55. Briefly, a two- plasmid system consisting of an inducible cas9/λ-Red expression plasmid and 323 
a guide RNA (gRNA) plasmid were used to introduce double-strand breaks at the desired genomic loci. 324 
gRNAs were designed using CRISPy-web56 after uploading the EcN genome sequence (GenBank: 325 
CP007799.1). Templates for homologous recombination at the cut site were generated as follows: where 326 
available, strains with the desired knockouts (ΔtrpR::FRT-kan-FRT or ΔtnaA::FRT-kan-FRT, respectively) 327 
from the KEIO collection57 were transformed with pSIJ858 and the FLP recombinase gene was induced to 328 
remove the kanamycin resistance gene. Resulting colonies were screened for kanamycin sensitivity. The 329 
ΔtrpR::FRT or ΔtnaA::FRT loci were amplified using oligos binding 500 bp up and downstream of the FRT 330 
site to generate PCR products of approximately 1 kb. For infA, the fragment was generated by first 331 
amplifying 500 bp upstream and 500 bp downstream of infA from the EcN genome and then fusing these 332 
2 fragments using overlap-extension PCR. For the folE(T198I) genomic mutation, the folE gene was 333 
amplified in 2 parts, introducing the T198I mutation in the oligos used for the overlap-extension PCR. The 334 
resulting dsDNA fragments were purified and co-transformed with the gRNA plasmid to generate 335 
markerless gene knockouts or mutations in EcN. CRISPR/Cas9 and gRNA expression plasmids were 336 
cured from the strains as described previously55. In the case of infA, plasmid pUC-H2RD which expresses 337 
a synthetic infA gene (see below) was transformed into NΔ2 before the CRISPR experiment, to provide a 338 
functional copy of the infA gene for survival. All genome modifications were verified using Sanger 339 
sequencing.  340 
 341 
Serotonin production genes and plasmids. Genes and plasmids used in this study are listed in Suppl. 342 
Table S1. Genes for serotonin production were selected from mammalian or plant protein sequences, 343 
codon-optimized for E. coli using the online tool from IDT (idtdna.com/CodonOpt),and synthesized by 344 
GeneArt® (ThermoFischer Scientific) or ordered as gBlocks® from Integrated DNA Technologies, 345 
Belgium. Plasmid pUC-H2R was used as a template for generating the pUC- series of plasmids. The 346 
pathway operon consisted of promoter BBa_J23107, a TPH gene, a TDC gene, and a synthetic copy of 347 
the infA gene (Supplementary Figure 1d). Parts of pUC-H2R were amplified and the TPH and/or TDC 348 
gene was replaced with alternatives genes using Gibson assembly. Plasmid pMUT1 (GenBank: 349 
A84793.1) was isolated from wild-type EcN and amplified to serve as the pMUT backbone. Elements that 350 
could enable plasmid transfer were removed, a kanamycin resistance gene and the H2R or M1R operons 351 
(without infA) were inserted to generate pMUT-H2R or pMUT-M1R, respectively. To generate the plasmid 352 
pMUT14-ser, the hok/sok toxin-antitoxin plasmid stability element (GenBank: MK134376, Region 58002-353 
58601) was additionally inserted into the pMUT-M1R backbone (Supplementary Figure 1f). The TPH gene 354 
was removed from pMUT14-ser to generate pMUT11-trm, and both TPH and TDC were removed to make 355 
pMUT09-ctrl.  356 
 357 
Pathway optimization using RBS libraries. RBS strength libraries were designed using the ‘RBS 358 
calculator v1.1’59 choosing library sizes of  4-6 variants for each gene, ranging in theoretical strength from 359 
50 to 50000 arbitrary units. Mutations in the RBS were introduced with oligos containing degenerate bases 360 
and using Gibson assembly60. Transformants were picked randomly and RBSs sequenced after testing 361 
the strains’ metabolite production profiles.  362 
 363 
In vitro metabolite production. For metabolite production, strains were grown in a modified M9 medium 364 
containing 1x M9 salts (M6030, Sigma Aldrich), 0.2% (w/v) glucose, 0.1% (w/v) casamino acids (Cat.No. 365 
C2000, Teknova), 1 mM MgSO4, 50 µM FeCl3, 0.2% (v/v) 2YT medium (composition see below), and 50 366 
mg/L of L-tryptophan unless stated otherwise. Kanamycin was added at a final concentration of 50 mg/L 367 
unless stated otherwise. Three single colonies were picked from each strain, grown in 300 µl medium in 368 





diluting this preculture 1:100 into fresh medium, and cells were grown for 24 h under the same conditions. 370 
Afterwards, the culture supernatant was separated from cells using a 0.2 µm pore size filter, and frozen 371 
at -20°C until analysis by LC-MS. All data shown are mean +/- SD from at least 3 biological replicates.  372 
 373 
Plasmid stability testing. Six single colonies each were picked from strains NΔ2 + pMUT-H2R, NΔ2 + 374 
pUC-H2R, NΔ2 + pUC-H2RD and NΔ3 + pUC-H2RD and grown in 300 µl 2YT medium (containing 1.6 % 375 
(w/v) tryptone, 1% (w/v) yeast extract, 0.5% (w/v) NaCl) without kanamycin in 96 deep-well plates and 376 
shaken at 250 rpm at 37°C for 24 hours. The optical density (OD630) of the cultures was measured and 377 
cultures were diluted 1:1000 into fresh medium, and cells were plated on LB-Agar plates with and without 378 
kanamycin daily, corresponding to approximately 10 doublings every 24h. Colony forming units on LB-379 
Agar plates +/- kanamycin were counted daily. At time points t=0, 50 and 100 generations, cultures were 380 
diluted 1:100 into the modified M9 medium described above (without kanamycin) and serotonin production 381 
was measured as described.    382 
 383 
Bacterial growth curves. Cells were grown as described under ‘In vitro metabolite production’ with the 384 
following modifications: after inoculation of the main culture, 200 µl were transferred into a flat-bottom, 385 
clear 96-well microtiter plate and the plate sealed with a gas-permeable membrane (Z380059, Sigma 386 
Aldrich). Growth was recorded using the BioTek™ ELx800 plate reader by measuring the optical density 387 
at 630nm every 10 minutes. Cultures were grown at 37°C with 700 rpm orbital shaking.  388 
 389 
Quantification of metabolites by LC-MS. Detection of serotonin, tryptamine, tryptophan and 5-HTP were 390 
conducted by liquid chromatography mass spectrometry (LC-MS) measurements on a Dionex UltiMate 391 
3000 UHPLC (Fisher Scientific, San Jose, CA) connected to an Orbitrap Fusion Mass Spectrometer 392 
(Thermo Fisher Scientific, San Jose, CA). The system used an Agilent Zorbax Eclipse Plus C18 2.1 x 100 393 
mm, 1.8 µm column kept at 35°C. The flow rate was 0.350 mL/min with 0.1% formic acid (A) and 0.1% 394 
formic acid in acetonitrile (B) as mobile phase. The gradient started as 5% B and followed a linear gradient 395 
to 35% B over 1.5 min. This solvent composition was held for 3.5 min after which it was changed 396 
immediately to 95% B and held for 1 min. Finally, the gradient was changed to 5% B until 6 min. The 397 
sample (1 uL) was passed on to the MS equipped with a heated electrospray ionization source (HESI) in 398 
positive-ion mode with sheath gas set to 60 (a.u.), aux gas to 20 (a.u.) and sweep gas to 2 (a.u.). The 399 
cone and probe temperature were 380°C and 380°C, respectively, and spray voltage was 3500 V. Scan 400 
range was 50 to 500 Da and time between scans was 100 ms. Detection of serotonin (160.07646 ion), 401 
tryptamine (144.08158 and 161.10775 ions) and tryptophan (205.09785 ion) was conducted in full scan 402 
whereas the 5-HTP detection was carried out after HCD fragmentation (221.09>162.05553, 25% HCD 403 
CE). Quantification of the compounds was based on calculations from calibration standards analyzed 404 
before and after sets of 24 samples. All reagents used was of analytical grade. 405 
 406 
Animal studies and sample collections. All animal experiments were performed in compliance with 407 
Columbia University Medical Center IACUC protocols AC-AAAV1460. Male mice (C57BL/6) were 408 
purchased from Taconic Biosciences or Jackson Laboratories at 6-8 weeks of age. Animals were group-409 
housed on a 12-h light:dark cycle (lights on from 7:00-19:00) at constant temperature with ad libitum 410 
access to food and water in a Specific Pathogen Free (SPF) facility. Upon delivery, mice were given one 411 
week to adjust to new location. Mice then underwent a 7-day, 3-rotation microbiome normalization 412 
protocol. On day one, three, and five of the normalization protocol, mice were randomly mixed. On day 6, 413 
mice were mixed one last time and separated in their respective cohorts with 2-3 cages per cohort with 3-414 
5 mice in each cage, exact numbers depending on experiment. On day seven of the microbiome 415 
normalization protocol, mice began day zero of the experimental protocols. Mice were tagged for 416 
identification and housed in groups of 3-5 mice in bottle fed cages, set in designated racks, restricted to 417 
PI access only, and opened only under a laminar flow hood. Fecal samples were collected at day zero of 418 
the experimental protocol and then were orally gavaged every 24hrs at the same time of day for 10 days. 419 
Mice were gavaged 200ul sterile PBS or freshly grown 109 cells of oN9, oN11, or oN14 in sterile PBS. 24 420 
hours after the last gavage, fecal pellets were collected and mice were either euthanized for serum, 421 






In vivo metabolite analysis. Serum, tissue samples, and fecal samples were analyzed for serotonin, 5-424 
hydroxytrytophan, tryptamine, and tryptophan. For serum: blood samples were collected via the inferior 425 
vena cava post euthanasia, samples were mixed 1:1 with 0.9% NaCl, 0.2% Ascorbic acid. Samples were 426 
kept at room temperature for 10 minutes then placed on ice until centrifugation at 2000g for 10 minutes at 427 
4°C. Supernatant was saved for analysis and immediately frozen at -20°C. For tissue analysis: colon 428 
tissue was weighed and immediately frozen on liquid nitrogen after collection and cryofractured using 429 
stainless steel microvials (Biospec 2007) with a single 6.34 mm stainless steel bead (Biospec 430 
11079635ss) beat for 30s in BeadBeater (Biospec 112011). Tissue was then resuspended in 0.9% NaCl, 431 
0.1% Ascorbic Acid, centrifuged at 2000g for 10 minutes at 4°C. Supernatant was saved for analysis and 432 
immediately frozen at -20°C. For fecal samples: samples were weighed, placed in Corning Cryovials with 433 
0.5 ml of 0.9% NaCl, 0.1% Ascorbic Acid with 200ml Zirconia/Silica beads (Biospec 11079101z) and beat 434 
for 5 minutes in BeadBeater at 4°C. Samples were centrifuged at 2000g for 10 minutes at 4°C. 435 
Supernatant was saved for analysis and immediately frozen at -20°C. 436 
 437 
Gene expression analysis. Tissue cryofractured according to the protocol under ‘in vivo metabolite 438 
analysis’ above. Tissue was then resuspended in Trizol (Invitrogen) according to the instructions of the 439 
manufacture for RNA isolation. Total RNA was resuspended in 30 µL of RNase-free water. RNA was 440 
converted to cDNA with iScript gDNA Clear cDNA synthesis Kit (BioRad 1725035) according to 441 
manufacture instructions. Quantitative Real Time polymerase chain reaction (qPCR) was performed in 442 
triplicates in 384 well-plates on Applied Biosystems QuantStudio6 Flex Real-Time PCR System according 443 
to manufacture instructions. Primers used are listed in Suppl. Table S2. Cyclophilin was used as the 444 
housekeeping gene. Relative mRNA levels were quantified using the ∆∆Cτ method. 445 
 446 
Immunohistochemistry analysis. Colon samples were collected and 5mm sections were cut in the mid-447 
colon and fixed in either a Methanol-Carnoy (60% Methanol, 30% Chloroform, 10% Acetic Acid) Solution 448 
or 4% Paraformaldehyde (PFA) in Phosphate Buffered Solution (PBS) for 24 hours. Fixed samples were 449 
then washed three times and stored in 70% ethanol. Samples were kept intact with digesta in the lumen, 450 
embedded in Paraffin and cut luminally at 4 µm and either prepped for Immunohistochemistry or subjected 451 
to Hematoxylin and Eosin staining. For Immunohistochemistry: PFA fixed slides were used for Serotonin 452 
(5-HT) antibody staining and Methacarn fixed samples were used for Muc2, Green Fluorescent Protein 453 
(GFP), and Chromogranin A (CgA) antibody staining. All slides were baked for 2 hours at 57°C, de-454 
paraffinized in xylene and an ethanol-water gradient, rehydrated, then treated with an antigen retrieval 455 
solution of 10mM sodium citrate, pH 6.0 for 30 minutes at 90°C. Slides were blocked for 30 minutes at 456 
room temperature with 5% fetal bovine serum (FBS) in PBS and then incubated with primary antibodies 457 
at 4°C overnight in 5% FBS in PBS. Slides were washed with PBS three times, incubated with secondary 458 
antibody for 2 hours at room temperature in PBS, washed three times in PBS, incubated with DAPI (4’,6-459 
diamidino-2-phenylindole) at 10µg/ml for 5 minutes, washed three times in PBS and mounted using 460 
glycerol. Slides stained with primary antibodies pre-conjugated with Alexa fluorophores did not undergo 461 
secondary antibody staining. Antibodies Used: Anti-GFP rabbit IgG with Alexa Fluor 594 Conjugate (Life 462 
Technologies A21312). Anti-Muc2 polyclonal rabbit (Santa Cruz Technologies sc-15334). Anti-463 
Chromagranin A polyclonal rabbit (Abcam ab15160). Anti-Serotonin polyclonal goat (Abcam ab66047). 464 
Secondary Anti-Rabbit Alexa Fluor 568 (Thermo-Scientific Novex a11011). Secondary anti-goat IgG Alexa 465 
Fluor 488 (Abcam ab150077). All images were taken with Nikon Eclipse Ti2-E Inverted Microscope 466 
System, image conversion and cell size (particle) analysis performed using NIS-Elements, Advanced 467 
Research Software and ImageJ (FIJI) for Macbook version 2.0.0-rc-69/1.52i. 468 
 469 
Total gastrointestinal transit. Carmine red, which cannot be absorbed from the lumen of the gut, was 470 
used to study total GI transit time61. A 6% solution of carmine red (300 µl; Sigma-Aldrich) suspended in 471 
0.5% methylcellulose (Sigma-Aldrich) was administered by gavage through a 21-gauge round-tip feeding 472 
needle. The time at which gavage took place was recorded as T0. After gavage, fecal pellets were 473 
monitored at 10-minute intervals for the presence of carmine red. Total GI transit time was considered as 474 






Metagenomic 16S sequencing and analysis. Fecal pellets were collected from mice at Day 0 and Day 477 
10 and immediately stored at -20°C until paired-end sequencing. Genomic DNA was extracted from fecal 478 
pellets using the Epicenter gram positive kit plus an initial bead beating step with 0.1mm Zirconia beads. 479 
PCR amplification of the 16S rRNA V4 region and multiplexed barcoding of samples were done in 480 
accordance with previous protocols62. The V4 region of the 16S rRNA gene was amplified with 1x 481 
NEBNext q5 Hot Start HiFi PCR Master Mix using custom primers according to the method from Kozich 482 
et al.62. Sequencing was done with the Illumina MiSeq system (300V2 kit). Sequenced pair reads were 483 
prepared using USEARCH v10.0.240_i86osx64. Forward and reverse reads were paired and filtered to a 484 
minimum length of 240 with maximum expected error of 1. Sequences were dereplicated, clustered with 485 
minimum cluster size of 2, and mapped to OTUs at 97% identity63. OTU taxonomy was assigned with the 486 
RDP classifier64. Sequences aligned using PyNAST within Conda with QIIME1, python 2.7, matplotlib 487 
1.4.3. Tree built with FastTree read with RStudio package ape. OTU data analysis and visualization 488 
preformed using Graphpad Prism and RStudio with gglot2 and phyloseq packages. 489 
 490 
Behavioral testing and analysis. Forced Swim Test: Each mouse was placed in clear cylindrical tanks 491 
(30cm height x 20cm) with 15cm of water at 23-25°C for 6 minutes and recorded following previously 492 
described methods48. Mice were then towel dried and placed under heat lamp to dry to prevent 493 
hypothermia and then placed back in their original cage. Recordings were de-identified and a blinded 494 
observer, scored recordings for the time spent immobile during the last 4 minutes of the 6-minute test as 495 
described by Can et al48. Open Field Test: Each mouse was placed in a white, open-roof, well lite, 50 cm 496 
(length) x 50 cm (width) x 38 cm (height) chamber and recorded for 10 minutes following previously 497 
described methods47. Mice were then placed back into their original cage. Fecal pellets produced during 498 
the 10-minute test were counted. Recordings were then post processed and analyzed using 499 
BehaviorCloud as previously described47. Mouse tracking software recorded total path of movement of 500 
each mouse, total distance traveled, time spent in the inner zone defined as the inner 40 cm square and 501 
outer zone defined as the outer 10 cm border closest to the walls, number of times entering the inner 502 
zone, and distance traveled within the inner zone.  503 
 504 
Statistical analysis. Group means, fold change, standard errors/deviations were calculated in Microsoft 505 
Excel. For statistical significance, samples compared using ordinary one-way ANOVA with Tukey’s post 506 
hoc correction was performed with plotted statistical values using ANOVA multiple comparisons in 507 
Graphpad Prism. A value of p<0.05 was considered significant and one-way ANOVA P values marked 508 
accordingly in text and multiple comparisons ANOVA P values marked on corresponding figures. Error 509 
bars represent standard error of the mean, unless otherwise noted. 510 
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Figure 1: Engineering and in vitro characterization of serotonin-producing bacteria. (a) Overall 658 
study design to engineer a serotonin biosynthetic pathway into E. coli Nissle and to optimize production 659 
in the GI tract to modulate host physiology and behavior. (b) Characterization of candidate serotonin 660 
production pathways from different eukaryotic tryptophan hydroxylase (TPH) and tryptophan 661 
decarboxylase (TDC) genes. Combinations of TPH and TDC genes were expressed from a high copy 662 
plasmid in NΔ2. Serotonin (5-HT) production was observed with pathways ‘H2R’, ‘H2C’, and ‘M1R’ (left 663 
panel). Feeding the substrate 5-HTP to TDC showed that all enzymes produced some serotonin, but the 664 
‘R’ enzyme from rice had the highest conversion (right panel). (c) Moving the 5-HT pathway from a high 665 
copy pUC vector to the native EcN plasmid pMUT1 restored strain fitness to wild-type levels. (d) Stable 666 
5-HT production over 100 cell generations in the absence of antibiotic selection for the plasmid. (e) 667 
Plasmids pMUT-H2R and pMUT-M1R were optimized for serotonin production in oN by combinatorially 668 





analyzed by LC-MS to identify combinations maximizing 5-HT production while minimizing 5-HTP and 670 
tryptamine production. (f) Corresponding RBS strengths for ‘H2R’ pathway from (e) is shown; y-axis TPH, 671 
x-axis TDC; grey boxes indicate combinations not tested. (g) Engineering steps to improve serotonin 672 
production. From left to right: EcN wild-type + pUC-H2R produced about 2 mg/L 5-HT, and 25-fold more 673 
tryptamine. Knockout of trpR and tnaA (NΔ2) further increased tryptamine, but not serotonin production, 674 
leading to a ≈60:1 ratio. Lowering the RBS for TDC (pUC-H2Ropt) improved this ratio to 6:1. Pathway 675 
transfer from a pUC to a pMUT1-based plasmid reduced both titers, but serotonin production was 676 
recovered when introducing a mutation in the folE gene (oN). The highest 5-HT titer (7.8 mg/L +/- 0.4) 677 
was achieved with plasmid pMUT-M1R, and in strain oN the tryptamine to 5-HT ratio was reduced to ≈3:1. 678 
(h) Final strains for in vivo testing were derived from oN + pMUT-M1R and show either no (oN9: oN + 679 
pMUT09-ctrl), tryptamine only (oN11: oN + pMUT11-trm) or serotonin and tryptamine (oN14: oN with 680 
pMUT14-ser) production in vitro. All data shown are mean values with error bars of standard deviation 681 
from n=3 biological replicates. 5-HT, 5-hydroxytryptamine (serotonin); 5-HTP, 5-hydroxytryptophan; H1, 682 
human TPH1; H2, human TPH2; M1, mouse TPH1; M2, mouse TPH2; C, cataranthus TDC; G, guinea pig 683 
TDC; R, rice TDC; RBS, ribosome binding site; TRM, tryptamine; TRP, tryptophan; TDC, tryptophan 684 
decarboxylase; TPH, tryptophan hydroxylase 685 
 686 






Figure 2. In vivo bacterial localization and serotonin production in the mice gut. (a) Experimental 689 
overview of mice protocol and endpoints. (b) Concentration of engineered strains in the proximal colon, 690 
which is the most densely populated region 24 hours after the last gavage. Colonies on LB+kanamycin 691 
plates, measured as colony-forming units (CFU) per gram of fecal matter, are shown (n=6). (c) 692 
Immunohistochemical staining with anti-Green Fluorescent Protein (GFP) antibody in a section of the mid-693 
colon, with a scale bar of 100µm. (d-f) Mean serotonin (5-HT), in mg/L in the serum (d), mg/g biomass in 694 




(n=7-8). Error bars are the standard error of the mean. All p-values are from one-way ANOVA with Tukey’s 696 
post hoc correction for multiple comparison testing. (g) Immunohistochemical staining with anti-serotonin 697 






Figure 3. Changes in intestinal physiology and gene expression induced by engineered bacteria. 700 
(a) Quantitative Real Time-PCR (RT-PCR) measurements of gene expression of MUC2 in colonic tissue 701 
measured as relative mRNA by ∆∆Cτ (n=6). (b) Immunohistochemical staining with anti-Muc2 antibody in 702 
the mid-colon, scale bar is 400µm. (c) Expression of serotonin biosynthesis and transporter genes TPH1, 703 
TPH2, and SERT in the colon by RT-PCR (n=6). (d-e) Expression of 5-HT receptors HTR1B HTR1D, 704 
HTR3, HTR4, and HTR7 in the colon by RT-PCR (n=6). (f) Total gastrointestinal transit time from mouth 705 
to anus using a 6% Carmine Red solution (Methods) (n=7-8). All p-values shown are from one-way 706 
ANOVA with Tukey’s post hoc correction for multiple comparison testing. Data are mean values with error 707 







Figure 4. Assessment of anxiety and emotional behavioral changes in mice with engineered gut 711 
bacteria. (a) Time spent immobile of mice during the last four minutes of a six-minute Forced swim test 712 
(FST) (n=9-10). (b) Number of fecal pellets (# of fecal boli) produced during 10-minute open field test 713 
(OFT) (n=7-10). (c) Average total distance traveled of mice during OFT (n=7-10). (d) Time spent in both 714 
the inner 40 cm x 40 cm zone or outer 10 cm ring during OFT (n=7-10). (e) Representative tracking pattern 715 
of a single mouse from each cohort. Tracking patterns for all mice are shown in Suppl. Figure S6c. All p-716 
values shown are from one-way ANOVA with Tukey’s post hoc correction for multiple comparison testing. 717 
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Supplementary Figure S1. Design and in vitro characterization and optimization of 5-HT production 
in engineered strains. (a) Effect of tryptophan concentration in medium on metabolite production. (b) 
Stability of pUC-based and pMUT-based serotonin production plasmids over 100 generations of growth 
without antibiotic selection. At each time point, cells were plated on LB Agar plates +/- kanamycin, and 
ratios of colonies were calculated (n=6). (c) Growth curves for all key strains shown in Figure 1. A clear 
growth defect is visible when combining strain NΔ2, but not N(wild-type), with pUC-based 5-HT production 
plasmids. pMUT-based pathway expression does not affect growth rate (n=4 per strain). (d) Metabolite 
production with RBS library from pUC-H2R, generating plasmids pUC-H2Ropt (variant B) and pUC-H2RD. 
(e) Theoretical considerations for required serotonin productivity (P, in mg/L*OD630*h) and colonization to 
achieve physiologically relevant concentrations of around 5-30 mg/L61 5-HT in the gut. Underlying 
assumptions were based on expected bacterial load and the surface area of the intestinal tract62 assuming 







Supplementary Figure S2. Microbial localization and in vivo metabolite concentrations. (a) 
Comparison of colonization localization and density of the mouse intestine between a lab E. coli strain 




(b) Graphical illustration of the elongated mouse intestines from esophageal hiatus at the diaphragm to 
the rectum. Red markers illustrate locations of sample collection for engineered bacterial density 
measurement in subsequent sections. (c) Bacterial concentration in the Duodenum, Jejunal-ileal junction, 
cecum, proximal colon, distal colon, and fecal matter 24 hours after last gavage. Samples plated on LB 
Agar plates plus kanamycin and colonies counted measured as colony-forming units (CFU) per gram of 
fecal matter (n=6). Data points shown at y=0 were below the level of detection of 103 CFU/gram. (d) 
Tryptophan concentration measured as mg/L in the serum, mg/g biomass in cleaned homogenized colon 
tissue, mg/g biomass of fecal material. (n=7-8). All p-values shown are from one-way ANOVA with Tukey’s 
post hoc correction for multiple comparison testing. All other comparisons not shown were not significant 






Supplementary Figure S3. Intestinal cell specific and immunomodulatory effects. (a) RT-PCR of 
CDX2, a marker for goblet cells, and BM1 and LGR5, markers for intestinal stem cells, (n=6). (b) RT-PCR 
of known markers for intestinal inflammation including IL6, IL1β, NFKβ, IL17A, TNFα, (n=6). (c) Hemoxylin 
and Eosin staining of colonic tissue, scale bar 100µm. (d) Colon length used as measure for chronic 
inflammation, tissue measured immediately after euthanasia, outstretched from proximal colon at cecal-
colonic junction to distal colon 5 mm before the rectum measured in centimeters. (n=7-8). For bar plots: 
data are mean values with error bars as standard error of the mean. For box plot: center line, mean; box 






Supplementary Figure S4. Neuroendocrine, intestinal permeability, and kynurenine pathway 
effects. (a) RT-PCR of known neuroendocrine marker, Chromogranin A, CGA (n=6). (b) Enterochromaffin 
cell size measured as CgA positive cells measured as analyzed particles using ImageJ Particle Analysis 
tool limited to cells of physiological relevance at least 5 µm in size and no greater than 70 µm in size, 
(n=75-123) For box plot: center line, mean; box limits, set at group standard deviation. (c) 
Immunohistochemical staining with anti-CgA antibody in the mid-colon, scale bar is 100µm. (d) RT-PCR 
of TJP1 (Tight Junction Protein 1 or ZO-1), TJP2 (Tight Junction Protein 2 or ZO-2), and OCLN all 
measures of intestinal integrity and intestinal permeability, (n=6). (e) RT-PCR of IDO1, IDO2, and TDO2 
the rate limiting enzymes of the Kynurenine pathway, (n=6). Data are mean values with error bars as 







Supplementary Figure S5. Analysis of composition and diversity of fecal microbiome during in 
vivo studies. (a) Fecal microbiome 16S sequencing phylum level classification of all four groups 
combined at day 0 and at day 11, twenty-four hours after the last gavage. Colors represent the seven 
identified phyla in the samples. Each phyla represents percent relative abundance of the average of (n=8-
32 per group) the samples in that group(s) at that time point. Each column cumulatively sums to 100% of 
the total identifiable microbes (b) At the genus level, the heatmap represents the average relative 
abundance of genus found in the fecal matter at greater than 0.1% in groups PBS, oN9, oN11, and oN14 
at day 11 (n=8 per group). (c) Weighted UniFrac distance plotted as a 2D principle component analysis. 
ANISOM R value of 0.07403 with insignificance of p=0.155. All data generated using USEARCH and 








Supplementary Figure S6. Gastrointestinal motility and behavioral analysis on additional mouse 
cohorts. (a) Forced swim test time spent immobile of additional cohort of mice during the last 4 minutes 
of a 6-minute test analyzed by a blinded trained observer, time spent immobile recorded in seconds, (n=9-
10). (b) Average total distance traveled of additional mice cohort in each experimental group measured 
by BehaviorCloud animal tracking software, (n=9-10) and time spent in the 40 cm x 40 cm inner zone 
measured by BehaviorCloud animal tracking software, recorded in seconds, (n=7-10). (c) Video tracking 
pattern of each mouse from experimental cohort in Figure 4b-e (tracking patterns for each mouse in each 
group, n=7-10). All p-values shown are from one-way ANOVA with Tukey’s post hoc correction for multiple 
comparison testing. All other comparisons not shown were not significant with p>0.05. Data are mean 







Supplementary Figure S7. Behavioral analysis on mouse cohort from different commercial vendor. 
Physiological and behavioral findings confirmed in mice ordered from Jackson Laboratories, an alternative 
vendor from initial experimentation. (a) Total gastrointestinal transit time from mouth to anus using a 6% 
Carmine Red solution (Methods). (n=9-10). (b) Number of fecal boli from mice during open field test (OST) 
(n=9-10). (c) Average total distance traveled of additional mice cohort in each experimental group 
measured by BehaviorCloud animal tracking software, (n=9-10). (d) Average time spent in the 40 cm x 40 
cm inner zone, number of entries into inner zone, and the total distance traveled in inner zone during OFT 
(n=7-10). All p-values shown are from one-way ANOVA with Tukey’s post hoc correction for multiple 
comparison testing. All other comparisons not shown were not significant with p>0.05. Data are mean 







Supplementary Table S1. Strains, plasmids, and genes used in this study. 
Name Relevant features Source / Reference 
Strains   
N Wild-type E. coli Nissle 1917 (EcN) Ardeypharm GmbH 
NΔ2 EcN ΔtrpR,  ΔtnaA, attTn7::GFP this study 
NΔ3 EcN ΔtrpR,  ΔtnaA, ΔinfA,   attTn7::GFP this study 
NΔ2 –pMUT1 EcN ΔtrpR,  ΔtnaA,  attTn7::GFP , cured of pMUT1 this study 
oN EcN ΔtrpR,  ΔtnaA, folE(T198I),  attTn7::GFP , cured of 
pMUT1 
this study 
oN9 oN + pMUT09-ctrl this study 
oN11 oN + pMUT11-trm this study 
oN14 oN + pMUT14-ser this study 
Plasmids    
pMUT1 Native plasmid of E. coli Nissle 1917 A84793.1  
pMUT nucleotides 1 – 1323 and 1664 – 3117 from pMUT1   this study 
pUC-H2R PBBa_J23107, human cTPH2 (RBS=5000), rice TDC (RBS=10000), 
infA, pUC backbone 
GeneArt® /  
this study 
pUC-H2Ropt PBBa_J23107, human cTPH2 (RBS=5000), rice TDC 
(RBS=700), infA, pUC backbone 
this study 
pUC-H2RD PBBa_J23107, human cTPH2 (RBS=5000), rice TDC 
(RBS=50), infA, pUC backbone 
this study 
pUC-H1R PBBa_J23107, human cTPH1 (RBS=5000), rice TDC 
(RBS=10000), infA, pUC backbone 
this study 
pUC-M1R PBBa_J23107, mouse cTPH1 (RBS=3700), rice TDC 
(RBS=10000), infA, pUC backbone 
this study 
pUC-M2R PBBa_J23107, mouse cTPH2 (RBS=5000), rice TDC 
(RBS=10000), infA, pUC backbone 
this study 
pUC-H2G PBBa_J23107, human cTPH2 (RBS=5000), guinea pig TDC 
(RBS=10000), infA, pUC backbone 
this study 
pUC-H2C PBBa_J23107, human cTPH2 (RBS=5000), Catharanthus 
roseus TDC (RBS=10000), infA, pUC backbone 
this study 
pMUT-H2R PBBa_J23107, human cTPH2 (RBS=5000), rice TDC 
(RBS=700), pMUT1 backbone 
this study 
pMUT-M1R PBBa_J23107, mouse cTPH1 (RBS=2300), rice TDC 
(RBS=250), pMUT1 backbone 
this study 
pMUT09-ctrl PBBa_J23110, pMUT1 backbone, hok/sok locus this study 
pMUT11-trm PBBa_J23110, rice TDC (RBS=700), pMUT1 backbone,  
hok/sok locus 
this study 
pMUT14-ser PBBa_J23110, mouse THP1 (RBS=18000), rice TDC 
(RBS=700), pMUT1 backbone,  hok/sok locus 
this study 
Genes/Proteins   
folE (GCHI) GTP cyclohydrolase I Locus tag 
ECOLIN_12170, 
Protein AID79293.1 
infA translation initiation factor IF-1, native gene on EcN 
genome 
Locus tag  
ECOLIN_04590, 
Protein AID77906.1 









Supplementary Table S2. qPCR primers used in this study. 
Gene Forward Primer Reverse Primer 
CYCLO 5’-GACGAAGGTAGCCAGTCACAAG-3’ 5’-AATCAGGCCTGTGGAATGTGAG-3’ 
MUC2 5’-ATGCCCACCTCCTCAAAGAC-3’ 5’- GTAGTTTCCGTTGGAACAGTGAA-3’ 
CDX2 5’-CAAGGACGTGAGCATGTATCC-3’ 5’-GTAACCACCGTAGTCCGGGTA-3’ 
BM1 5’-AAATCCCCACTTAATGTGTGTCC-3’ 5’- CTTGCTGGTCTCCAAGTAACG-3’ 
LGR5 5’-GGACCAGATGCGATACCGC-3’ 5’- CAGAGGCGATGTAGGAGACTG-3’ 
IL6 5’-CTGCAAGAGACTTCCATCCAG-3’ 5’-AGTGGTATAGACAGGTCTGTTGG-3’ 
IL1β 5’- GCAACTGTTCCTGAACTCAACT-3’ 5’-ATCTTTTGGGGTCCGTCAACT-3’ 
NFKβ 5’-ATGGCAGACGATGATCCCTAC-3’ 5’-TGTTGACAGTGGTATTTCTGGTG-3’ 
IL17A 5’-TTTAACTCCCTTGGCGCAAAA-3’ 5’- CTTTCCCTCCGCATTGACAC-3’ 
TNFα 5’- CAGGCGGTGCCTATGTCTC-3’ 5’-CGATCACCCCGAAGTTCAGTAG-3’ 
TPH1 5’- AACAAAGACCATTCCTCCGAAAG-3’ 5’- TGTAACAGGCTCACATGATTCTC-3’ 
TPH2 5’-GTGACCCTGAATCCGCCTG-3’ 5’-GGTGCCGTACATGAGGACT-3’ 
SERT 5’- CTCCGCAGTTCCCAGTACAAG-3’ 5’- CACGGCATAGCCAATGACAGA-3’ 
CHGA 5’- CAGGCTACAAAGCGATCCAG-3’ 5’- GCCTCTGTCTTTCCATCTCC-3’ 
TJP1 5’-GCCGCTAAGAGCACAGCAA-3’ 5’-TCCCCACTCTGAAAATGAGGA-3’ 
TJP2 5’- GTTTGCCGTTCAGCAGCTTAG-3’ 5’-CTTCAAAACCTCGGTCGTCAT-3’ 
OCLN 5’-TGAAAGTCCACCTCCTTACAGA-3’ 5’-CCGGATAAAAAGAGTACGCTGG-3’ 
IDO1 5’-CAAAGCAATCCCCACTGTATCC-3’ 5’-ACAAAGTCACGCATCCTCTTAAA-3’ 
IDO2 5’-CCTCATCCCTCCTTCCTTTC-3’ 5’-GGAGCAATTGCCTGGTATGT-3’ 
TDO2 5’-AGGAACATGCTCAAGGTGATAGC-3’ 5’-CTGTAGACTCTGGAAGCCTGAT-3’ 
HTR1b 5’-CGCCGACGGCTACATTTAC-3’ 5’-TAGCTTCCGGGTCCGATACA-3’ 
HTR1d 5’-ATCACCGATGCCCTGGAGTA-3’ 5’-GCGAGAAGAGTGGAGGGATG-3’ 
HTR3 5’-CCTGGCTAACTACAAGAAGGGG-3’ 5’-TGCAGAAACTCATCAGTCCAGTA-3’ 
HTR4 5’-AGTTCCAACGAGGGTTTCAGG-3’ 5’-CAGCAGGTTGCCCAAGATG-3’ 
HTR7 5’-TGCGGGGAGCAGATCAACTA-3’ 5’-GACAAAGCACACCGAGATCAC-3’ 
 
H1 = hTPH1 TPH1 from Homo sapiens, catalytic domain: amino acids 
103 to 416 
UniProt ID P17752 
H2 = hTPH2 TPH2 from Homo sapiens, catalytic domain: amino acids 
144 to 462 
UniProt ID Q8IWU9 
M1 = mTPH1 TPH1 from Mus musculus., catalytic domain: amino acids 
106 to 419  
UniProt ID P17532 
M2 = mTPH2 TPH2 from Mus musculus, catalytic domain: amino acids 
142 to 460 
UniProt ID  Q8CGV2 
R = rTDC TDC from Oryza sativa subsp. japonica (Rice) Uniprot ID  Q6ZJK7 
G = gTDC TDC (called AADC, aromatic-amino-acid decarboxylase in 
mammals) from Cavia porcellus (Guinea pig) 
UniProt ID  P22781 
C = cTDC TDC from Catharanthus roseus (Madagascar periwinkle) UniProt ID  P17770 
